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Zusammenfassung 
Perizyten sind murale Zellen des mikrovaskulären Systems. Sie entstehen aus dem Mesenchym 
und ummanteln kapilläre Endothelzellen auf der abluminalen Seite. Sie spielen eine zentrale Rolle 
in der Ausreifung von neu gebildeten Gefäßen und stellen ein Charakteristikum des ruhenden 
Endothels in den meisten mikrovaskulären Systemen dar. Die Perizytenforschung ist durch die 
begrenzte Verfügbarkeit an stabilen Perizyten-spezifischen Markern aufgrund von überlappender 
Markerexpression in unterschiedlichen mesenchymalen Zellen eingeschränkt. Um neue und 
funktionell relevante Perizytenmarker zu identifizieren, wurde eine Expressionsanalyse von fünf 
unterschiedlichen humanen primären Perizyten und anderen mesenchymalen Zellen (Endothel-
zellen, Adipozyten, Fibroblasten, mesenchymale Stammzellen) durchgeführt. Diese Transkriptom-
analyse identifizierte unter anderem die zwei G-Protein gekoppelten Rezeptoren, Prostaglandin-E 
Rezeptor 2 (PTGER2) und Sphingosin-1 Phosphat Rezeptor 3 (S1PR3), als neue Perizyten-
angereicherte Transkripte. Nur vaskuläre glatte Muskelzellen wiesen vergleichbare 
Expressionslevel an S1PR3 auf. 
Anschließende zelluläre Studien zeigten erstmalig, dass S1PR3 in Perizyten Gαi und Gαq aktiviert 
und die Phosphorylierung der leichten Myosin-Kette reguliert. Um die Rolle von S1PR3 in 
Perizyten in physiologischem Kontext zu untersuchen, wurden Co-Kultur Experimente mit 
Endothelzellen und Perizyten mit S1PR3 Herunterregulierung durchgeführt und transkriptomische 
Veränderungen beider Zelltypen verfolgt. Die Expression von S1PR3 in Perizyten ergab subtile 
aber klare Veränderungen in der Expression von Zell-Zell und Zell-Extrazellulärer Matrix 
Molekülen. MPRIP, ein Regulator von RhoA und der leichten Myosin-Kette, wurde als eines der 
physiologisch vielversprechendsten regulierten Gene identifiziert. Funktionelle in vitro Analysen 
von Perizyten mit einer S1PR3 Herunterregulierung resultierten ebenso in einer verringerten 
Transmigration und zunehmender Zellgröße. 
Bemerkenswerterweise war PTGER2 ausschließlich in Perizyten exprimiert. Eine transkriptomische 
Analyse von co-kultivierten Perizyten mit PTGER2 Herunterregulierung und Endothelzellen zeigte 
Veränderungen in der Expression von zellteilungsassoziierten Genen (Herunterregulierung von 
Proliferationsinhibitoren). Funktionelle in vitro Analysen von Perizyten mit einer PTGER2 
Herunterregulierung hatten dementsprechend eine gesteigerte Zellteilung zur Folge. 
Um die Validierung der Expression von S1PR3 und PTGER2 in Perizyten und funktionelle Studien in 
vivo zu ermöglichen, sind Mausmodelle mit konditionaler Deletion dieser Gene erforderlich. Auf 
Grundlage der Expressionsdaten und der zellulären Studien, und dem Fehlen von S1pr3 floxed 
Mauslinien wurden Experimente für die Generierung von konditionalen S1pr3 Mäusen 
vorgenommen. Hierzu wurde die aufeinanderfolgende Integration von zwei LoxP Sequenzen 
mittels CRISPR/Cas Technologie (Cas9 Wildtyp) durchgeführt. 
Zusammenfassend hat diese Studie PTGER2 als neuen Perizytenmarker und S1PR3 als neuen 
muralen Zellmarker in der mesenchymalen Zelllinie identifiziert. Beide Rezeptoren kontrollieren 
wichtige Funktionen der Perizyten. Darüber hinaus erwies sich CRISPR/Cas als eine geeignete 
Methode, um konditionale S1pr3 knockout Mäuse zu generieren. 
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Summary 
Pericytes are mural cells of the microvascular system of mesenchymal origin, which abluminally 
ensheath capillary endothelial cells (EC). Pericytes play a pivotal role in the maturation of newly 
formed vessels and are a hallmark of the quiescent endothelium in most microvascular beds. 
Pericyte-based research is hampered by the limited availability of robust pan-pericyte markers 
due to their overlapping marker expression with various cells of mesenchymal origin. In order to 
identify novel functionally relevant pericyte markers, an expression profiling of five different 
human primary pericyte populations and other mesenchymal cell populations (EC, adipocytes, 
fibroblasts, mesenchymal stem cells [MSC]) was performed. Among others, this screen identified 
Prostaglandin E receptor 2 (PTGER2) and Sphingosine-1-phosphate receptor 3 (S1PR3), two G-
protein-coupled receptors (GPCRs), as novel, highly pericyte-enriched transcripts. Only S1PR3 
showed comparable expression levels also in smooth muscle cells (SMC).  
Subsequent cellular studies demonstrated for the first time that S1PR3 signals via Gαi and Gαq in 
pericytes and regulates myosin light chain (MLC) phosphorylation. To study the role of pericyte-
expressed S1PR3 in a physiological setting, comparative co-culture experiments of EC with S1PR3-
silenced pericytes were performed and transcriptomic profiles were traced. The expression of 
S1PR3 by pericytes resulted in subtle, but distinct transcriptomic changes, including changes in 
cell-cell as well as cell-extracellular matrix interaction molecules. MPRIP, a regulator of RhoA and 
MLC phosphorylation, was identified as one of the most promising candidate genes. Functional in 
vitro assays of S1PR3 silenced pericytes resulted in reduced transmigration capacity and increased 
cell size.  
Notably, PTGER2 was exclusively expressed by pericytes. Transcriptomic analyses of co-cultured 
pericytes silenced for PTGER2 revealed expression changes of proliferation-associated genes 
(downregulation of negative regulators).  Correspondingly, functional in vitro assays of PTGER2 
silenced pericytes resulted in enhanced proliferation. 
To enable the validation of pericyte-expressed S1pr3 and Ptger2 and further functional studies in 
vivo, mouse models for the conditional deletion of these genes are required. Based on the 
expression profiling and cellular screening experiments and the fact that conditional mice for 
S1pr3 are not available, experiments were set out with the aim to generate S1pr3 floxed mice by 
CRISPR/Cas technology. Sequential integration of two LoxP sites using Cas9 wildtype was 
successfully used to generate conditional S1pr3 mice. 
Taken together, the experiments identified PTGER2 as novel pericyte marker and S1PR3 as novel 
mural cell marker within the mesenchymal cell lineage that both control important pericyte 
functions. Furthermore, CRISPR/Cas technology proved as a suitable approach to generate 
conditional S1pr3 knockout mice. 
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1. Introduction  
1.1 The vascular system 
The vascular system of vertebrates consists of two highly branched tubular networks: the blood 
and the lymphatic vascular system. The heart and the following network of hierarchically 
structured tissue including afferent arteries and arterioles, capillaries (exchange vessels) and 
heart afferent venules and veins, are building the blood vascular system (Adams and Alitalo, 
2007). For it is by the heart's vigorous beat that the blood is moved, perfected, activated, and 
protected from injury and coagulation. The heart is the tutelary deity of the body, the basis of life, 
the source of all things, carrying out its function of nourishing, warming, and activating body as a 
whole (William Harvey, De Motu Cordis, 1628). Indeed, the heart pumps O2- and nutrient-rich 
blood to the tissues and deoxygenated CO2-rich blood back to the lung circulation. Thereby gases, 
liquids, nutrients, warmth and signaling molecules are transported through the organized and 
specialized blood vessels between different organs and tissues, regulating tissue fluid homeostasis 
(Herbert and Stainier, 2011). The lymphatic vascular system is an unidirectional blind-ended 
network. It drains interstitial fluid through a conduit system of collecting vessels, lymph nodes, 
lymphatic trunks and ducts and returns the fluid back into the venous system. Lymphatic vessels 
thereby control macromolecule and protein drainage, as well as immune cell trafficking (Adams 
and Alitalo, 2007; Alitalo, 2011). About 75 % of all deaths are correlated with structural changes 
and dysfunctions (atherosclerosis, diabetes, stroke, aneurysms, myocardial infarction, 
neurodegenerative disorders and cancer) of the vascular system emphasizing its importance 
(Carmeliet, 2003; Folkman, 2007).  
 
1.1.1 Vessel architecture and function 
The inner layer of a vessel wall, termed tunica intima, consists of a single cobble-stone-like layer 
of endothelial cells (EC) covered by a basement membrane (BM) (Neufeld et al., 2014).  EC are 
very heterogenous depending on the specific needs of certain organs (Potente and Mäkinen, 
2017). Three EC vessel phenotypes are classified: continuous, fenestrated and discontinuous 
endothelium. Continuous endothelium can be predominantly found in the brain, where it 
maintains the blood brain barrier (BBB) through specialized tight junctions and a continuous BM. 
Fenestrated endothelium is characterized by intercellular gaps and continuous BM to ensure 
required fluid exchange in organs like intestine and kidney. Organs like liver, spleen and bone 
marrow require unrestricted cell trafficking and fluid exchange. In these organs the endothelium 
is discontinuous with even larger gaps and a discontinuous BM (Cleaver and Melton, 2003).  
EC of the microvasculature (capillaries, small arterioles and venules) are more or less covered with 
pericytes. Pericytes are mural cells that are embedded in the BM to directly interact with EC. The 
tunica intima in large caliber vessels is enveloped by two additional layers, named tunica media 
and tunica externa/adventitia. The tunica media consists of a smooth muscle cell (SMC) layer, 
proteoglycans, elastin and collagen, whereas the tunica adventitia is composed of elastic and 
collagenous fibers (Cleaver and Melton, 2003; Neufeld et al., 2014). 
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1.1.2 Developmental blood vessel formation 
The first functional organ in the vertebrate embryo is the cardiovascular system and it is essential 
for O2 and nutrient supply of the embryo (Jin and Patterson, 2009). During development, blood 
vessels develop by de novo formation of a primitive vascular plexus from angioblasts, called 
vasculogenesis. Early in embryonic development mesodermal stem cells differentiate into 
hemangioblasts, which can give rise to the hematopoietic lineage and the endothelial cell lineage. 
On embryonic day 7.0, hemangioblast-derived cells called angioblasts (endothelial precursor cells) 
and hematopoietic precursor cells migrate out of the mesoderm and form blood islands, in which 
the angioblasts surround hematopoietic precursors. The blood islands fuse to a cord-like structure 
and give rise to a primitive luminized vascular plexus (Risau, 1997; 1995). The first major 
embryonic vessels formed by this process are the dorsal aorta and the cardinal vein. Arterial and 
venous specification follows EC differentiation (Swift and Weinstein, 2009). The remodeling of the 
primitive vascular plexus to a mature vascular network involves a second process termed 
angiogenesis. 
 
1.1.3 Physiological angiogenesis 
Angiogenesis is defined as the growth of blood vessels from pre-existing vessels (Carmeliet, 2005; 
Risau, 1997) and can be divided into sprouting angiogenesis and intussusception (non-sprouting 
angiogenesis) (Djonov et al., 2000; Potente et al., 2011; Risau, 1997). After birth, angiogenesis 
contributes to the growth of organs, however, in adulthood the vasculature is quiescent except 
during the progress of the cycling ovary, pregnancy and wound healing (Carmeliet, 2005; Risau, 
1997). Inadequate or excessive vessel growth contribute to diseases such as myocardial 
infarction, stroke, obesity-associated disorders, cancer and eye disease (Folkman, 2006; Potente 
et al., 2011). Therefore, the formation of new blood vessels needs to be tightly regulated (Potente 
et al., 2011). 
 
1.1.3.1 Phases of angiogenesis  
Nutrient and O2 deprivation initiate proangiogenic stimuli leading to the recruitment of new blood 
vessels (angiogenic switch). Initially, hypoxia inducible-factor α (HIF1α) is stabilized and activates 
the transcription of vascular endothelial growth factor A (VEGFA) (Fraisl et al., 2009). Upon VEGF 
stimulation, EC get activated and particular EC are selected to become a tip cell. VEGF further 
loosens EC junctions and matrix metalloproteases (MMPs) degrade the BM, shared by EC and 
pericytes. Tip cells develop filopodia leading to a coordinated tissue invasion towards the 
angiogenic stimulus and vessel sprouting into avascular areas (Adams and Alitalo, 2007; Distler et 
al., 2003; Gerhardt et al., 2003; Potente et al., 2011). Following stalk cells are less motile, produce 
BM and associate with mural cells. Stalk cells form EC junctions and the vessel lumen. After lumen 
formation, the new vessel is perfused, which is a key inducer of vascular quiescence (vessel 
maturation) (Potente et al., 2011). Junctions of the quiescent EC (phalanx cells) are further 
strengthened and mural cells (pericytes, SMC) are recruited (Dejana, 2004; Potente et al., 2011). 
Pericytes, integrated into the BM, wrap around the EC and stabilize the new blood vessel. This 
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mature primitive plexus undergoes vascular remodeling upon changes in metabolic demands such 
as the lactating breast and tumor growth. Finally, a hierarchically structured vascular network is 
formed by regulating vessel density, either through new vessel sprouts or selective regression of 
redundant branches (Baffert et al., 2006; Wacker and Gerhardt, 2011).    
 
1.1.3.2 Signaling pathways in EC  
VEGF is the most intensely investigated regulator of angiogenesis. The VEGF family consists of the 
vertebrate VEGF-A to VEGF-D, placenta growth factor (PIGF), parapoxvirus VEGF-E and snake 
venom VEGF-F. Deletion of just one copy of Vegfa results in embryonic lethality demonstrating 
the importance of VEGF-A in vascular development (Carmeliet et al., 1996; Ferrara et al., 1996). 
VEGF-A was first described as vascular permeability factor due to its permeability-inducing 
property (Keck et al., 1989; Senger et al., 1983; Sun et al., 2012b). Furthermore, VEGF-A promotes 
survival, proliferation and migration (Bernatchez et al., 1999; dela Paz et al., 2012; Simons et al., 
2016). However, alternative splicing variants of VEGF-A trigger different effects. VEGF165 binds to 
heparin-sulfate proteoglycans (HSPG) resulting in a gradient of VEGF signaling, which is important 
for vessel outgrowth. VEGF121 instead, is freely diffusible and does not bind HSPG (Cohen et al., 
1995; Koch et al., 2011). All VEGF bind with high affinity to the three receptor tyrosine kinases 
VEGFR1-3, of which VEGFR2 is the main signaling receptor in EC (Simons et al., 2016). Upon VEGF-
A binding, VEGFR2 dimerizes, autophosphorylates and activates downstream signaling pathways 
like phospholipase Cy (PLCy), focal adhesion kinase (FAK), Src, mitogen-activated kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K) signaling (Koch and Claesson-Welsh, 2012). Neuropilin-1 
(NRP1) and Neuropilin-2 (NRP2) are known co-receptors for VEGFR2 enhancing its signaling 
(Ferrara et al., 2003; Neufeld et al., 2002). However, NRP1 can also signal independently of 
VEGFR2 (Roth et al., 2016). VEGF-A binds with higher affinity to VEGFR1 than to VEGFR2. VEGFR1 
is described to have a weak kinase activity. Therefore, VEGFR1 as well as its alternative splicing 
variant VEGFR1 (soluble) act as VEGF-A trap antagonizing VEGFR2 signaling (Chappell et al., 2009; 
Hiratsuka et al., 1998). Whereas VEGFR1 and VEGFR2 are predominantly expressed in vascular 
endothelial cells, lymphangiogenesis is primarily regulated by VEGF-C binding to VEGFR3, mainly 
expressed by lymphatic EC (Kaipainen et al., 1995, 1995).  
Together with VEGFR2/VEGF-A signaling, the Notch pathway plays a major role in controlling 
angiogenesis. As mentioned above, VEGF/VEGFR2 stimulates tip cell and filopodia formation 
(Gerhardt et al., 2003). Notch signaling in contrast inhibits tip cell formation in neighboring stalk 
cells (Phng and Gerhardt, 2009; Roca and Adams, 2007). Endothelial cells express Notch receptors 
NOTCH1/NOTCH4 (Roca and Adams, 2007; Wu et al., 2005) and corresponding Notch ligands 
Jagged1, Jagged2, Dll1 and Dll4 (Beckers et al., 1999; Villa et al., 2001). During sprouting 
angiogenesis, tip cells express high levels of Dll4, which in turn activates Notch signaling in 
NOTCH1 expressing stalk cells (Hellström et al., 2007; Leslie et al., 2007; Lobov et al., 2007). 
VEGFR2/VEGF-A signaling induces Dll4 expression in tip cells and conversely activation of Notch 
signaling in the stalk cells downregulates VEGFR2 and upregulates VEGFR1 (Funahashi et al., 2010; 
Suchting et al., 2007). This feedback mechanism (lateral inhibition) of VEGF and Notch signaling 
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selects the tip cell and is substantial for controlled branching of blood vessels into a hierarchically 
ordered vascular network. 
 
1.2 Pericytes 
Endothelial cells are the active center in the formation of new blood vessels and angiogenesis 
research in the 1990´s mainly focused on EC. However, this research ignored that maturation of 
the newly formed vascular network is dependent on mural cells (pericytes and SMC). This 
changed upon gain of interest in the maturation processes of angiogenesis. 
Already in 1871, Eberth described the presence of pericytes (Stricker et al., 1872). Yet, the 
discovery of pericytes is assigned to the French scientist Charles-Marie Benjamin Rouget 
describing contractile cells surrounding small blood vessels (Rouget, 1873). Since its discovery, the 
definitions of a pericyte, found in the literature, are still conflicting and confusing. Pericytes are 
described as: i) contractile and motile cells as described by Rouget (Rouget, 1873), ii) contractile 
cells, covering capillaries outside of the BM (Blood, 1988), iii) undifferentiated adventitial cells 
(Stedman, 1995), iv) SMC/pericytes of the capillaries (Fabry et al., 1993), v) stem or mesenchymal 
cells that can differentiate into fibroblasts or SMC (Ding et al., 2004; Dore-Duffy et al., 2006). The 
currently accepted definition of a mature pericyte is a cell that is associated to microvessels 
within the BM. However, more practical criteria like location, gene expression pattern and 
morphology are nowadays used to identify pericytes (Armulik et al., 2011). Still, the 
differentiation between pericytes and SMC, surrounding larger vessels, is challenging. 
 
1.2.1 Morphology 
Pericytes are located on the abluminal side of blood microvessels, but not on lymphatic capillaries 
(Armulik et al., 2011; Marchetti and Piacentini, 1990). Predominantly, pericytes wrap the 
endothelial layer in capillaries, whereas in terminal precapillary arterioles and venules a transition 
to SMC occurs (Díaz-Flores et al., 1991). The morphology of pericytes is heterogeneous and 
depends on the location and type of vessel (Joyce et al., 1984). Mostly, pericytes appear as 
stellate-shaped cells with a sophisticated network of branches surrounding EC (Weibel, 1974). The 
cell body is round and primary processes running parallel to the length of the capillary. Primary 
processes give rise to secondary perpendicular processes that attach to EC (Armulik et al., 2011). 
Covering of EC by pericyte cytoplasmic processes is incomplete, but the processes can span more 
than one EC suggesting a role of pericytes in integrating EC functions (Gerhardt and Betsholtz, 
2003). In contrast, pericytes in the kidney glomerulus, named mesangial cells, are round, compact 
and show less contact to the vessel surface (Armulik et al., 2005). 
Pericyte density and the proportion of the covered EC surface vary depending on organ, species 
and physiological/pathological conditions. The covered vessel area ranges from 10-50%, whereas 
the ratio pericytes to EC varies from 1:100 (skeletal muscle) to 1:1 (retina, brain). These 
differences are organ- and function-dependent, since pericyte density and coverage positively 
correlate with permeability of certain vessel beds. The high pericyte coverage in the central 
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nervous system indicates their important role in contributing to the blood-brain barrier (Shepro 
and Morel, 1993).  
 
1.2.2 Origin 
Vessel development in the embryo occurs via de novo formation of a primitive vascular plexus 
(vasculogenesis). Mesodermal stem cells give rise to so called angioblasts, which further 
differentiate into EC. EC and pericytes probably share a common progenitor cell. Depending on 
their location, pericytes originate from mesenchymal stem cells (mesodermal origin) or the neural 
crest during vasculogenesis. The majority of the pericytes in the head and neck region, as well as 
the thymus, arise from the neural crest (Bergwerff et al., 1998; Etchevers et al., 2001; Müller et 
al., 2008). Pericytes from gut (Wilm et al., 2005), liver (Asahina et al., 2011) and lung (Que et al., 
2008) instead derive from the pleural and peritoneal mesothelium (mesodermal origin). Here, 
mesothelial cells undergo endothelial to mesenchymal transition (EndMT), migrate into the organ 
and transdifferentiate into pericytes, but also SMC or fibroblasts (Hall, 2006). This indicates a 
close ontogenic relationship between EC, mural cells (pericytes and SMC) and fibroblasts. 
Yamashita et al. showed that VEGFR2 expressing mesoderm cells differentiate upon VEGF 
stimulation into endothelial cells, whereas PDGF-B stimulation gives rise to mural cells (Yamashita 
et al., 2000). Moreover, transdifferentiation of embryonic EC into mesenchymal cells, expressing 
smooth muscle actins, should be taken into consideration (DeRuiter et al., 1997).  
The origin of pericytes during developmental and adult angiogenesis is not fully explored. Mainly 
three different scenarios are discussed in the literature: i) Pericytes proliferate and develop out of 
pre-extisting ones (primarily in the CNS) (Armulik et al., 2011; Rajantie et al., 2004), ii) pericytes 
derive from blood pluripotent stem cells (described also in tumors) (Yamashita et al., 2000 
Bababeygy et al., 2008), and iii) pericytes derive from tissue progenitor stem cells (pericytes 
themselves, myofibroblasts, EC) (Birbrair et al., 2014; Diaz-Flores et al., 1992; Hall, 2006). EC can 
give rise to perivascular cells via EndMT (Zeisberg et al., 2007, 2008). During EndMT, EC lose their 
adhesion properties and cell polarity and transform to motile mesenchymal cells. Concurrently, 
these cells were shown to express mesenchymal markers like PDGFRβ, migrate perivascular and 
differentiate (Chen et al., 2016). Pericytes themselves are described to represent a perivascular 
stem cell niche providing a source of mesenchymal stem cells (MSC) (da Silva Meirelles et al., 
2008). They can transdifferentiate into osteocytes, chondrocytes and adipocytes (Crisan et al., 
2008a). 
 
1.2.3 Molecular signature of pericytes 
The morphological diversity and the close ontogenic relationship to other cell types mirrors the 
diversity on the molecular level of pericytes. In addition to morphological and structural criteria, 
the expression of well-established markers is used to identify pericytes. Well-established markers 
are Desmin, Neural/glial antigen 2 (NG2/CSPG4), platelet-derived growth factor receptor beta 
(PDGFRβ), alpha smooth muscle actin (αSMA), Endosialin (CD248) and regulator of G-protein 
signaling 5 (RGS5) (Díaz-Flores et al., 2009). These markers are described in section 1.2.3.1 to 
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1.2.3.4.  Other markers, described in the literature (Table 1) include CD13 (alanyl 
aminopeptidase), SUR2 (ATP-binding cassette), Kir6.1 (potassium inwardly rectifying channel), 
DLK1 (delta-like 1 homolog) (Armulik et al., 2011). Common transgenic markers for murine studies 
are XlacZ4 (Tidhar et al., 2001), Ng2-dsRED (He et al., 2016; Zhu et al., 2008), Pdgfrβ-eGFP (He et 
al., 2016). However, none of the markers is a pan-pericyte marker (Díaz-Flores et al., 2009). 
Pericyte marker expression is strongly dependent on species, vessel type, organ, pathological 
condition and activation state of the vessel. Whereas progenitor cells are positive for Pdgfrβ, but 
negative for Ng2, αSMA and Desmin, intermediate pericytes express all four makers. Mature 
pericytes instead lose the expression of Pdgfrβ (Song et al., 2005). Consequently, next to 
morphology, a combination of several pericyte markers is state-of-the-art to identify pericytes 
(Díaz-Flores et al., 2009; Gerhardt and Betsholtz, 2003). 
 
1.2.3.1 PDGFRβ 
The tyrosine kinase receptor PDGFRβ is one of the most important molecules expressed by 
pericytes. The PDGF-B/PDGFRβ signaling axis between EC and pericytes is substantial for the 
recruitment of mural cells during angiogenesis (chapter 1.2.4). PDGFB- and PDGFRβ-deficient mice 
die around birth with severe vascular defects (Levéen et al., 1994; Lindahl et al., 1997; Soriano, 
1994). PDGFRβ is expressed by mesenchymal cells, myofibroblasts, smooth muscle cells and 
neuronal progenitor cells (Lindahl et al., 1997; Winkler et al., 2010). Despite the fact that PDGFRβ 
is expressed by other cells, it is considered as the most reliable pericyte marker. Therefore, 
Pdgfrβ-Cre driver mice (Chen et al., 2016; You et al., 2014) as well as Pdgfrβ-eGFP reporter mice 
(He et al., 2016) are widely used in the literature. 
 
1.2.3.2 NG2 
NG2 (CSPG4) is a chondroitin sulfate transmembrane proteoglycan. NG2 is expressed on the 
membrane of several cells including oligodendrocyte progenitors, chondroblasts, smooth muscle 
cells and pericytes (Goretzki et al., 1999; Murfee et al., 2005). Mainly perivascular cells of the 
arterioles and capillaries, but not venules, express NG2 (Murfee et al., 2005). Furthermore, tumor 
pericytes are positive for NG2 (Schlingemann et al., 1991). There has been considerable 
controversy in NG2 as a marker of mature pericytes (Song et al., 2005) or activated pericytes 
(Ozerdem et al., 2001, 2002; Schlingemann et al., 1991) in literature. Yet, the majority of 
published papers suggest that NG2 is a marker of activated pericytes since it is consistently 
expressed by mural cells in developing vascular structures (angiogenesis or vasculogenesis). 
However, while NG2 indicates to be a suitable marker for developing pericytes in the 
microvasculature, smooth muscle cells are positive for NG2 (Ozerdem et al., 2001). Global NG2 
knockout mice are viable and without obvious phenotype (Grako et al., 1999). However, upon 
induction of pathological angiogenesis in the adult mouse retina, neovascularization is 
significantly reduced (Ozerdem and Stallcup, 2004).  Concerning the functional role of NG2, it 
participates as a co-receptor in angiogenic growth factor signaling and binds basic fibroblast 
growth factor (bFGF) and PDGF-AA, which might induce proliferation and migration of pericytes 
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(Goretzki et al., 1999; Ozerdem et al., 2001). It functions as cell surface receptor for extracellular 
matrix components like Collagen IV, which is a basic component of the BM surrounding EC and 
pericytes. Binding of Collagen IV induces cytoskeletal reorganization and enhances motility 
(Ozerdem et al., 2001). NG2-positive pericytes play also a role in the crosstalk of pericytes with EC 
by binding integrin α3β1 and induction of EC motility and morphogenesis during 
neovascularization (Fukushi et al., 2004). Pericyte-specific knockout of NG2 in intracranial 
melanomas results in structural deficits of the vasculature and decreased pericyte coverage, 
supporting a NG2-dependent mechanism in the crosstalk of pericytes and EC (You et al., 2014). 
Even though NG2 is not exclusively expressed by pericytes, pericyte-specific deletion of NG2 (Ng2-
Cre mouse) (Cooke et al., 2012) or transgenic constructs (Ng2-dsRED) (He et al., 2016) for 
isolation of NG2-positive pericytes are well established in literature. 
 
1.2.3.3 αSMA and Desmin 
αSMA and Desmin are both contractile proteins of the cell cytoskeleton. αSMA is one member of 
six different mammalian isoforms of the cytoskeletal protein actin. Whereas β- and γ-actin are 
ubiquitously expressed, αSMA is mainly expressed in smooth muscle cell lineages and 
myofibroblasts (Bergers and Song, 2005). Its main function is the regulation of vascular 
contractility and blood pressure (Schildmeyer et al., 2000). αSMA is a widely used marker to 
identify pericytes (Herman and D’Amore, 1985; Schlingemann et al., 1990; Verbeek et al., 1994). 
Albeit, the expression of αSMA is heterogenous and dependent on several conditions. Pericytes 
from different organs and species show differences in αSMA expression. Brain and retina (rat and 
bovine) pericytes lack αSMA expression, while pericytes from other organs express αSMA (Nehls 
and Drenckhahn, 1991; Skalli et al., 1989; Verbeek et al., 1994). In turn, brain pericytes from the 
chicken do show αSMA expression (Gerhardt et al., 2000). Next, αSMA abundance is related to 
the localization in the microvasculature. Pre- and post-capillary vessels are positive for αSMA in 
their microfilament bundles suggesting a role of these cells in the regulation of capillary blood 
flow. Mid-capillaries instead are negative for αSMA (Nehls and Drenckhahn, 1991). Last, αSMA 
expression levels differ upon the activation state of pericytes. In vitro studies indicate that αSMA 
may be a marker of dedifferentiation (to a smooth muscle like cell). Cultured pericytes show an 
upregulation of αSMA upon TGFβ stimulation and downregulation of αSMA after bFGF treatment 
(Verbeek et al., 1994). Together with in vivo studies, the upregulation of αSMA is believed to 
indicate the transition phase from a quiescent to an activated phenotype, as seen in tumors 
(Morikawa et al., 2002).  
Desmin is a muscle-specific class III intermediate filament and is expressed in mature skeletal, 
cardiac, smooth muscle cells and pericytes (Herrmann et al., 1989). It is expressed by mature as 
well as immature pericytes (Nehls et al., 1992; Verhoeven and Buyssens, 1988). Mice deficient for 
Desmin are viable, but show defects in all muscle tissues due to myocyte cell death and 
mitochondria defects (Milner et al., 2000). Desmin builds a three dimensional scaffold that 
connects nucleus, mitochondria, desmosomes and myofibrils to keep cell integrity (Capetanaki et 
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al., 1997) and is also associated with vessel stability. Coverage with Desmin-positive pericytes is 
positively correlated with vessel development (Chan-Ling et al., 2004). 
 
1.2.3.4 RGS5 and Endosialin 
Regulator of G-protein signaling 5 (RGS5) belongs to a family of about 25 proteins. RGS are 
described to negatively regulate G-protein coupled receptor (GPCR) signaling (Hollinger and 
Hepler, 2002). RGS5 is a GTPase activating protein for Gαi and Gαq and diminishes sphingosine-1-
phosphate (S1P), PDGFB, angiotensin II and endothelin-1 signaling (Cho et al., 2003). It was 
discovered as pericyte- and SMC-specific transcript in PDGFB-deficient mouse embryos, in which 
developing vessels are almost absent of pericytes. Here, the RGS5 positive signal overlapped with 
PDGFRβ and NG2 expression (Bondjers et al., 2003). RGS5-deficient mice are viable and have no 
obvious vascular phenotype (Nisancioglu et al., 2008). However, Berger et al. identified RGS5 as 
the first marker that is specific for activated pericytes as its expression is induced in the 
vasculature upon physiological (ovulation and wound healing) and pathological (astrocytoma and 
pancreatic islet carcinoma) angiogenesis (Berger et al., 2005). Furthermore, RGS5 deficiency leads 
to vascular normalization in pancreatic carcinomas (Hamzah et al., 2008). Yet, RGS5 is not 
expressed in every tissue and tumor (Bergers and Song, 2005) and under certain pathological 
conditions (subcutaneous tumor formation/ growth  and oxygen-induced retinopathy) no 
differences in the vasculature were observed in the RGS5-deficient mice (Nisancioglu et al., 2008). 
Endosialin (Cd248 or tumor endothelial marker 1 [TEM1]) is one of the four surface C-type lectin 
domain proteins of the Endosialin family. It was originally discovered as tumor endothelial marker 
(Christian et al., 2001; Rettig et al., 1992; St Croix et al., 2000). However, subsequent studies 
identified Endosialin expression restricted to activated stromal pericytes and myofibroblasts 
(Christian et al., 2008; MacFadyen et al., 2007; Rybinski et al., 2015). Endosialin is an onco-fetal 
protein, which shows high expression during embryonic development but no or little expression in 
healthy adult tissues (Lax et al., 2007; MacFadyen et al., 2007; Rupp et al., 2006). In pathological 
conditions, Endosialin expression is highly associated with multiple cancers and inflammation 
(Hasanov et al., 2017; Mogler et al., 2015; Viski et al., 2016). Despite several studies of Endosialin 
expression in physiological and pathological conditions, the mechanism of its action needs further 
investigation. What ligand binds Endosialin and how it signals, are still not explored. First 
mechanistic investigations have shown that Endosialin mediates pericyte proliferation by 
modulating PDGFRβ signaling (Tomkowicz et al., 2010).    
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Table 1 Pericyte markers 
 
Pericyte Marker Gene  Expression by other cell types References 
PDGFRβ (Platelet-
derived growth factor) 
Pdgfrb 
SMC, neuronal progenitors, 
myofibroblasts, MSC 
(Chen et al., 2011; Farahani and 
Xaymardan, 2015; Funa and 
Sasahara, 2014; Lindahl et al., 
1997) 
NG2 (chondroitin 
sulfate proteoglycan) 
Cspg4 
Adipocytes, SMC, neuronal 
progenitors, microglial cells, 
developing cartilage, bone, muscle 
(Chang et al., 2012; Fukushi et al., 
2003; Ozerdem et al., 2001; Zhu 
et al., 2016) 
αSMA (alpha-smooth 
muscle actin) 
Acta2 
SMC, myofibroblasts, 
myoepithelium, hepatic 
perisinusoidal cells 
(Bergers and Song, 2005; 
Gugliotta et al., 1988; Rønnov-
Jessen and Petersen, 1996; 
Schmitt-Gräff et al., 1991) 
Desmin Des SMC, MSC 
(Liu et al., 2013; Nehls et al., 
1992) 
RGS5 (regulator of G 
protein signaling 5) 
Rgs5 SMC (Bondjers et al., 2003) 
Endosialin Cd248 
SMC, myofibroblasts, mesenchymal 
cells during development 
(Christian et al., 2008; MacFadyen 
et al., 2007; Virgintino et al., 
2007) 
Angiopoietin 1 (Ang1) Angpt1 SMC (Wakui et al., 2006) 
Sur2 (ATP-binding 
cassette, subfamily C 
(CFTR/MRP)) 
Abcc9 SMC, renal tubular epithelium 
(Bondjers et al., 2006; Zhou et al., 
2008) 
Kir6.1 (potassium 
inwardly rectifying 
channel, subfamily J) 
Kcnj8 SMC (Bondjers et al., 2006) 
DLK1 (delta-like 1 
homolog) 
Dlk1 
SMC, adipocyte progenitors, 
hepatoblasts 
(Bondjers et al., 2006; 
Mitterberger et al., 2012; Tanaka 
et al., 2009) 
CD13 (Amino-peptidase 
N) 
Anpep 
SMC, activated endothelium, renal 
epithelial cells 
(Dermietzel and Krause, 1991; 
Hauwaert et al., 2013; Mina-
Osorio et al., 2008) 
Zink finger protein 201 Zic1 Neuronal cells 
(Daneman et al., 2010; 
DiPietrantonio and Dymecki, 
2009; He et al., 2016) 
Vitronectin Vtn Respiratory epithelial cells, SMC 
(Dufourcq et al., 1998; He et al., 
2016; Salazar-Peláez et al., 2015) 
Interferon induced 
transmembrane protein 
1 
Ifitm1 Primordial germ cells 
(He et al., 2016; Tanaka et al., 
2005) 
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1.2.4 EC-pericyte interactions 
Pericytes and EC are anatomically in close contact and both contribute to the BM by which they 
are separated and embedded (Mandarino et al., 1993). At certain points, pericytes and EC contact 
each other directly due to fenestrations in the BM. Different types of direct contacts are 
described: i) Inserted cytoplasmic fingers of pericytes in endothelial invaginations with tight-, gap- 
and adherence-junctions (peg socket contacts), ii) close contacts of both membranes (occluding 
contacts), iii) adherens junctions with microfilament bundles of pericytes and fibronectin 
(adhesion plaques). These junctions are said to be the sites of N-cadherin mediated cell-cell 
contacts (Armulik et al., 2011; Gerhardt and Betsholtz, 2003). Next to the close anatomical 
relationship of pericytes and EC, paracrine and juxtacrine communication via diverse signaling 
pathways, including PDGF-B/PDGFRβ, angiopoietins, sphingosine-1-phosphate and transforming 
growth factor β (TGFβ) signaling, occurs (Armulik et al., 2011).   
PDGF was originally discovered in platelets and serum, in vitro acting as mitogen for fibroblasts, 
glial cells and SMC. The PDGF family consists of four ligands, in which PDGF-A to PDGF-D can form 
homodimers, and PDGF-A and PDGF-B build heterodimers. The PDGFs bind to two cell-surface 
receptor tyrosine kinases, PDGFRα and PDGFRβ, where PDGFRβ binds PDGF-B/PDGF-D and 
PDGFRα binds PDGF-A/PDGF-B/PDGF-C (Betsholtz et al., 2001). Binding of the ligand leads to 
autophosphorylation and subsequent signal propagation including Ras-MAPK, PI3K, FAK and PLCγ 
signaling pathways. PDGF-B induces cellular responses like cell growth, motility and 
differentiation (Heldin et al., 1998) and is a critical factor in the maturation of newly formed blood 
vessels, since it initiates the recruitment of pericytes. Its expression is mainly induced by hypoxia, 
thrombin and various growth factors (Heldin and Westermark, 1999). PDGF-B, predominantly 
expressed by tip cells, binds to HSPG via its C-terminal retention motifs, composed of a stretch of 
positively charged amino acid residues (Gerhardt and Betsholtz, 2003; Ostman et al., 1991). 
Consequently, PDGFRβ-positive mural cells (pericytes and SMC) are co-recruited with the 
angiogenic sprout via a temporal and spatial PDGF-B gradient (Hellström et al., 1999). Deletion of 
either PDGF-B or PDGFRβ resulted in perinatal lethality with leakage and hemorrhage in the 
microvasculature (Levéen et al., 1994; Soriano, 1994). Similarly, deletion of the retention motif 
lead to partial detachment of pericytes (Lindblom et al., 2003). Furthermore, the EC-specific 
expression of PDGF-B is critical for pericyte coverage of the vasculature, since EC-specific deletion 
of PDGF-B results in pericyte deficiency (Enge et al., 2002). VEGF signaling interacts with PDGF-
B/PDGFRβ signaling via regulation of PDGF-B expression and suppression of PDGFRβ signaling. 
Interestingly, a positive feedback loop between VEGF-C/VEGFR3 and PDGF-B/PDGFRβ regulates 
vessel maturation via inducton of PDGF-B (Onimaru et al., 2009). However, VEGF-A is described to 
be a negative regulator of vessel maturation. VEGFR2 and PDGFRβ assemble a receptor complex 
in perivascular cells upon VEGF-A stimulation, thereby suppressing PDGFRβ signaling (Greenberg 
et al., 2008). Additionally, publications show that specific blocking of VEGF-A and PDGF-B in age-
regulated macular degeneration suppresses subretinal neovascularization and might be a 
potential therapeutic approach (Dong et al., 2014). 
Introduction 
 
15 
 
The Angiopoietin-Tie (Ang-Tie) system is a major signaling pathway of vessel maturation and 
stability. The Ang-Tie family consists of four Angiopoietins (Ang-1 to Ang-4). While Ang-1 and Ang-
2 are the best characterized Angiopoietins. Ang-3 and Ang-4 are orthologues found in mouse and 
human. All the Angiopoietins are ligands for the receptor Tie-2 (Thomas and Augustin, 2009), 
whereas the receptor Tie1, exclusively expressed by EC, is an orphan receptor. Tie-1 controls Tie-2 
signaling in a context-dependent manner (tip or stalk cell) and is important for controlling 
angiogenesis and vascular remodeling (Savant et al., 2015). Whereas the PDGF-B/PDGFRβ axis 
reflects an endothelial-to-pericyte signaling loop, the Ang-Tie axis has reverse orientation since 
Ang-1 is constitutively expressed by perivascular cells and its main receptor Tie-2 is predominantly 
expressed by endothelial cells. However, there is evidence that Tie-2 is also expressed by 
pericytes/SMC (Teichert et al., 2017) and subtypes of monocytes and macrophages (De Palma et 
al., 2005). Ang-1 is the agonistic ligand of Tie-2. Ang1-deficient mice phenocopy the embryonically 
lethal vascular defects in Tek (Tie-2)-deficient mice (Suri et al., 1996; Dumont et al., 1994). Ang-2, 
only expressed by EC and released upon EC activation from Weibel-Palade bodies (Fiedler et al., 
2004), was described as antagonist of Tie-2 (Sato et al., 1995), however, Ang-2 acts as partial 
agonist in a context-dependent manner (Kim et al., 2016; Korhonen et al., 2016). Taken together, 
Ang-1 induces vessel quiescence and maturation in a paracrine manner, Ang-2 as autocrine ligand 
mediates mainly vessel destabilization (Augustin et al., 2009). Interestingly, morphological 
analysis of Ang-1 or Tek null mice demonstrated a lack of mural cells (Suri et al., 1996). A role of 
Tie-2 in pericyte recruitment was suggested, since various in vivo and in vitro studies prove that 
overexpression of Ang-2 results in pericyte loss (Hammes et al., 2004; Stratmann et al., 1998; 
Zhang et al., 2003). However, mice with signaling-deficient Tie-2 receptors as well as Tek null mice 
showed normal pericyte recruitment to Tie-2-negative vessels (Jones et al., 2001; Tachibana et al., 
2005). Recently, Tie2 expression on pericytes was identified. Pericyte-expressed Tie2 mediates 
vessel maturation by controlling pericyte migration in tumors (Teichert et al., 2017). 
In addition to Ang/Tie signaling, sphingosine-1-phosphate (S1P) signaling is indispensable for 
vascular maturation. This signaling pathway will be discussed in more detail in chapter 1.3. 
TGFβ signaling plays a major role in pericyte differentiation. It is involved in the induction of mural 
cell formation from undifferentiated mesenchymal cells and in the proliferation and 
differentiation of mural cells and EC. Two distinct type I TGFβ receptors, activin receptor-like 
kinase (Alk)-1 and -5, and endoglin (Li et al., 1999), a transmembrane accessory receptor for TGFβ, 
are expressed in pericytes and EC (Armulik et al., 2011). Concurrently, both cell types express the 
latent pro-form of the ligand TGFβ, which is activated by the cooperation of both cells (Sato and 
Rifkin, 1989). The active TGFβ is described to inhibit proliferation and migration of EC (Sato and 
Rifkin, 1989), downregulate VEGFR2 expression in EC (Patterson et al., 1996) and induce 
differentiation of mural cell precursors to SMC/pericyte fate (Hirschi et al., 1998). In general, the 
role of TGFβ signaling in vascular development and maintenance is complex. Since both, receptors 
and ligand, are expressed by pericytes and EC, it is difficult to investigate the primary roles of 
TGFβ signaling in each cell compartment. For example, TGFβ is described to be pro- and anti-
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angiogenic. Indeed, cellular responses differ depending on the TGFβ concentration and the 
composition of the receptors (Goumans et al., 2003).     
 
1.2.5 Functions of pericytes 
Pericytes have multiple functions that depend on developmental stage and organ. However, 
pericytes do not only play important roles in physiological processes, but are also described in 
various pathological conditions as fibrosis, cancer and diabetic retinopathy, which will be 
discussed in the following two chapters. 
 
1.2.5.1 Pericytes in health 
Vessel stabilization and regulation of blood flow are the most often associated functions of 
pericytes. A quiescent, mature vasculature is characterized by an inactive, resting EC layer 
enveloped by pericytes (Armulik et al., 2005; Hirschi and D’Amore, 1997). Pericytes induce 
quiescence in a paracrine manner by secreting Ang-1 (Thomas and Augustin, 2009). Further, 
pericytes mechanically stabilize the vessel wall with their processes incorporated in the BM. The 
number of pericytes is correlated with the resistance of microvessels to high blood pressure, since 
pericytes hinder vessels to dilate immoderately (Gerhardt and Betsholtz, 2003; Hellström et al., 
2001; Laties et al., 1979). Vasoconstriction and vasodilation for the regulation of capillary blood 
flow is induced by local compression of EC by pericytes (Nakano et al., 2000). From their discovery 
on, pericytes are described to be contractile cells (Rouget, 1873). They express contractile 
proteins (αSMA, tropomyosin and myosin) and cholinergic/adrenergic (α2, β2) receptors, which 
mediate the contraction or relaxation of pericytes (Ferrari-Dileo et al., 1992). Vasoactive 
molecules, such as nitric oxide, endothelin-1 and angiotensin II bind to pericytes (Ferrari-Dileo et 
al., 1996; Haefliger et al., 1994; Lee et al., 1989). Even though most of the studies were performed 
in vitro, pericyte contraction could be shown in vivo upon treatment with vasoactive substances 
(Hirschi and D’Amore, 1996; Tilton et al., 1979). Pericyte contractility and their presence 
(umbrella-like structure) at endothelial cell-cell junctions modify the intercellular transport. 
Therefore, vascular permeability positively correlates with pericyte coverage (Rodriguez-Baeza et 
al., 1998; Sims and Westfall, 1983). The highest pericyte coverage is seen in retina and brain, 
where the presence of a continuous endothelium is a specific tissue demand of these organs 
(Armulik et al., 2010). Pericyte contractility is also suggested to play a critical role in neutrophil 
transmigration. During inflammation, neutrophil activation, rolling and transmigration through 
the blood vessel wall is an important process, that is well understood. Recent evidence shows that 
pericytes also play a role in immune cell trafficking across vessel walls. Whereas increased 
cytoskeletal contractility of EC promotes neutrophil transmigration (Stroka and Aranda-Espinoza, 
2011), pericyte relaxation is needed to allow neutrophils to enter in the surrounding tissue (Wang 
et al., 2012). Furthermore, pericytes secret chemokines (MIF, Interleukin 8) and upregulate 
adhesion molecules (ICAM-1) to attract immune cells (Pieper et al., 2013; Proebstl et al., 2012; 
Stark et al., 2013). Pericytes can act as macrophage-like cells with the properties to incorporate 
macromolecules/soluble and small molecules (Kida et al., 1993; Kristensson and Olsson, 1973; 
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Mato et al., 1996) and to convert into macrophages (Barón and Gallego, 1972; Maxwell and 
Kruger, 1965). However, these studies were mainly done in the brain (Balabanov et al., 1996; 
Thomas, 1999). Pericytes are also involved in adaptive immune responses, since they can act as 
antigen-presenting cells via expression of major histocompatibility complex (MHC) II (Fujikawa et 
al., 1989; Hurtado-Alvarado et al., 2014).  In summary, pericytes contribute to the immunological 
defense of the vasculature during inflammation processes (Navarro et al., 2016), complementing 
with their ability to induce blood coagulation after microvascular injury or rupture (Bouchard et 
al., 1997; Thomas, 1999).  
Pericytes display tissue-specific functions, since they adjust to the special need of each organ. As 
described above, the ability of pericytes to modify immunological responses are mainly 
characterized in the brain. Brain pericytes are involved in the formation of the blood brain barrier 
(BBB) together with EC and astrocytes. The BBB is a continuous endothelium to protect the brain 
from the invasion of potential toxic factors coming from the blood. Deletion of pericytes leads to 
increased transcytosis and defects in the polarization of astrocyte endfeet in the brain (Armulik et 
al., 2010). Hepatic stellate cells (HSC) or Itoh cells are the pericytes of the liver (Sato et al., 2003). 
The liver endothelium is fenestrated and discontinuous, however HSC and EC have close contact 
through incomplete BM components and extracellular matrix. HSC represent around 10 to 15 % of 
the total number of resident cells in physiological condition. Their major roles include regulation 
of ECM, storage of Vitamin A and recruitment of inflammatory cells during liver diseases (Sato et 
al., 2003; Sims, 2000). Kidney pericytes are called mesangial cells and represent 30 % of the 
glomerular cells. Their main function is the contribution to the glomerular basement membrane 
and splitting of vascular loops, resulting in a large filtration surface. In Pdgfb and Pdgfrβ null mice, 
mesangial cells are almost completely deleted in severely destructed glomeruli (Betsholtz, 2004). 
 
1.2.5.2 Pericytes in disease 
The vasculature is quiescent under physiological conditions. Angiogenesis occurs in rare 
physiological processes, but is mainly induced under pathological conditions. Therefore, next to 
EC also pericytes moved into the focus of various pathologies. 
Diabetes causes pathological changes of the microvasculature especially in the retina and the 
kidney. Diabetic retinopathy is accompanied by an early loss of pericytes, named pericyte drop 
out, caused by chronic hyperglycemia. Acellular-occluded capillaries, microaneuryms and 
thickening of the vascular basement membrane are following. Further on, an increase of vascular 
permeability and resulting edema or the formation of new blood vessels via VEGF-A develop. This 
impaired vascularization leads to blindness in one third of all patients (Hammes et al., 2002). The 
mechanism of pericyte drop out in diabetic retinopathy is not fully explored. Publications show 
that a hyperglycemia-induced inhibition of PDGF signaling (Geraldes et al., 2009) or an 
upregulation of Ang-2 (Hammes et al., 2004) might be the underlying mechanisms. In diabetic 
nephropathy, massive ECM deposition and thickening of the glomerular basement membrane are 
hallmarks. Repetitive mechanical stretch of mesangial cells (pericytes of the kidney) induces their 
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proliferation, increases ECM synthesis and reduces ECM-degrading enzymes during early diabetic 
nephropathy (Gruden et al., 2000; Kanwar et al., 2008). 
Fibrosis is the process of massive ECM deposition and scar formation as a response to chronic 
injury of a tissue. Mainly inflammatory cells are recruited and myofibroblasts are activated. The 
origin of myofibroblasts is continuous to be a major challenge in fibrosis research. One hypothesis 
is that pericytes detach from the EC, migrate and transdifferentiate into collagen-producing 
myofibroblasts. This hypothesis was proven in lung (Hung et al., 2013), liver (Fabris and 
Strazzabosco, 2011) and kidney fibrosis (Schrimpf and Duffield, 2011). Even though accumulating 
evidence indicates that pericytes might be a source of myofibroblasts, the used genetic fate 
mapping strategies are still no final proof due to overlapping marker expressions of mesenchymal 
lineages. 
Pericytes, together with EC, fibroblasts, leukocytes and the ECM compartment, are part of the 
tumor stroma. Tumor vessels are highly disorganized, leaky and tortuous. The basement 
membrane is discontinuous or absent and pericytes are loosely attached to EC. The recruitment of 
pericytes occurs via PDGF-B/PDGFRβ as in physiological angiogenesis (Abramsson et al., 2002). 
Pericyte coverage is dependent on the tumor entity and can range from high to no coverage. High 
pericyte coverage has been associated with poor outcome and increased tumor growth (Gee et 
al., 2003). In contrast, tumors with low pericyte coverage and compromised vessel structure 
facilitate blood vessel invasion and metastasis (Cooke et al., 2012). Anti-angiogenic treatment 
targeting EC seems to eliminate immature, uncovered vessels, whereas mature covered vessels 
are protected (Ellis and Hicklin, 2008). There is evidence that after stopping anti-angiogenic 
treatment, pericytes are critical for fast neovascularization (Mancuso et al., 2006). These 
observations led to the idea to treat EC and pericytes simultaneously with anti-VEGF and anti-
PDGF strategies which revealed promising results (Bergers et al., 2003; Erber et al., 2004). 
However, other publications show no better outcome after depletion of pericytes or inhibition of 
PDGFRβ signaling (Nisancioglu et al., 2010; Sennino et al., 2007). As mentioned above, pericytes 
are suggested as negative regulator of metastasis. However, the underlying mechanisms are not 
fully understood. Pericytes may act as a barrier that hinders tumor cells to intravasate into the 
circulation. Moreover, it is hypothesized that pericyte-deficient vessels are leaky resulting in 
interstitial volume and local pressure. This pressure leads to compression of tumor vessels, 
induction of hypoxia pathways and tumor metastasis through epithelial-mesenchymal transition 
(EMT) (Cooke et al., 2012). Another study shows that a subset of pericytes (Endosialin-positive 
pericytes) promote cell-contact dependent tumor cell intravasation (Viski et al., 2016). Different 
publications also suggest a role of pericytes in the colonization and growth of tumors at distant 
sites (Kienast et al., 2010; Welti et al., 2012). It has been shown that pericytes modulate the 
immune response against tumor cells. Mature, RGS5-deficient pericytes and normalized vessels 
promote immune cell migration into the tumor and lead to prolonged survival (Hamzah et al., 
2008). In contrast, RGS5-expressing pericytes are able to inhibit the activity of CD4- and CD8-
positive T-cells (Bose et al., 2013; Merelli et al., 2014). In summary, pericytes as part of the tumor 
microenvironment are crucially involved in tumor development and metastasis. 
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1.3 Sphingosine-1-phosphate receptor family 
Sphingosine, the precursor of sphingosine-1-phosphate (S1P), has already been identified around 
1884 (Thudichum and Royal College of Physicians of London, 1884). S1P is a lipid mediator and 
acts via five isoforms of the S1P receptors (S1PR), a family of G-protein coupled receptors. The 
pleiotropic effects of S1P on diverse cell types are still not fully unraveled. Extensive research on 
S1P signaling has revealed its fundamental impact on angiogenesis, cardiogenesis, neurogenesis, 
limb development and immunity by influencing cell migration, differentiation and survival (Blaho 
and Hla, 2011; Mendelson et al., 2014). 
 
1.3.1 S1P 
S1P is a lysophospholipid, a minor lipid component of the cell membrane. S1P is derived by 
sequential degradation of sphingomyelin and glycosphingolipids in the cell membrane (Figure 1). 
The intermediate product ceramide is then further degraded into sphingosine. The majority of 
sphingosine is produced by degradation in lysosomes (Proia and Hla, 2015). The catabolically 
generated sphingosine is phosphorylated by one of the sphingosine kinases (SPHK), SPHK1 and 
SPHK2, to generate S1P. SPHK1 is generally localized in the cytoplasm, but can translocate to the 
cell membrane upon activation (Pitson et al., 2003). SPHK2 is primarily localized in the nucleus 
(Igarashi et al., 2003). After formation in the cytoplasm, S1P can follow three pathways: i) S1P is 
exported to the cell surface by a specific S1P transporter, SPNS2 (Fukuhara et al., 2012), and binds 
its receptors, ii) S1P is degraded by the S1P lyase (Zhou and Saba, 1998) or iii) S1P is recycled by 
dephosphorylation through S1P phosphatases, SGPP1 and SGPP2, to produce ceramide (Le Stunff 
et al., 2007; Proia and Hla, 2015).  
The levels of S1P in the cell are tightly regulated by a balance of synthesis and degradation. 
Sphingolipid metabolism occurs in almost every cell. However, some cell types are metabolically 
prone to synthesize S1P and whereas other cells are specialized to degrade S1P and keep levels 
low (Olivera et al., 2013). The association of different cell types with diverging S1P metabolism 
results in the generation of a S1P concentration gradient between blood (~1 µM S1P)/lymph 
(~100 nM S1P) and the surrounding tissue (0.5-75 pmol/mg S1P) (Xiong and Hla, 2014). During 
embryonic development, red blood cells are the main source of plasma S1P (Xiong et al., 2014), 
whereas postnatally, red blood cells and EC supply the plasma with S1P (Pappu et al., 2007; 
Venkataraman et al., 2008). EC play an important role in the maintenance of the S1P gradient due 
to their strategic position between the two compartments (blood and tissue) with very different 
S1P concentrations. EC express enzymes for the synthesis (SPHK1/2) as well as for the 
degradation (SGPP and S1P lyase) or export (SPNS2) of S1P, which allows a continuous filtration of 
S1P across the endothelial membrane (Venkataraman et al., 2008). Conditional deletion of the 
S1P transporter SPNS2 in EC reduces the level of circulating S1P in the blood by 50% (Fukuhara et 
al., 2012). However, reduced levels of S1P on the luminal side alone are not able to induce S1P-
driven lymphocyte trafficking. This suggests that EC might be able to regulate S1P levels on the 
abluminal side to induce lymphocyte trafficking by hitherto unknown mechanisms. 
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S1P is highly hydrophobic and is therefore mainly bound to carrier proteins, such as HDL (60%) 
and albumin (30 %) (Proia and Hla, 2015). HDL binds S1P via apolipoprotein M (ApoM) that 
controls S1P level in the blood and binding to its receptors (Christoffersen et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Synthesis, metabolism and export of S1P 
Sphingomyelin (SM) and glycosphingolipids (GSL) are localized in the cell membrane. The degradation of 
sphingolipids to ceramide (cer) and subsequently to sphingosine (sph) occurs in lysosomes and the cell 
membrane. Sph is phosphorylated by SPHK1/2 to produce S1P. Once produced, S1P can follow three 
pathways: a) S1P can be irreversibly degraded by S1P lyase, b) S1P can be dephosphorylated and recycled for 
ceramide (cer) synthesis in the golgi and c) S1P can be transported out of the cell by its transporter SPNS2. 
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1.3.2 S1P receptors  
S1P mainly exerts its effects by interacting with the five high-affinity S1P receptors (S1PR1-5), 
even though there is evidence that S1P acts as an intracellular (second) messenger (Maceyka et 
al., 2012; Spiegel and Milstien, 2003). The five G-protein coupled receptors are structurally very 
similar, but show different expression patterns and distinct coupled signaling pathways.   
In 1990, S1PR1 was discovered as endothelial differentiation gene (EDG-1) that is solely expressed 
in EC (Hla and Maciag, 1990). Further studies revealed that S1PR1 is the most highly expressed 
receptor of the S1PR family and is ubiquitously expressed in different organs and cell types 
(Regard et al., 2008). S1pr1 global knockout mice die around embryonic day (E) 12.5 to 14.5 due 
to massive hemorrhages with abnormal pericyte and SMC coverage of vessels (Liu et al., 2000). 
The EC-specific deletion of S1pr1 in mice mimicks the phenotype seen in the global knockout, 
indicating the important role of S1PR1 in vascular development (Allende et al., 2003). S1PR1 is 
exclusively coupled to Gαi mediating Rac activation (Lee et al., 1996) and binding of S1P to S1PR1 
has been described to induce vascular barrier integrity (Gaengel et al., 2012). Rac activity is 
required for S1P-induced endothelial cytoskeleton rearrangement and adherens junctions 
assembly (Singleton et al., 2005). In vitro, S1PR1 signaling induces the migration and proliferation 
of EC and SMC (Kluk and Hla, 2001; Paik et al., 2001). Furthermore, S1P can transactivate VEGF 
receptors in the context of migration and proliferation. In detail, S1PR1 induces Src activation 
resulting in VEGFR2 phoshorylation. This transactivation leads to the activation of signaling 
cascades that induce vascular remodeling and movement. At the same time the activated VEGFR2 
receptor stimulates SPHK1 and increases S1P levels. Subsequent ERK/MAPK signaling results in 
DNA synthesis (Spiegel and Milstien, 2003). 
S1PR2 was discovered as a receptor being predominantly expressed in lung and heart (Okazaki et 
al., 1993). Further studies identified S1PR2 as ubiquitously expressed in different organs and cells 
(Blaho and Hla, 2014). Global deletion of S1pr2 in mice did not cause any obvious phenotype 
except smaller litter sizes (Ishii et al., 2002). Double deletion of S1pr1 and S1pr2 resulted in a 
more severe phenotype than S1pr1 global knockout with embryos mostly dying before E12.5 
(Kono et al., 2004). S1PR2 signals via Gαi, Gαq and Gα12/13. Surprisingly, S1PR2 showed contrast 
effects on cell migration, proliferation and cytoskeleton reorganization compared to S1PR1 and 
S1PR3 (Okamoto et al., 2000). 
S1PR3 is highly homologous to S1PR1 and is described to be ubiquitously expressed (Yamaguchi et 
al., 1996). In the vascular system, expression of S1PR3 is mainly indicated in EC and SMC (Lee et 
al., 1999). Intriguingly, global knockout of S1pr3 shows no obvious phenotype (Kono et al., 2004), 
whereas an increased perinatal lethality was observed for the S1pr2/S1pr3 double knockout (Ishii 
et al., 2002). Double null mice for S1pr1 and S1pr3 were mimicking the S1pr1 knockout 
phenotype. S1pr1/S1pr2/S1pr3 triple null embryos display a substantially more severe phenotype 
with a less developed capillary network compared to S1pr1 null embryos (Kono et al., 2004). This 
implies that S1P receptors 1-3 have redundant or cooperative functions during embryonic 
development. In different cell types, including SMC (Fujii et al., 2014), S1P receptor 3 is described 
to signal via Gαi, Gαq and Gα12/13 (Figure 2) (An et al., 1998, 1999, 2000; Ancellin and Hla, 1999; 
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Windh et al., 1999) and it induces migration and adherens junctions formation in endothelial cells 
in vitro (Ancellin and Hla, 1999; Lee et al., 1999). Interestingly, crosstalk of S1PR3 and PDGFRβ 
signaling concerning cell migration was observed in SMC (Mousseau et al., 2012a). PDGFRβ 
signaling activates and translocates SPHK1 to the cell membrane, which leads to the formation of 
S1P that in turn activates S1P receptors after cellular export (Spiegel and Milstien, 2003). 
In contrast to the S1P receptors 1-3, the expression of S1PR4 is limited to lymphoid tissues (such 
as thymus, spleen and bone marrow) (Gräler et al., 1998) and S1PR5 is restricted to brain (Im et 
al., 2000). The functions of both receptors are still not fully explored.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Described downstream signaling pathways activated by S1PR3 
S1PR3 signals via Gαi, Ras, Raf and Mek to ERK activation. Phosphorylation (activation) of ERK results in 
proliferation and migration. S1PR3 activates RhoA resulting in migration and stress fiber formation (cell 
morphology changes). Calcium release is induced by PLC activation via Gαq leads to cell migration and 
contraction. 
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1.3.3 S1P in health and disease  
S1P signaling is an important regulator of vascular development via its S1P receptors 1-3. 
Especially S1PR1 on endothelial cells is important for embryonic cardiovascular development and 
the maintenance of vascular integrity. Phenotypic analysis of genetic mouse models deleted for 
S1PR2 and/or S1PR3 indicate accessory or partially redundant roles for these receptors during 
vascular development (as described in 1.3.2) (Proia and Hla, 2015). However, S1PR2 and S1PR3 
are described to be expressed by mural cells, thereby regulating vascular tone (Bischoff et al., 
2000; Murakami et al., 2010; Ohmori et al., 2003; Tosaka et al., 2001). Next to the importance of 
S1P in embryonic vascular development, it is critical in embryonic neurogenesis (Mizugishi et al., 
2005). In the adult nervous system, S1P regulates neurotransmission (Chan et al., 2012). Elevated 
level of S1P in the blood and lymph nodes, sensed by its receptors, are an important mechanism 
for trafficking of cells (immune cells, hematopoietic cells). Thereby, S1P regulates the egression of 
B- and T-cells from lymphoid tissues (Pappu et al., 2007) into the blood or hematopoietic stem cell 
mobilization from the bone marrow into the circulation (Juarez et al., 2012; Massberg et al., 
2007).  
S1P and its receptors are expressed in every organ of the body and are involved in many 
physiological processes as indicated above. Therefore, it is not surprising that the S1P/S1PR axis is 
implicated in various pathophysiological conditions in almost every organ (Maceyka et al., 2012). 
Multiple sclerosis (MS) is a chronic autoimmune disease of the brain characterized by immune cell 
infiltration, demyelination and neurodegeneration. S1P signaling is substantially involved in the 
trafficking of auto-reactive adaptive immune cells. Fingolimod (FTY720), a sphingosine analog, is 
an established treatment for MS. It was approved in 2010 by the US Food and Drug 
Administration as first-line treatment for relapsing forms of MS. FTY720 acts as a functional 
antagonist as it is phosphorylated by SPHK2 to produce the potent agonist FTY720-phosphate for 
S1PR1 and S1PR3-5. Its binding results in internalization and downregulation of the receptors 
(Brinkmann et al., 2010; Proia and Hla, 2015). Moreover, FTY720 modifies the retention of auto-
reactive T-cells in the lymph nodes that are known to damage the nervous system (Proia and Hla, 
2015). 
Substantial evidence indicates an involvement of S1P in cancer by regulating angiogenesis, tumor 
cell proliferation and survival, metastasis and immune cell infiltration. Thus, S1P signaling in 
cancer is complex but opens opportunities for potential therapeutics targeting the S1P/S1PR axis. 
Elevated mRNA and protein levels of SPHK1 are described in different types of cancer and is 
correlated with disease progression and reduced patient survival (Johnson et al., 2005; Kohno et 
al., 2006; Li et al., 2008, 2009). Confirming these observations, inhibition of SPHK1 in xenograft 
models results in reduced tumor growth, angiogenesis and chemo resistance (Guan et al., 2011; 
Pyne and Pyne, 2010). In general, S1PR1 and S1PR3 expression in tumors promotes migration, 
whereas S1PR2 expression inhibits migration (Pyne and Pyne, 2010). Inhibition of the crosstalk of 
S1PR1/S1PR3 and PDGFRβ signaling by FTY720 and sunitinib malate (VEGFR/PDGFRβ kinase 
inhibitor) of breast cancer in vivo results in reduced tumor angiogenesis and vessel normalization. 
FTY720 thereby potentiates the effects of sunitinib malate (Mousseau et al., 2012b). Potential 
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new therapeutics can target S1P signaling on multiple levels including sphingosine kinases, 
sphingosine lyases, sphingosine phosphatases and S1P receptors. These inhibitors were shown to 
be effective in many animal models of human diseases (Maceyka et al., 2012). 
Atherosclerosis is an inflammatory disease of the wall of large vessels. Atherosclerotic vessels 
show increased expression of S1PR3. Consistently, S1pr3 null mice form significantly smaller 
lesions upon arterial injury response suggesting a role of S1PR3 in the migration of SMC in 
atherosclerotic conditions and immune cell recruitment (Keul et al., 2011; Shimizu et al., 2012). In 
addition, S1pr2 knockout mice exhibit reduced macrophage content and lesion size of 
atherosclerotic plaques indicating a role of S1PR2 in myeloid cell recruitment (Skoura et al., 2011). 
Endothelial barrier disruption and vascular permeability are the hallmarks of acute lung injury, 
caused by infections (bacterial, viral), sepsis or trauma (Ware and Matthay, 2000). Treatment with 
FTY720 or S1P reduce vascular permeability in LPS-induced lung injury models (McVerry et al., 
2004; Peng et al., 2004). Furthermore, S1PR3 is described to be a novel biomarker in acute lung 
injury (Sun et al., 2012a). In summary, S1P signaling is complex and plays important roles in 
physiology and pathology. Further understanding of S1P signaling pathways might improve 
therapeutic options in pathology. 
 
1.4 Prostaglandin signaling 
Prostaglandins are eicosanoid lipid mediators acting on at least nine known prostaglandin 
receptor variants. Prostaglandins have diverse physiological functions in the CNS, cardiovascular, 
gastrointestinal, genitourinary, endocrine and respiratory system. However, their function in 
modulating the immune system is most studied. Extensive research on prostaglandin signaling 
revealed its implication in many diseases like cancer, inflammation, cardiovascular diseases and 
hypertension (Hata and Breyer, 2004; Narumiya et al., 1999). 
 
1.4.1 Prostaglandins 
Eicosanoids (greek: eicos = twenty) consist of prostanoids (prostaglandins, prostacyclins and 
thromboxanes), epoxyeicosatrienoic acids and leukotrienes and are produced in every 
mammalian cell, except erythrocytes. The different eicosanoids are generated by sequential 
metabolism of arachidonic acid (C20) by individual synthase enzymes (Figure 3). Arachidonic acid 
is esterified to glycerophospholipids in the cell membrane. Upon release of arachidonic acid by 
phospholipase A2, it undergoes oxidation by different enzymes (Balsinde et al., 2002). The 
synthesis of prostanoids is initiated by the conversion of arachidonic acid via an unstable 
endoperoxide Prostaglandin G2 (PGG2) to Prostaglandin H2 (PGH2), which serves as a substrate for 
the prostaglandin synthase enzymes (Bonvalet et al., 1987; Smith, 1992). This conversion is 
mediated by two cyclooxygenases, COX-1 and COX-2. COX-1 is constitutively expressed in most 
tissues, whereas COX-2 is tightly regulated and not expressed under normal physiological 
conditions. But its expression is induced in various inflammatory settings. Both COX enzymes are 
located at the endoplasmatic reticulum (ER) and nuclear membrane to uptake released 
arachidonic acid (Smith et al., 2000).  
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Figure 3: Synthesis and export of prostanoids 
Phospholipase A2 (PLA2) initiates the release of arachidonic acid from glycerophospholipids in the cell 
membrane. Arachidonic acid is metabolized by COX-1 and COX-2 to the intermediate prostaglandin H2 
(PGH2). Cell-type specific expression of prostaglandin synthase enzymes (TxAS, thrombaxansynthase; PGDS, 
prostaglandin-D synthase; PGES, prostaglandin-E synthase; PGIS, prostaglandin-I synthase; PGFS, 
prostaglandin -F synthase) generate thromboxane A2 (TXA2), prostacyclin PGI2 and prostaglandins PGE2, 
PGD2 and PGF2α. These prostanoids are exported by prostanoid transporters to subsequently activate 
diverse G-protein coupled receptors (TP, thromboxane receptor; DP, prostaglandin D2 receptor, IP, 
prostaglandin I2 receptor; FP, prostaglandin F2 receptor; EP, prostaglandin E2 receptor). These prostanoids 
are also able to enter the nucleus and activate peroxisome proliferator-activated receptor γ (PPARγ). 
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In a cell-dependent mechanism, a heterogeneous family of PGH2 metabolizing enzymes forms five 
bioactive prostanoids: thromboxane A2 (TXA2), prostacyclin PGI2 and prostaglandins PGE2, PGD2 
and PGF2α (Breyer et al., 2001; Funk, 2001). These prostanoids are exported by prostaglandin 
transporters (PGT) or other transporters to activate cell surface G-protein coupled receptors (TP, 
DP, PTGER1-4, IP, FP) (Schuster, 1998). Prostanoids are not stored but are synthesized de novo. 
Due to their short half-lives (seconds to minutes), they are considered as local hormones. 
Therefore, they are not transported to distal sites of the body and have autocrine or paracrine 
effects on target cells in close proximity. Prostanoids are described to potentially enter the 
nucleus and activate nuclear hormone receptors as PPARγ (Funk, 2001).  
 
1.4.2 Prostaglandin E receptors and their functional role 
PGE2 is the major product in the arachidonic acid metabolism in many physiological settings. 
PGE2 exerts a variety of partly opposing functional effects on different tissues. These diverse 
effects of PGE2 are a result of the existence of four G-protein coupled receptors EP1-4 (gene 
symbol: PTGER1-4) and their differential expression in various tissues as well as their distinct 
coupling to intracellular signaling pathways (Bos et al., 2004). For example, PGE2 can induce 
smooth muscle relaxation or constriction (Davis et al., 2004; Walch et al., 2001). Thus, 
investigation of the four prostaglandin receptors is challenging due to their simultaneous 
expression in tissues/cells and the different binding affinities to PGE2 (EP3/EP4 > EP1/EP2) 
(Abramovitz et al., 2000). The prostaglandin receptors can be divided in three groups according to 
the activation of a certain type of heterotrimeric G-protein by each of the receptors: i) relaxant 
receptors EP2 and EP4 (via Gs), ii) contractile receptor EP1 (via Gq) and iii) inhibitory receptor EP3 
(via Gi) (Bos et al., 2004). 
In human, EP1 was described to be expressed in the myometrium (Senior et al., 1991), pulmonary 
veins (Norel et al., 2004), mast cells (Wang and Lau, 2006), colon (Smid and Svensson, 2009) and 
keratinocytes (Konger et al., 2009). Whereas in mice, EP1 transcription is detectable in lung, 
stomach and kidney (Watabe et al., 1993). EP1 null mice appeared without any obvious 
phenotype. However, studies in EP1-deficient mice revealed functions in the context of stress 
responses, chemical carcinogenesis and inflammatory thermal hyperalgesia (Moriyama et al., 
2005; Mutoh et al., 2002; Tanaka et al., 2012). Originally, EP1 as well as EP3 were described to 
induce smooth muscle constriction (Bos et al., 2004; Coleman et al., 1994). EP3 is widely 
expressed and is the only receptor in the prostanoid receptor family that has three splice variants 
arising from alternative splicing of the C-terminal tail. Major research was performed on the 
receptor splice variants and their signal transduction. However, the physiological relevance of EP3 
is still poorly understood. First studies in EP3 null mice suggest a role in fever generation, type I 
allergy, tumor angiogenesis and pain perception (Amano et al., 2009; Kunikata et al., 2005; Ueno 
et al., 2001; Ushikubi et al., 1998). 
The receptors EP2 and EP4 were first thought to be the same receptor. However, next to the fact 
that they are both coupled to adenylate cyclase, their pharmacological binding and structure are 
different (Bos et al., 2004). EP2 is expressed in almost every organ but at much lower levels than 
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EP4 (Katsuyama et al., 1995). Overall, EP2 is the least abundant prostaglandin receptor (Ricciotti 
and FitzGerald, 2011). It was originally described to induce smooth muscle relaxation in the cat 
trachea (Gardiner, 1986) and recent studies further confirmed a role on proliferation of SMC (Yau 
and Zahradka, 2003). EP2 null mice show impaired ovulation/fertilization and salt-sensitive 
hypertension (Hizaki et al., 1999; Kennedy et al., 1999). Furthermore, EP2 regulates angiogenesis, 
gastrointestinal secretion and motility, cellular immune responses and spatial learning (Dey et al., 
2006; Kamiyama et al., 2006; Nataraj et al., 2001; Yang et al., 2009). EP4 is the most widely 
distributed prostaglandin receptor. Even though, EP4 and EP2 signal via Gs, both receptors induce 
different functional actions. This might arise from the structural differences of the C-terminal tail 
length which is important for agonist-induced desensitization and internalization (Bastepe and 
Ashby, 1999; Desai et al., 2000). EP4 null mice on a C57BL/6 background die within three days 
after birth due to a patent ductus arteriosus (Segi et al., 1998). Breeding of EP4 null mice in a 
mixed background can improve the survival and allowed the investigation of the functional role of 
EP4. Physiological functions of EP4 include the closure of the ductus arteriosus, induction of bone 
formation and Langerhans cell migration/maturation (Kabashima et al., 2003; Segi et al., 1998; 
Yoshida et al., 2002).  
 
1.4.3 Prostaglandin signaling in health and disease 
Prostaglandins are generally considered as pro-inflammatory mediators. During inflammation, 
induction of COX-2 through inflammatory stimuli and growth factors results in production of 
prostaglandins. Pharmacological agents, known as nonsteroidal anti-inflammatory drugs (NSAIDs), 
block prostaglandin synthesis by inhibiting COX-1/-2 and are commonly used as therapeutic for 
pain, fever and inflammation (Hata and Breyer, 2004). However, inhibition of both COX enzymes 
leads to gastrointestinal adverse effects based on the blockage of COX-1 derived prostanoids in 
the gastric epithelium. Therefore, NSAIDs with selective blockage of COX-2 (COXIB) are used for 
the treatment of arthritis or chronic inflammatory diseases (Ricciotti and FitzGerald, 2011). PGE2 
is of particular interest in inflammatory reactions, since it leads to the typical signs of 
inflammation: redness, swelling and pain. This symptoms are based on increased blood flow, 
arterial dilatation and increased vascular permeability (Funk, 2001). The membrane associated 
PGES (mPGES) is described to play an important role in the synthesis of PGE2 in the context of 
inflammation (Trebino et al., 2003). Dependent on the receptor expression, PGE2 can exert pro- 
or anti-inflammatory responses. For example, prostaglandin signaling via EP2 and EP4 induces 
swelling in collagen-induced arthritis and hyperalgesia via EP1 (Honda et al., 2006; Moriyama et 
al., 2005). In contrary, anti-inflammatory effects are mostly seen in allergy and inflammatory 
processes (Kunikata et al., 2005; Matsuoka et al., 2000). Additionally, PGE2 binding of different 
prostaglandin receptors on immune cells (B- and T-cells, dendritic cells and macrophages) 
regulates cytokine expression profiles and differentiation of these cells (Egan et al., 2004; 
Johansson et al., 2013; Yao et al., 2009). This leads to the induction of pro- or anti-inflammatory 
effects (Ricciotti and FitzGerald, 2011). 
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Many human cancers are described to have elevated levels of COX and PGE2. PGE2 is considered 
as a tumor-promoting factor. Clinical studies and epidemiological studies indicate that long term 
(10-15 years) use of NSAIDs reduces the risk of colon and rectal cancers of about 50% (Rosenberg 
et al., 1991). Furthermore, strong evidence for the effects of NSAIDs on cancer risk is given by 
several rodent and clinical studies, in which different kind of cancers were treated with NSAIDs 
(Fischer et al., 2011b). These effects of NSAIDs on cancer risk might be explained by the regulation 
of COX-dependent (anti-inflammatory effects) and COX-independent (anti-tumor effects) targets 
(Wang and DuBois, 2006). Chronic inflammation is associated with an increased cancer risk, for 
example in hepatocellular carcinoma or gastric cancer (Alison et al., 2011; Uemura et al., 2001). 
Here, NSAIDs reduce the risk of cancer by their anti-inflammatory and analgesic effects via the 
inhibition of COX. At the same time, high doses of NSAIDs inhibit tumor cell growth and induce 
apoptosis by the regulation of different targets (NFκB, Par-4, Bcl-XL) in a COX-independent manner 
(Kashfi and Rigas, 2005; Zhang and DuBois, 2000; Zhang et al., 2000). PGE2 and its receptors are 
the major prostaglandin players in cancer. Elevated levels of COX-2 and higher catalytic activity of 
mPGES are the main drivers of increased PGE2 levels in cancer (Nakanishi and Rosenberg, 2013). 
Next to its pro-inflammatory and pro-tumorigenic effects, PGE2 signaling influences the tumor 
microenvironment by the induction of tumor angiogenesis through the expression of pro-
angiogenic factors (VEGF and bFGF) and by shifting the cytokine expression to a more 
immunosuppressive pro-tumorigenic environment (Hernández et al., 2001; Huang et al., 1998; 
Tsujii et al., 1998; Yang et al., 2003). Complementary, deletion of prostaglandin receptors (EP1-4) 
confirmed the tumorigenic role of PGE2. Here, specific EP receptor profiles in different cancers 
affected cancer incidence. Deletion of EP1 and EP4 lead to a decrease of preneoplastic lesions in 
the intestine (Mutoh et al., 2002; Watanabe et al., 1999), whereas EP3 deletion contributes to 
squamous cell carcinoma in the skin (Shoji et al., 2005). EP2 accelerates the number and size of 
intestinal polyps in a mouse model of human familial adenomatous polyposis (Sonoshita et al., 
2001). Blockage of EP1 with a receptor antagonist reduced tumor burden in a carcinogen-induced 
breast cancer model (Kawamori et al., 2001). COX inhibitors, targeting the PGE2/EP axis, are 
promising drugs for the prevention or treatment of cancer. However, mPGES- or EP-inhibitors 
may offer an alternative to NSAIDs (Wang and DuBois, 2006).  
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1.5 Aim of the study 
So far, pericytes, the mural cells of the microvasculature, have been identified by using a mixture 
of different criteria including morphology, location and gene/protein expression pattern. Until 
now, the recognition by using pericyte markers is the most convenient method from a practical 
perspective (Armulik et al., 2011). However, the definition of pericytes by this approach faces 
some challenges: i) Pericytes are a heterogenous cell population within the mural cells and none 
of the established markers recognizes all pericyte phenotypes since their expression is highly 
dynamic and dependent on the tissue and activation state (Bergers and Song, 2005; Díaz-Flores et 
al., 2009). ii) Pericytes are cells of mesenchymal origin and the expression of the established 
pericyte markers are overlapping with various mesenchymal cells (SMC, adipocytes, fibroblasts, 
MSC) (Armulik et al., 2011; Díaz-Flores et al., 2009).  
Therefore, the aim of the present study was the identification of unique pericyte-specific markers 
in the vascular niche and their potential functional role in pericytes in vitro and in vivo. Expression 
profiling by microarray analysis of different pericyte populations and various mesenchymal cell 
populations was performed to discover novel pericyte markers. The role of the detected pericyte-
specific transcripts in a physiological setting was investigated by comparative co-culture 
experiments of EC with pericytes silenced for the novel markers and subsequent transcriptomic 
profiling. These transcriptomic analyses were combined with functional in vitro studies to relate 
gene expression changes with functional phenotypes. In addition, mouse models with targeting 
the identified genes should be generated to extend the understanding of the role of the novel 
pericyte markers in vivo. 
Results 
 
31 
 
2 Results 
2.1 Pericyte-specific expression of S1PR3 and PTGER2  
Distinct molecular markers are currently used for pericyte detection. However, their expression is 
dynamic due to the diverse characteristics, functions and locations of pericytes. Moreover, among 
these markers is no single entirely pericyte-specific marker (Armulik et al., 2011; Bergers and 
Song, 2005). Therefore, a microarray-based expression screening of primary human muscle 
pericytes (MP), lung pericytes (LP), pancreas pericytes (PancP), brain pericytes (BP) and placenta 
pericytes (PlaP) compared to other cells of mesenchymal origin (human umbilical arterial 
endothelial cells [HUAEC], human umbilical venous endothelial cells [HUVEC], human saphenous 
vein endothelial cells [HSAVEC], adipocytes [Adi], mesenchymal stem cells [MSC], fibroblasts [Fib]) 
was performed in biological replicates (n>3) to identify pericyte-specific transcripts. Pericytes, 
adipocytes, fibroblasts and MSC used for microarray analysis showed typical morphological 
features (elongated cell shape and long cell processes) of mesenchymal cells compared to EC 
(Figure 4). Additionally, pericytes displayed tissue-specific cell morphology. 
 
 
 
 
 
 
 
 
Figure 4: Cell morphologies of human pericytes and other mesenchymal cells 
(A-C) Phalloidin stained human primary pericytes, (D-G) other mesenchymal cells and (H-I) EC. (A-C) Primary 
human pericytes are shown: (A) Brain pericytes, BP; (B) Lung pericytes, LP; (C) Placenta pericytes (PlaP). (D-
G) Other primary human mesenchymal cells are shown: (D) adipocytes, Adi; (E) fibroblasts, Fib; (F) 
mesenchymal stem cells, MSC; (G) umbilical artery smooth muscle cells, HUASMC; (H, I) Human primary 
endothelial cells are shown: (H) umbilical vein endothelial cells, HUVEC; (I) saphenous vein endothelial cells, 
HSAVEC. Scale bars: 100 µm.  
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To analyze different gene expression profiles, a clustering of the microarray data was created 
(Figure 5A). The gene expression profiles of the different endothelial cells (EC) clustered and 
showed the most different gene expression compared to the other mesenchymal cells. Pericytes 
revealed organ-specific gene expression profiles, except for PancP. All mesenchymal lineages, 
except for EC, expressed the well-established pericyte markers described in literature (Figure 5B, 
left) (Armulik et al., 2005). Whereas all EC lack pericyte marker expression, CSPG4 (NG2) seemed 
to be the most abundantly expressed gene in pericytes compared to Adi, MSC and Fib. In contrast, 
endothelial-specific (CDH5, KDR, PECAM1) and fibroblast-specific (S100A4) genes were almost 
exclusively expressed in the corresponding cells (Figure 5B, right). Altogether, this quality control 
analysis verified the microarray data to use it for novel pericyte marker identification. 
 
 
Figure 5: Human primary cells show lineage-specific expression pattern 
(A) Clustering tree of the microarray analysis performed with primary human pericytes, endothelial cells 
and different mesenchymal cells  (B) Heatmap depicting the expression pattern of pericyte-specific, 
fibroblast- and EC-specific genes (n=3-6). High expression is marked in red and low expression in blue. MP – 
muscle pericytes, LP – lung pericytes, PancP – pancreas pericytes, BP – brain pericytes, PlaP – placenta 
pericytes, HUAEC – human umbilical arterial endothelial cells, HUVEC – human umbilical venous endothelial 
cells, HSAVEC – human saphenous vein endothelial cells, Adi - adipocytes, MSC – mesenchymal stem cells, 
Fib – fibroblasts, EC – endothelial cells. n= number of independent experiments. 
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In total, 13 genes were identified to be differentially expressed in pericytes compared to the other 
mesenchymal lineages (Figure 6A, B). Among them, five transcripts are only marginally described 
(C20orf127, LOC441019, LOC100130835, LOC100131866, C14orf149, CCDC34). Other transcripts 
were described to be involved in translation (ELOF1, MRPL55), cell division (PIGU), post-
translational modification (DPH3) and extracellular matrix (Col7A1). Pathway analysis using 
Ingenuity Software and Gene Set Enrichment Analysis did not unveil any pathways, which could 
have gained further knowledge. However, S1PR3 and PTGER2, coding for two G-protein coupled 
receptors, were identified as the most promising genes for further analysis. 
For validation, microarray samples (Figure 7A) and biological replicates (Figure 7B) were 
investigated for S1PR3 and PTGER2 expression. The expression of both genes was not only 
significantly higher in all pericyte populations compared to the other mesenchymal cells but also 
almost exclusively restricted to pericytes. Since pericytes are mural cells of the microvasculature 
and pericytes are discussed as phenotypic variants of vascular SMC, human dermal blood 
endothelial cells (HDBEC), human brain microvascular endothelial cells (HBMEC) and smooth 
muscle cells (SMC) were included in the validation (Figure 7B). Whereas PTGER2 expression was 
absent in these cells, S1PR3 expression was detected in SMC. 
 
 
 
 
 
 
 
 
 
Figure 6: Primary human pericytes show distinct gene expression compared to other mesenchymal cells  
(A) Heatmap and (B) list showing the expression changes of the differentially expressed genes in pericytes 
compared to other mesenchymal lineages (n=3-6). High expression is marked in red and low expression in 
blue.    MP – muscle pericytes, LP – lung pericytes, PancP – pancreas pericytes, BP – brain pericytes, PlaP – 
placenta pericytes, HUAEC – human umbilical arterial endothelial cells, HUVEC – human umbilical venous 
endothelial cells, HSAVEC – human saphenous vein endothelial cells, Adi – adipocytes, MSC – mesenchymal 
stem cells, Fib – fibroblasts. n= number of independent experiments. 
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To confirm the expression of S1PR3 and PTGER2 in mouse pericytes, a protocol for the isolation of 
a mural cell-enriched population via FACS was established (Figure 8). The lung was chosen as a 
model organ, since it is highly vascularized and will as such provide sufficient cells for gene 
expression analysis. Therefore, lungs from adult mice (8-12 weeks) were resected and digested for 
preparation of single cell suspensions. Collagenase IV turned out to be the most efficient digestion 
enzyme. For subsequent FACS, cells were gated according to SSC-A and FSC-A to exclude cell 
debris. Doublets were removed by FSC-H and FSC-A gating. Leukocytes (CD45 positive), 
erythrocytes (TER119 positive), lymphatic endothelial cells (LYVE1 positive), alveolar epithelial 
cells (Podoplanin, PDPN positive) and FxCycle positive cells (dead cells) were excluded. FxCycle-
CD45−TER119−LYVE1−PDPN−CD31- and FxCycle-CD45−TER119−LYVE1−PDPN−CD31+ were sorted for 
subsequent gene expression analysis.  
Figure 7: S1PR3 and PTGER2 are specifically expressed by pericytes 
(A) Quantification of S1PR3 and PTGER2 gene expression in microarray samples and (B) biological replicates 
of pericytes, endothelial cells and other mesenchymal cells (n=3) by qPCR. Expression was normalized to the 
housekeeping gene B2M.  MP – muscle pericytes, LP – lung pericytes, PlaP – placenta pericytes, PancP – 
pancreas pericytes, BP – brain pericytes, HUAEC – human umbilical arterial endothelial cells, HUVEC – 
human umbilical venous endothelial cells, HSAVEC – human saphenous vein endothelial cells, HDBEC – 
human dermal blood endothelial cells, HBMEC – human brain microvascular endothelial cells, Adi – 
adipocytes, MSC – mesenchymal stem cells, Fib – fibroblasts, SMC – smooth muscle cells. Values are 
mean±SD, *p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments. 
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The purity of the sorted cells was confirmed by qPCR (Figure 9) detecting the expression of EC 
markers (Cd31, Vegfr2, Cdh5), pericyte markers (Ng2, Desmin, Pdgfrb), a fibroblast marker 
(Pdgfrα) and the novel pericyte markers (S1pr3, Ptger2). Pericyte markers, except for Desmin, and 
the fibroblast marker Pdgfrα were higher expressed in the mural cell enriched population 
(FxCycle-CD45−TER119−LYVE1−PDPN−CD31-) compared to the EC population (Figure 9C), whereas 
endothelial makers were primarily expressed in the EC compartment (FxCycle-
CD45−TER119−LYVE1−PDPN−CD31+) (Figure 9B). S1pr3 and Ptger2 were exclusively expressed in the 
mural cell enriched population (Figure 9A). 
Together, these experiments validated S1PR3 and PTGER2 as pericyte-specific transcripts in vitro 
and in vivo both in human and mouse.  
Figure 8: Isolation of a mural cell-enriched population from the murine lung 
Representative FACS schemes for the isolation of a mural cell-enriched population. FxCycle
-
CD45
−
TER119
−
LYVE1
−
PDPN
−
CD31
-
 and FxCycle
-
CD45
−
TER119
−
LYVE1
−
PDPN
−
CD31
+
 cells were sorted for 
gene expression analysis. 
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Figure 9: Mural cell enriched population express S1pr3 and Ptger2 
(A) Quantification of S1pr3 and Ptger2, (B) EC- and (C) pericyte-/fibroblast-specific marker gene expression 
in the isolated mural cell enriched population (FxCycle
-
CD45
−
TER119
−
LYVE1
−
PDPN
−
CD31
-
) and isolated EC 
(FxCycle
-
 CD45
−
TER119
−
LYVE1
−
PDPN
−
CD31
+
) by qPCR (n=2). Hprt was used as housekeeping gene. n= 
number of independent experiments.  
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2.2 S1PR3 signals via Gαi and Gαq 
S1PR3 has been described to signal via the three Gα proteins: Gαi, Gα12/13 and Gαq (An et al., 1998; 
Ancellin and Hla, 1999). In order to investigate which S1PR3 pathways are active in pericytes, 
downstream signaling molecules were analysed upon S1P stimulation in S1PR3 silenced vs. 
control-silenced pericytes. Extracellular signal-regulated kinase 1/2 (ERK 1/2) is known to be 
phosphorylated upon S1P activation of Gαi (Tao et al., 2009). S1P stimulation only of siControl 
transfected pericytes showed phosphorylation of ERK 1/2 in a time-dependent manner (Figure 
10A) but no significant increase in phosphorylation of ERK 1/2 if S1PR3 was silenced with two 
different siRNAs (Figure 10A) or TY52156, a selective S1PR3 receptor antagonist (Figure 10B) 
(Murakami et al., 2010). S1PR3 was down-regulated by approximately 90% after 48 h and 70-80% 
after 72 h using two different siRNAs (Figure 11). Gαi can be inhibited by the ADP-ribosylating 
activity of pertussis toxin (PTX) (Gunther et al., 2000). Gαi inhibition prevented the 
phosphorylation of ERK 1/2 after S1P stimulation in pericytes (Figure 10C). In summary, these 
data demonstrate that S1PR3 signals via Gαi in pericytes.    
For analysis of the Gα12/13 pathway, downstream signaling molecules of RhoA were investigated. 
RhoA is described to be an effector of the myosin light chain phosphatase (MLCP), which regulates 
myosin light chain (MLC) phosphorylation of myosin II (Amano et al., 2010). S1P stimulation of 
pericytes resulted in a time-dependent increase of MLC phosphorylation (Figure 12). Selective 
inhibition of S1PR3 by TY52156 prevented the phosphorylation of pMLC2 after S1P stimulation. In 
conclusion, these data indicate that S1PR3 regulates MLC phosphorylation potentially via Gα12/13 
signaling in pericytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: S1PR3 signals via Gαi in human pericytes 
(A) Representative immunoblotting images and corresponding quantifications for pERK/ERK1/2 in 1 µM S1P 
treated (0, 1, 5, 10 min) BP upon silencing of S1PR3 (n=5), (B) treatment with S1PR3 inhibitor TY52156 (1 
µM, 4h, n=4) or with (C) the Gαi inhibitor pertussis toxin (PTX, 200 ng, 4h, n=3). *p<0.05, **p<0.01, 
***p<0.001, n= number of independent experiments.  
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S1PR3 signaling to Gαq was examined by calcium release assay as activation of Gαq is described to  
result in increased intracellular calcium levels (Hirota et al., 2007). Pericytes, silenced for S1PR3 by 
siRNAS or S1PR3 inhibitor TY52156, were preincubated with the fluorescent dye Rhod4. The 
intensity of Rhod4 increases upon binding to Ca2+. 10 sec upon stimulation with S1P, the rapid 
release of Ca2+ from the endoplasmatic reticulum into the cytosol was measured as increase of 
fluorescence intensity over time (Figure 13A). After 3 min, cytosolic Ca2+ levels were back to basal 
levels. siRNA- or TY52156-mediated silencing of S1PR3 in pericytes significantly reduced Ca2+ from 
the endoplasmatic reticulum. The area under the curve of the fluorescent signals was calculated 
for all conditions (Figure 13B). Thus, S1PR3 signals via Gαq in pericytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: S1PR3 knockdown upon siRNA transfection 
Quantification of S1PR3 gene expression in BP upon siRNA mediated silencing of S1PR3 after 48 h (n=3) and 
72 h (n=3). Hprt was used as housekeeping gene. *p<0.05, **p<0.01, ***p<0.001, n= number of 
independent experiments.  
 
*** 
*** 
Figure 12: S1PR3 inhibition results in reduced MLC phosphorylation 
(A) Representative immunoblotting images for pMLC2/tubulin in 1 µM S1P treated (0, 1, 5, 10 min) BP upon 
treatment with 1 µM S1PR3 inhibitor TY52156 for 4 h (n=3). (B) Corresponding quantifications for 
immunoblot experiments (in A) of pMLC/tubulin. *p<0.05, **p<0.01, ***p<0.001, n= number of 
independent experiments.  
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To exclude that S1PR1 may be responsible for the remaining effects upon S1PR3 silencing, S1PR1 
mRNA and protein expression was investigated in pericytes. Comparing S1PR1 and S1PR3 
expression in the microarray data (described above) of pericytes from different organs with 
different endothelial cells, showed an inverse expression of both receptors (Figure 14A). S1PR3 
was exclusively expressed in pericytes, whereas S1PR1 was strongly expressed in EC, but absent in 
pericytes. This result was confirmed in biological replicates with BP and HUVEC. Again, S1PR1 
showed very low mRNA and protein expression in pericytes (Figure 14B, C), suggesting that S1PR1 
does not play a role in pericytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: S1PR1 is not expressed by pericytes 
(A) Heatmap of S1PR1 and S1PR3 in primary human pericytes, endothelial cells and different mesenchymal 
cells. (B) Quantification by qPCR of S1PR1 and S1PR3 in BP. B2M was used as housekeeping gene (n=2). (C) 
Immunoblotting of S1PR1 in BP and HUVEC. βActin was used as loading control (n=1). MP – muscle 
pericytes, LP – lung pericytes, PancP – pancreas pericytes, BP – brain pericytes, PlaP – placenta pericytes, 
HUAEC – human umbilical arterial endothelial cells, HUVEC – human umbilical venous endothelial cells, 
HSAVEC – human saphenous vein endothelial cells. n= number of independent experiments. 
 
Figure 13: S1PR3 signals via Gαq in human pericytes 
(A) Calcium release analysis of stimulated (S1P, 1 µM) BP after S1PR3 silencing or treatment with the S1PR3 
inhibitor Ty52156 (1 µM). (B) Quantification of the area under the curve of the relative fluorescent 
intensities shown in A (n=3). *p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments.  
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2.3  Establishment of a co-culture system of pericytes and EC 
EC and pericytes are in close contact. Both interact closely via paracrine and juxtacrine signaling 
based on their anatomical relationship. In a biological setting, pericytes are always associated 
with EC, whereas EC exist without pericyte contacts (see chapter 1.2.4). To gain functional insights 
of S1PR3 and PTGER2 in pericytes and contacting EC, a co-culture system of S1PR3 or PTGER2 
silenced pericytes and EC was established. Shortly, S1PR3 or PTGER2 were silenced in pericytes 
before culturing on a monolayer of EC (Figure 15A). After 24 hours of co-culturing, pericytes and 
EC were separated via FACS.  For subsequent FACS, cells were gated according to SSC-A and FSC-A 
to exclude cell debris. Doublets were removed by SSC-H and SSC-A gating. CD31+ endothelial cells 
and pericytes marked with an integrated membrane label were collected (Figure 15B). RNA of 
both populations was sent for gene expression profiling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4  Functional analysis of S1PR3 and PTGER2  
 
To verify the robustness of the generated expression profiles, the expression of cell-specific genes 
was examined. Pericytes showed a significant knockdown of S1PR3 and PTGER2 in the 
corresponding datasets (Figure 16A). EC had a low expression intensity of S1PR3 and PTGER2 and 
no expression change upon S1PR3 or PTGER2 knockdown in the respective co-cultured pericytes 
(Figure 16B). Both populations expressed cell-specific genes (Figure 16C). Pericytes were 
NG2/CSPG4- and ACTA2 (αSMA)-positive, while EC were CD31-positive. The data confirms the 
purity of both populations after separation via FACS. 
 
 
Figure 15: BP and EC gene expression profiling upon co-culture 
(A) Scheme depicting the workflow for gene expression profiling of BP and EC upon co-culturing. S1PR3 or 
PTGER2 silenced BP and primary EC were co-cultured for 24 h and separated by FACS followed by gene 
expression profiling. (B) Representative FACS sorting schemes for the separation of BP and EC after co-
culturing. CD31
+
 cells and pericyte label
+
 (PKH) cells were sorted for microarray analysis. 
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The expression data of non-silenced vs. S1PR3 or PTGER2 silenced pericytes as well as the 
corresponding EC were evaluated by separate analysis (Figure 17). Both, S1PR3 and PTGER2 
silenced pericytes, showed differentially expressed genes (log2FC threshold 0.4/-0.4, 143 [S1PR3]/ 
262 [PTGER2] genes). However, gene expression changes in EC were not as pronounced as in the 
respective pericytes (log2FC threshold 0.2/-0.2, 13 [S1PR3]/ 10 [PTGER2] genes). This small 
number of differentially expressed genes in EC could not be validated by qPCR (data not shown). 
Therefore, the following chapters will be confined to the analysis of S1PR3 and PTGER2 in 
pericytes.  
In pericytes, genes with a significant fold change of 30% in the silenced vs non silenced pericyte 
population were evaluated by Molecular Signature Database Analysis (MSigDB). MSigDB allows to 
generate an overlap of differentially expressed genes in pericytes with the existing collection of 
annotated gene sets (Subramanian et al., 2005). Hallmark gene sets, representing genes that are 
involved in biological processes, and Reactome gene sets, deriving from the Reactome pathway 
database, were used for analysis. 
Figure 16: Pericytes and endothelial cells express cell-specific genes after co-culture 
(A) Quantification of the S1PR3 and PTGER2 expression (mean intensity, microarray) in pericytes- and (B) 
endothelial cells (n=3-6). (C) Pericyte marker (NG2, ACTA2) and endothelial cell marker (CD31) expression in 
EC and BP. *p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments.  
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2.4.1 Microarray analysis prompts towards S1PR3 interference with the 
actin/myosin skeleton in pericytes 
To gain insights into the functional role of S1PR3 in pericytes, gene expression data was analysed. 
Among the top genesets, overlapping with significantly regulated genes, MTORC1 signaling 
(FDR=1.88x10-03) and cell junction organization, cell-ECM interaction and cell-cell communications 
(FDR=2.59/2.68x10-03; Figure 18A, B, C) were identified . To complement these findings, co-culture 
experiments with S1PR3 silenced pericytes were performed and gene expression of particular 
genes was validated by real time (RT) quantitative PCR (qPCR). Asparagine synthetase (ASNS), 
included in the MTORC1 signaling gene set, was upregulated upon S1PR3 knockdown (Figure 
18D). ASNS is involved in amino acid metabolism and regulates mTORC1 activity (Krall et al., 
2016). Differentially regulated genes (MPRIP, MYH10, SDC1) of the cell-cell and cell-ECM genesets 
were successfully validated (Figure 18E). Myosin phosphatase rho interacting protein (MPRIP) 
targets the myosin phosphatase and therefore regulates myosin light chain phosphorylation. 
MPRIP binds the myosin phosphatase but also directly RhoA resulting in myosin phosphatase 
regulation by RhoA (Surks et al., 2003). MPRIP is known to influence pericyte cytoskeletal 
remodeling (Durham et al., 2014). Myosin heavy chain 10 (MYH10) is a non-muscle myosin and 
described to be involved in cell polarity, adhesion and migration (Bresnick, 1999). Syndecan 1 
(SDC1) is a transmembrane (type I) heparan sulfate proteoglycan and mediates cell binding, 
signaling and cytoskeletal organization (Beauvais et al., 2009). These results suggest a role of 
S1PR3 in cell morphology in respect of actin-myosin skeleton, migration and adhesion. 
Figure 17: Separate gene expression analysis of pericytes and EC after co-culture 
(A) Separate gene expression analysis of pericytes silenced for S1PR3 or PTGER2 and corresponding (B) EC 
after 24h of co-culture. Depicted is the differential expression profile according to the log2 Fold Change 
(FC). Red line indicates the log2FC threshold (pericytes: log2FC 0.4/-0.4; EC: log2FC 0.2/-0.2) used for 
analysis.  
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To verify the biological relevance, functional in vitro assays of S1PR3 silenced pericytes were 
performed. Cell migration towards a gradient (FCS, conditioned media of HUVEC) of S1PR3 
silenced pericytes was significantly decreased, as seen by xCELLigence real time cell analysis 
(RTCA) or Boyden chamber assay (Figure 19A and B). The xCELLigence system is an electronical 
Boyden chamber assay that allows quantitative kinetic measurements in real-time without the 
use of labeling. These results go in line with the diminished phosphorylation of MLC2 upon S1PR3 
silencing (Figure 12A and B). Since S1PR3 silenced pericytes are less migratory and expression of 
genes (MYH10, SDC1), responsible for cell adhesion and cell-ECM interaction were downregulated 
upon S1PR3 knockdown, adhesion assays were performed. However, adhesion of S1PR3 silenced 
pericytes on a monolayer of EC (Figure 19C) as well as mono-cultured pericytes using xCELLigence 
system (data not shown) was not changed. 
 
 
 
 
Figure 18: Molecular Signature Database analysis of BP silenced for S1PR3 co-cultured with EC 
(A) Molecular Signature database (Hallmark, Reactome) analysis of S1PR3 silenced BP vs. control-silenced 
(siCo) BP after co-culture with EC. (B, C) Heatmap of differently regulated genes (Genesets ´mTORC1 
Signaling´ and ´Cell junction organization/cell-ECM interactions/cell-cell communication´) in pericytes 
silenced for S1PR3. (D, E) Validation of corresponding genes of mTORC1 signaling (D) and cell 
junction/ECM/cell-cell communication (E) by qPCR in microarray samples and biological replicates (n=5). 
*p<0.05, **p<0.01, ***p<0.001, ns=non significant, n= number of independent experiments. 
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Even though cell adhesion was not changed in S1PR3 silenced pericytes, the morphology of the 
cells appeared different compared to control cells. Knockdown cells showed increased cell size, 
validated by image analysis of Phalloidin-positive area per cell (DAPI positive nucleus, Figure 20A 
and B). To gain further insight, live cell imaging was performed using Holomonitor microscope 
(Alm et al., 2013). The Holomonitor allows real-time imaging while the cells are cultured under 
standard conditions. Images of the cells are calculated based on the phase-shift of light through 
the cells compared to bypassed light. Thus, several cellular parameters can be measured at the 
same time. The analysis of S1PR3 silenced pericytes confirmed the change of morphology 
concerning cell volume and cell thickness compared to the corresponding control (Figure 20C). In 
summary, S1PR3 in pericytes interferes with the actin-myosin cytoskeleton of the cells resulting in 
increased migration and reduced cell size.  
 
 
 
 
 
 
 
 
 
 
Figure 19: Reduced migration of S1PR3 silenced pericytes 
(A, B) Migration analysis of mono-cultured S1PR3 silenced pericytes using (A) xCELLigence system (n=4) and 
(B) Boyden chamber assay (B, n=5). The migration was iniitated by using a FCS (xCELLigence) or conditioned 
HUVEC media (Boyden chamber assay) gradient. (C) Adhesion analysis of S1PR3 silenced pericytes (n=3) on 
EC. *p<0.05, **p<0.01, ***p<0.001, ns=non significant, n= number of independent experiments. 
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2.4.2 PTGER2 regulates pericyte proliferation 
Gene expression profiling data of PTGER2 silenced pericytes was analysed according to the S1PR3 
analysis (see chapter 2.4). MSigDB analysis revealed Il2-STAT5 signaling (FDR=5.82x10-05), 
apoptosis (FDR=7.96x10-05) and mitotic spindle (FDR=1.62x10-03) of the Hallmark genesets having 
the most significant overlap with the differentially expressed genes upon PTGER2 silencing (Figure 
21A). Six proliferation regulating genes were identified in the mitotic spindle geneset (Figure 21B), 
most notably the significantly downregulated genes Kinesin-associated protein 3 (KIFAP3) and 
tuberous sclerosis protein 1 (TSC1), two negative regulators of cell division (Figure 21C). 
Conversely, the apoptosis geneset included pro- (SMAD7, CASP3, GSN) and anti-apoptotic 
(BCL2L1, IGFR2) genes (Figure 21D), mostly being downregulated (Figure 21E).  
 
Figure 20: Increased cell size of S1PR3 silenced pericytes 
(A) Cell size analysis of S1PR3 silenced BP upon stimulation with 1 µM S1P for 6 h (n=6). (B) 
Representative images of phalloidin staining (20x, left; 63x, right) of S1PR3 silenced BP upon S1P 
(1 µM) stimulation for 6 h. (C) Representative analysis of average cell volume and cell thickness 
using Holomonitor software upon S1PR3 knockdown (24 h pst siRNA) compared to control cells 
for 18 hours (n=2). *p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments. 
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Corresponding to the downregulation of negative regulators of proliferation (Figure 21B and C), 
proliferation analysis of mono-cultured PTGER2 silenced pericytes using the xCELLigence system 
revealed a significant increase of proliferation compared to control silenced cells (Figure 22A). 
However, silencing of PTGER2 in pericytes did not change the level of apoptosis (Annexin V FACS) 
upon co-culture with EC (Figure 22B). Thus, PTGER2 signaling in pericytes influences the 
proliferation of pericytes in vitro. 
In summay, successfully identified novel pericyte markers S1PR3 and PTGER2 have functional 
relevance in pericyte biology which was verified in vitro.  
 
 
 
Figure 21: Molecular Signature Database analysis of BP silenced for PTGER2 co-cultured with EC 
(A) Molecular Signature database (Hallmark) analysis of PTGER2 silenced BP after co-culture with EC. Gene 
sets with an FDR<10
-3 
are indicated. (B) Heatmap of differently regulated genes (Geneset ´mitotic spindle´) 
in pericytes silenced for PTGER2 vs. control (siCo). (C) Quantification and validation of a corresponding gene 
(KIFAP) in biological replicates (n=3). (D) Heatmap of differently regulated genes (Geneset ´Apoptosis´) in 
pericytes silenced for PTGER2 vs. control. (E) Quantification of corresponding genes (GSN, SMAD7) in 
biological replicates (n =3). *p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments. 
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Figure 22: Increased proliferation in PTGER2 silenced pericytes 
(A) Proliferation analysis of mono-cultured PTGER2 silenced pericytes using xCELLigence system (n=3). (B) 
Cell death (n=3) analysis of co-cultured PTGER2 silenced pericytes with EC using Annexin V staining. 
*p<0.05, **p<0.01, ***p<0.001, n= number of independent experiments. 
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2.5 Generation of conditional S1pr3 mice using CRISPR/Cas 
To enable the analysis of S1pr3 and Ptger2 in pericytes in vivo, mouse models for the conditional 
deletion of these genes are required. The conditional knockout mouse for Ptger2 was kindly 
provided by the lab of Prof. Katrin Andreasson. However, S1pr3 conditional mice are not available. 
Therefore, CRISPR/Cas technology was used to generate a conditional mouse line. The strategy 
was to flank major parts of the coding sequence (exon 2) with LoxP sites (Figure 23). CRISPR/Cas is 
a new approach in the field of genome engineering for in vivo verification of target genes by using 
clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated 
protein-9 nuclease (Cas9) (Jinek et al., 2012; Mali et al., 2013). Originally, CRISPR systems are 
bacterial immune mechanisms that adapt and protect them from viral or plasmid nucleic acids 
(Barrangou et al., 2007; Fineran and Charpentier, 2012; Horvath and Barrangou, 2010; 
Wiedenheft et al., 2012). The CRISPR II system of S. pyogenes was adapted for targeted genome 
editing (Jinek et al., 2012). It is based on the initiation of a nuclease (Cas9) induced double strand 
break (DSB) at the gene locus of interest, which can then either be repaired by insertions and 
deletions (indels) via non-homologous end joining (NHEJ) or lead to specific nucleotide changes by 
homologous directed repair (HR). Here, the loxP sites should be introduced via HR. To induce site-
specific DSBs, two major components have to be introduced into cells: a Cas9 nuclease and a 
guide RNA (gRNA) that directs the nuclease to the specific DNA sequence by RNA-DNA 
complementary base pairing. The specific DNA target site has to be directly 5´ next to a 
protospacer adjacent motif (PAM, 5´-NGG) that is absolutely necessary for target binding (Mali et 
al., 2013). CRISPR/Cas is described to be more simple and precise than other methods used for 
DNA editing so far (Cong et al., 2013).  
 
 
 
 
Figure 23: S1pr3 gene locus with integrated loxP sites 
Schematic of the S1pr3 gene locus before and after loxP site integration. The loxP sites, flanking exon 2, are 
integrated via homologous recombination using CRISPR/Cas technology. CDS - coding sequence. 
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2.5.1 Double Nicking enables efficient genome editing in vitro and in vivo 
RNA-guided nucleases are known to induce site specific DSB. However gRNAs can bind DNA loci 
that show few mismatches, leading to off-target cleavage events (Hsu et al., 2013). Therefore, the 
double nickase system, favored to reduce off-target effects due to its higher specificity, was used. 
The nickase (Cas9n) has an aspartate-to-alanine substitution (D10A) and lost the ability to induce 
DSBs, but instead cuts only one strand of DNA. The concept of the double nickase system is that 
two specific gRNAs induce two single strand breaks in close proximity resulting in a cleavage of 
the target site with efficiencies similar to Cas9 wildtype (WT) system (Figure 24A). Simultaneously, 
off-target effects are reduced (Cong et al., 2013).  
To establish the CRISPR/Cas based integration of two LoxP sites in vitro and in vivo, the bicistronic 
vector px335 (nickase) and px330 (wildtype) expressing gRNA and Cas9 were amplified. An EGFP 
locus expressed under a CMV promotor was cloned into px330 and px335 to be able to proof 
transfection efficiency. To proof the target-specific cleavage and the homologous directed repair 
in vitro, a primary mouse embryonic fibroblast cell line (NIH3T3) was used. For the validation of 
the cleavage site, the following site-specific mutation was confirmed using the surveyor mutation 
assay (Figure 24B). First, NIH3T3 cells were transfected with the plasmids, expressing the eGFP 
reporter, the nuclease Cas9n and gRNAs, designed by the online tool of the Zhang laboratory. The 
efficiency of transfection was on average 50% (Figure 24C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Principle of surveyor mutation assay 
(A) Schematic of the CRISPR/Cas mechanism using Cas9n nickase that generates single-stranded cleavage. 
(B) Schematic protocol for the surveyor mutation assay. NIH3T3 cells were transfected with the CRISPR/Cas 
plasmid. PCR amplification of the DNA was performed following heating/cooling cycles to generate 
heteroduplexes (basepair mismatches). The Surveyor Nuclease cuts specifically at basepair mismatches. The 
fragments were analysed with size-based agarose gels. (C) Representative images of NIH3T3 cells 
(brightfield, 20x, top; GFP fluorescence, 20x, bottom) transfected with CRISPR/Cas plasmids. 
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Upon DNA isolation, PCR amplification of the DNA locus of interest was performed following 
heating and cooling cycles to melt and reassemble the DNA strands. Since not all cells were 
transfected and the cleavage process did not occur in all transfected cells, hetero-duplexes were 
build. The specialized nuclease (surveyor nuclease) digests the DNA only on 3´-side of 
mismatches, revealing different sized DNA fragments, that can be analysed by agarose gel 
electrophoresis (Figure 22B). Transfection of NIH3T3 cells with the corresponding CRISPR/Cas 
plasmids for LoxP site 1 (LoxP1) or 2 (LoxP2) resulted in specific digestion fragments (450bp for 
LoxP1; 645bp for LoxP2) after treatment with surveyor nuclease (Figure 25A, bottom). Agarose gel 
analysis of untreated DNA showed only one specific PCR amplicon in both cases (Figure 25A, top). 
This suggests that the chosen gRNAs directed the nuclease to the target sequence. 
Homologous recombination of DNA templates (containing the 34 bp LoxP sequence) was 
validated by transfection of NIH3T3 cells with the CRISPR/Cas plasmids including the 
corresponding pairs of gRNA and the single stranded DNA template. After DNA isolation of the 
cells, PCR amplification of the DNA loci LoxP 1 and LoxP 2 were performed using a primer 
specifically binding to the LoxP sequence. In case of LoxP integration, a PCR amplicon will be 
detectable. Here, homologous recombination was confirmed with both LoxP sites in NIH3T3 cells 
(Figure 25B). 
After verifying efficient LoxP integration in vitro, the efficiency of the double nickase system to 
target the S1pr3 locus was analysed in vivo. To assess toxicity of the constructs and the efficiency 
of integration in vivo a pilot test was performed (Figure 26A). Accordingly, the DNA template as 
well as the mRNA of Cas9n and the corresponding gRNAs were injected into the cytosol of 
zygotes. Within three days, the targeted zygotes developed to morulae under cell culture 
conditions and PCR analysis of single morula was performed. 75% of zygotes survived the 
injection and 66% of these zygotes developed to morulae (Figure 26B). In total, one morula was 
positive for both LoxP sites. Moreover, LoxP 2 integration showed significantly higher efficiency 
(68%) compared to LoxP 1 integration (4%). This result confirms that double nicking using the 
designed gRNAs and DNA fragments allows specific genome editing of the S1pr3 locus in vivo. To 
improve the recombination efficiency of LoxP 1, a higher concentration of the LoxP 1 constructs 
was injected in the new experiment (Figure 26C). Following injection, zygotes were developed to 
Figure 25: Site-specific cleavage and LoxP site integration in vitro 
(A) Representative agarose gel images of PCR amplified DNA fragments from NIH3T3 cells treated with 
CRISPR/Cas plasmids specifically targeting LoxP integration site of LoxP 1 and LoxP 2. DNA products were 
treated with or without surveyor nuclease. Specific digestion fragments are indicated with a red 
arrow. (B) Representative agarose gel images of integrated LoxP sites 1 and 2 using a primer binding 
specifically to the LoxP sequence. 
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two cell stage embryos under culture conditions before surgical transfer into pseudo-pregnant 
recipient mice. The higher concentration (total 350 ng/µl) did not increase the toxicity as seen in 
the percentage of transferred embryos. Twenty-one F0 pups were born (Figure 26C). As seen 
before, differences in the efficiencies of LoxP 1 (9.5%) and LoxP 2 (81%) integration were 
observed. Two pups carried both LoxP sites. However, the F1 generation (F0 crossed with WT 
mice) were either positive for one or the other LoxP site indicating that the LoxP sites were 
integrated on different alleles in both mice. Furthermore, sequencing of the S1pr3 locus often 
revealed indels and deletions instead of homologous directed integration (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Determination of the success rate using Cas9n nickase to target the S1pr3 locus in vivo 
(A) Schematic protocol for a pilot test of the Cas9n efficiency targeting the S1pr3 locus in vivo. CRISPR/Cas 
constructs were injected in the cytosol of zygotes. Upon 3 days of culturing morulae developed which were 
genotyped using sequential single cell PCR analysis. (B) Results of the pilot test using Cas9n to target the 
S1pr3 locus. (C) Results of the Cas9n constructs in zygotes that were implanted into foster mothers. 
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2.5.2 SCR7 reduces efficiency in combination with double nickase 
To reduce the probability of indels and promote HR, a new strategy using SCR7 was pursued. DSBs 
induce DNA repair through NHEJ or HR (Figure 27A). In a normal setting, NHEJ induced indels 
occur more frequently than HR mediated genome editing, since NHEJ takes place throughout the 
whole cell cycle, whereas HR is restricted to S- and G2-phase (Deriano and Roth, 2013). SCR7, a 
DNA ligase IV, was first described as an anti-cancer drug (Ma et al., 2016). Yet, by inhibiting NHEJ 
SCR7 is described to shift the balance and increase the efficiency of HR (Lin et al., 2016; Ma et al., 
2016). Therefore, zygotes were treated with SCR7 after injection of double nickase constructs. 
Additionally, the concentrations of the constructs were more shifted towards the LoxP 1 site and 
reduced for the LoxP 2 site. After transfer into mice, eight-teen pups were born (Figure 27B). The 
discrepancy between LoxP 1 and LoxP 2 efficiency was reduced. Nevertheless, the integration of 
both LoxP sites in one mouse or on one allele was not successful using the combination of the 
double nickase and SCR7. Besides, indels were even more detectable compared to the approach 
using double nickase alone (data not shown). 
 
 
 
 
 
 
 
Figure 27: Determination of the success rate using Cas9n nickase in combination with SCR7 to target the 
S1pr3 locus in vivo 
(A) Schematic for the principle of SCR7 (Ligase IV inhibitor) on DNA repair. Upon double strand breaks two 
different DNA repair mechanism (Non-homologous end-joining, NHEJ; Homologous recombination, HR) can 
occur. In normal conditions (without SCR7) NHEJ prevails, however with the use of SCR7 the balance shifts 
to homologous recombination due to the blockage of Ligase IV. (B) Results of the Cas9n constructs with 
SCR7 in zygotes that were implanted into foster mothers. 
 
 
Results 
 
53 
 
2.5.3 Wildtype nuclease mediates genome editing with increased efficiency 
To increase the efficiency of homologous recombination, the wildtype Cas9 nuclease was used for 
further in vivo studies. The Cas9 nuclease induces a DSB with the help of one single specific gRNA 
(Figure 26A). Initially, the target-specific cleavage and homologous directed repair of the new 
constructs (Cas9 and gRNA) were proven in vitro (data not shown). In vivo, the survival (97%) and 
the integration efficiency (LoxP 1 and LoxP 2: 26%) were increased compared to the double 
nickase (Figure 28B). Additionally, the integration of both LoxP sites was similarly effective. In 
total, 3 morulae showed positive recombination of LoxP 1 and LoxP 2. 
To further increase the probability of integrating both LoxP sites on one allele, the integration was 
performed sequentially (Figure 29A). Briefly, zygotes were injected with Cas9 WT constructs for 
LoxP 1 insertion. Afterwards male mice, homozygous or heterozygous for LoxP 1, were bred with 
C57BL/6N female mice to generate zygotes. Subsequently, these LoxP 1 positive zygotes were 
injected with LoxP 2 constructs. In total, 34% of the born pups were positive for LoxP 1 (Figure 
29B), of which four homozygous and two heterozgyous male mice were used for the generation 
of LoxP 1 positive zygotes (data not shown). The integration efficiency of LoxP 2 was less 
compared to the pilot test (Figure 29B). Albeit, seven mice were identified with both LoxP sites.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Determination of the success rate using Cas9 WT to target the S1pr3 locus in vivo 
(A) Schematic of the CRISPR/Cas mechanism using Cas9 WT. The Cas9 WT enzyme generates double strand 
breaks upon specific binding of one gRNA to the DNA region of interest. (B) Results of the pilot test using 
Cas9 WT to target the S1pr3 locus. 
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To confirm the presence of both LoxP sites on the same allele and the germline transmission of 
the floxed allele, breedings with the corresponding floxed mice and WT mice was initiated. 
Genotyping of the F1 generation (LoxP 1: 185 bp [wt]/219 bp [floxed], LoxP 2: 186 bp [wt]/ 220 bp 
[floxed]) revealed litters of two floxed mice carrying the floxed allele (Figure 27B and 28B). Sanger 
sequencing of the floxed allele verified the integration of intact LoxP sites (Figure 30A). In 
summary, conditional mice for S1pr3 were successfully generated by applying the CRISPR/Cas 
technology.  
 
 
 
 
Figure 29: Sequential integration workflow of LoxP sites into the S1pr3 gene locus 
(A) Schematic protocol of sequential integration of the 2 LoxP sites in the S1pr3 gene locus. LoxP 1 was 
solely integrated with the first CRISPR/Cas construct injection. LoxP 1 positive male F0 mice were used to 
breed LoxP 1 positive zygotes. These zygotes were injected with CRISPR/Cas constructs for LoxP 2. (B) 
Results of the sequential injection of LoxP 1 and 2 using Cas9 WT enzyme targeting the S1pr3 locus. 
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Figure 30: Germline transmission of the S1pr3 conditional allele 
(A) Schematic of the S1pr3 gene locus with two integrated LoxP sites. Relative positions of the genotyping 
primers for LoxP 1 (green triangles) and LoxP 2 (blue triangles) are indicated. Representative DNA 
sequences of the 2 PCR amplicons spanning the targeted locus confirmed the presence of two intact LoxP 
sites. (B) PCR products amplified from the two genotyping primer sets for LoxP 1 and LoxP 2. The smallest 
band represents the wildtype allele (+/+) and the middle band represents the floxed allele (fl/+). The third 
band is unspecific. CDS, coding sequence.  
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3 Discussion 
Many different markers have been described to identify and characterize pericytes. However, 
none of these markers is exclusively pericyte-specific (Armulik et al., 2011). Based on the results of 
a systematic expression profiling screen of cultured pericytes isolated from different organs and 
other mesenchymal cells (Figure 6), the present study was aimed at identifying pericyte-specific 
transcripts in the mesenchymal lineage and their contribution to vascular function in general and 
in pericytes specifically. Employing a combination of cellular and biochemical experiments, the 
study demonstrates that i) S1PR3 and PTGER2 are pericyte-specific transcripts in the 
mesenchymal lineage in mouse and human in the vascular niche; ii) S1PR3 signals via divers 
signaling pathways (Gαi, Gαq and presumably Gα12/13) in pericytes; iii) pericyte-specific deletion of 
S1PR3 in pericytes co-cultured with EC results in transcriptional regulation of cell junction and cell-
ECM interaction genes; iv) pericyte migration and cell size as well as signaling pathways of the 
actin-myosin skeleton are regulated by S1PR3 signaling in pericytes (Figure 31); v) pericyte-specific 
deletion of PTGER2 in vitro increases proliferation by transcriptional down-regulation of 
proliferation inhibitors; vi) CRISPR/Cas technology can be applied to generate S1pr3 conditional 
knockout mice by using Cas9 WT in a sequential approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: S1PR3 signaling in pericytes 
Schematic illustration of the proposed S1P/S1PR3 signaling in pericytes. EC predominantly express S1PR1, 
whereas pericytes express S1PR3. Under physiological conditions the maintenance of a S1P gradient from 
blood to tissue is important for vascular function (blood>tissue). S1PR1 signaling in EC sustains vessel 
integrity. In contrast, S1PR3 signaling is low under physiological conditions due to low S1P concentration in 
the tissue. However, if S1P is binding to S1PR3 it can signal via different pathways: 1) S1PR3 can signal via 
Gαi leading to phosphorylation of ERK1/2 via Ras/Raf/MEK pathway. ERK1/2 is known to positively regulate 
myosin light chain kinase (MLCK) resulting in phosphorylation of myosin light chain (MLC). 2) S1PR3 signals 
via Gα12/13 through RhoA and ROCK resulting in the inhibiton of myosin light chain phosphatase (MLCP). 
Furthermore, upon expression of S1PR3, myosin phosphatase Rho-interacting protein (MPRIP) is 
downregulated. This results in more RhoA activity, less MLCP activity and increased MLC phosphorylation. 
3) S1PR3 signals via Gαq by the induction of calcium release from the endoplasmatic reticulum (ER). All 
three pathways result in migration/contraction of pericytes. Genes marked in grey indicate literature 
evidence, whereas genes marked in black were investigated in this study. Basement membrane, BM. 
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3.1 Challenges of the identification of pericytes 
Pericytes have gained increasing attention as functionally significant contributors in physiological 
and pathological angiogenesis (Bergers and Song, 2005). Although the current definition of a 
mature pericyte as an embedded cell in the BM is accepted, the identification of pericytes and the 
phenotypic discrimination from other mural and/or mesenchymal cells are still challenging 
(Armulik et al., 2011; Bergers and Song, 2005). Mural cells are described to be a continuum of 
phenotypes reaching from SMC on large caliber vessels to pericytes ensheathing capillaries 
(Armulik et al., 2011). The term continuum stresses the complexity in discriminating ontogenetic 
related SMC and pericytes, but also the difficulties in distinguishing pericytes with a great 
mesenchymal potential from other cells of mesenchymal origin (Bergers and Song, 2005; Crisan et 
al., 2008a). This is highly dependent on the unavailability of an uniquely expressed marker for 
pericytes (Armulik et al., 2011). This study identified pericyte-specific transcripts in mesenchymal 
lineages. Human primary pericytes from different organs were used for a microarray expression 
analysis. The different pericytes were purchased from companies (BP and PlaP) or obtained from 
the laboratory of Dr. Bruno Peault (MP, PancP, LP). Even though the isolation protocols of the 
pericytes vary, the purity of cells was checked by pericyte marker expression (Crisan et al., 2008b, 
2008c). Additionally, pericytes show typical morphological features (elongated cell shape and long 
cell processes) of mesenchymal cells. However, each cell type used for the microarray differed in 
morphology. Interestingly, pericytes possess tissue-specific cell morphology (Figure 4). This might 
reflect the organ-/tissue-dependent diversity in pericyte functions (Bergers and Song, 2005). 
Indeed, clustering of the microarray data revealed organ-specific expression profiles in pericytes, 
except for PancP (Figure 5). The expression of established pericyte markers is strongly dependent 
on several criteria including species, vessel type, organ, pathological or activation state of the 
vessel (Armulik et al., 2011; Bergers and Song, 2005). This is in line with the observed divers 
pericyte marker expressions in the microarray analysis. Whereas LP, PancP and BP predominantly 
expressed NG2 (CSPG4), MP and PlaP primarily expressed Endosialin (Figure 5).  
Even though, pericytes and EC may originate of a common progenitor cell (Yamashita et al., 2000), 
EC do not express typical pericyte markers (Figure 5). Given the fact that established pericyte 
markers are known to be expressed in other cells of mesenchymal origin, it was not suprising that 
also fibroblasts, adipocytes and MSC expressed these markers (Figure 5). In fact, pericytes act as 
perivascular stem cell niche and can transdifferentiate into osteocytes, chondrocytes and 
adipocytes (Crisan et al., 2008a; da Silva Meirelles et al., 2008). Close ontogenic relationship is 
also given between pericytes and SMC/fibroblast, since their progenitor cells (mesothelial cells) 
undergo EndMT and can transdifferentiate into these three cell entities (Hall, 2006). Although the 
fibroblasts of two different companies express some pericyte markers (PDGFRβ, ACTA2, CD248), 
they are also positive for the fibroblast-specific transcript S100A4 in contrast to pericytes (Figure 
4). As the microarray-based expression analysis was performed with strict parameters to identify 
only transcripts expressed by pericytes, established pericyte markers (Table 1) did not appear in 
the pericyte-specific transcript list (Figure 6). 
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As SMC have not been included in the expression analysis, expression levels of S1PR3 and PTGER2 
were validated in biological replicates of SMC (Figure 7B). PTGER2 expression was not detectable 
in SMC. However, SMC expressed S1PR3 at comparable expression levels as pericytes, which was 
consistent with published studies describing S1PR3 in SMC (Mousseau et al., 2012a, 2012b; Ryu et 
al., 2002; Wamhoff et al., 2008). The classical concept of mural cells differentiates SMC and 
pericytes. Instead, emerging evidence indicates a range of intermediate mural cell phenotypes 
between the prototypical SMC and pericytes (Armulik et al., 2011; Díaz-Flores et al., 2009). Based 
on their close relationship, the proper phenotype of the cells used for the microarray can not be 
stated. Marker expression (S1PR3 and PTGER2) along the vascular bed needs to be analysed in 
vivo. However, this is limited by the unavailability of S1PR3- and PTGER2-specific antibodies. 
In vivo, the expression of S1pr3 and Ptger2 was high in an isolated mural cell enriched population 
compared to the endothelial compartment (Figure 9). The mural cell-enriched population was 
isolated by a negative selection approach due to the unavailability of working FACS antibodies 
against established pericyte markers (NG2, PDGFRβ). Leukocytes, erythrocytes, lymphatic 
endothelial cells alveolar epithelial cells and FxCycle positive cells (dead cells) were excluded from 
the mouse lung cell suspension. The remaining cell population was sorted according to CD31 
expression in CD31 positive (EC) and CD31 negative cells (mural cell enriched) (Figure 8). Pericyte- 
and EC-specific gene expression analysis confirmed adequate purity of the populations. Pdgfrα, 
known as pan-fibroblast marker (Driskell et al., 2013), was higher expressed in the mural cell 
enriched population, indicating the presence of fibroblasts in this population. However, Pdgfrα is 
known to be expressed in a subpopulation of pericytes in the lung (Hung et al., 2013). 
Furthermore, this study demonstrated that fibroblasts do not express S1PR3 and PTGER2 (Figure 6 
and 7). Nevertheless, expression analysis in this population for pericyte markers showed strong 
enrichment compared to the EC compartment (Figure 9).  
Hence, this study identified S1PR3 as mural cell-specific and PTGER2 as pericyte-specific transcript 
in human and mouse within the mesenchymal lineage. 
  
3.2 Human and mouse pericytes express functional S1PR3 
In this study, the significantly higher expression of S1PR3 in human pericytes of different tissues in 
comparison to other mesenchymal cells was discovered by microarray-based gene expression 
profiling and was confirmed on RNA level. This is in line with recently published publications, 
showing that S1PR3 is enriched in Pdgfrβ-/Ng2-positive brain pericytes (He et al., 2016) and that 
hepatic stellate cells, the pericytes of the liver, express S1PR3 (Liu et al., 2011). However, S1PR3 
expression was also detectable in SMC (Figure 7B). In accordance with that, few publications 
described the expression of a functional S1PR3 in SMC (Mousseau et al., 2012a, 2012b; Ryu et al., 
2002; Wamhoff et al., 2008). These data reflect the heterogeneity of mural cells and the 
difficulties to distinguish pericytes from SMC depending on the markers used in each study (as 
discussed above). Some studies suggest S1PR3 expression in endothelial cells (van Hooren et al., 
2014; Nussbaum et al., 2015; Waeber et al., 2004). In this and another recent study by He et al. 
(He et al., 2016), S1PR3 expression in EC was barely detectable compared to pericytes and the 
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expression seemed to be dependent on culture conditions (HUVEC, see Figure 7A and B). 
Furthermore, S1PR3 expression is known to be upregulated under pro-inflammatory conditions 
(Fischer et al., 2011a), which could explain the S1PR3 expression in endothelial cells in vivo in 
inflammation models (Nussbaum et al., 2015). The availability of exclusively global S1PR3 
knockout mice stresses the difficulty to state which S1PR3 expressing cells are causing angiogenic 
phenotypes (Kono et al., 2004). Our understanding of S1PR3 protein expression levels, though, is 
challenged by the fact that S1PR3 and S1PR1 are highly homolog and there is no commercially 
available antibody detecting specifically S1PR3. Therefore, investigators have to rely heavily on 
mRNA expression profiles, even though expression studies were done on protein levels showing 
S1PR3 expression on benign and malignant human tissues (Wang et al., 2014).  
The results of the present study show for the first time that indeed S1PR3 signals via Gαi and Gαq 
(Figure 10 and 13) in pericytes (An et al., 1998, 1999; Ancellin and Hla, 1999). Analysis of 
downstream signaling of RhoA (Gα12/13) revealed reduced phosphorylation of MLC2 upon S1PR3 
inhibition (Figure 12). However, MLC phosphorylation is not only described to be regulated by 
RhoA, but also by ERK and calcium (Amano et al., 2010; CHENG et al., 2015; Hong and Grabel, 
2006; Turner et al., 1999), illustrating the complexity of MLC phosphorylation regulation (Figure 
31). Accordingly, further investigations of the regulation of MLC phosphorylation and the 
involvement of RhoA (Gα12/13) are required by using MEK, ROCK and/or PLC inhibitors. 
Nevertheless, literature suggests that there is a complex and dynamic interplay of signaling 
pathways in the regulation of myosin phosphorylation (Cheng et al., 2015; Kaneko-Kawano et al., 
2012). In summary, S1PR3 interferes with the signaling that regulates the actin-myosin skeleton. 
In accordance with this, S1PR3 has a functional role in pericytes. Pericytes, silenced for S1PR3, 
show less migratory capacity and increased cell size (Figure 19 and 20). These results are in line 
with the pro-migratory effect seen in S1PR3 expressing hepatic stellate cells (Liu et al., 2011) and 
SMC (Mousseau et al., 2012a, 2012b; Ryu et al., 2002; Shimizu et al., 2012) via ERK1/2 and MAPK 
activation upon S1P stimulation. Furthermore, PDGFB/PDGFRβ and S1P/S1PR3 signaling act 
synergistically on SMC migration (Mousseau et al., 2012b). Apart from that, microarray-based 
gene expression profiling of S1PR3 silenced pericytes, co-cultured with EC, revealed differentially 
regulated genes overlapping with gene sets involved in cell junction organization, cell-ECM 
interaction, cell-cell communications and mTORC1 signaling. Similarly, S1P induced migration 
involves mTOR and ERK signaling in SMC (Tanski et al., 2005). Additionally, S1PR3 dependent 
regulation of MPRIP and subsequent dephosporylation of MLC (Durham et al., 2014) identified in 
pericytes (Figure 12, 18 and 31) point to the molecular mechanism by which S1PR3 regulates 
migration. SDC1 is a heparin sulfate proteoglycan and is part of the glycocalyx. It binds various 
components of the ECM and is an important regulator of cell-cell and cell-ECM interactions (Zeng, 
2017). A relation between EC-expressed S1PR1 and syndecan 1 on protecting the glycocalyx was 
described (Zeng, 2017; Zeng et al., 2014). However, the relationship between pericyte-expressed 
SDC1 and S1PR signaling is not explored. Still, the downregulation of SDC1 upon S1PR3 silencing in 
pericytes suggests an impairment of growth factor binding or ECM binding that is necessary for 
pericyte migration.      
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S1PR1 is the major S1P receptor in EC and signals upon S1P binding that is delivered by the blood 
in micromolar concentrations (Gaengel et al., 2012). The activation of S1PR1 leads to the 
inhibition of angiogenic sprouting and stabilization of endothelial VE-cadherin at the endothelial 
junctions. In short, S1PR1 signaling on EC maintains blood vessel integrity by protecting blood 
vessels against abnormal angiogenic signals (Gaengel et al., 2012; Xiong and Hla, 2014). EC serve 
as the gatekeeper between the circulation and the tissue by maintaining the S1P gradient. 
Through synthesis and export of S1P into the blood, EC control high S1P concentrations in 
circulating fluids. Whereas by controlling the intracellular crossing of S1P, EC sustain the low 
concentration on the abluminal side (Olivera et al., 2013). In a physiological scenario, pericytes 
that are located on the abluminal side, are exposed to a low S1P concentration suggesting minor 
S1PR3 signaling in pericytes. This is in line with the less migratory phenotype in pericytes upon 
S1PR3 silencing described in this study (Figure 19). Concurrently, S1PR1 signaling on EC maintains 
vessel integrity (Gaengel et al., 2012). Under certain pathophysiological conditions (inflammation 
and cancer), an increase of the S1P concentration in the tissue may occur (Olivera et al., 2013). In 
context of cancer and allergic inflammation, mast cells are considered to be stimulated and alter 
S1P homeostasis (Olivera, 2008; Olivera and Rivera, 2011). Furthermore, cancer and stromal cells 
can turn on S1P production while diminishing the degradation of S1P (Bandhuvula and Saba, 2007; 
Colié et al., 2009; Takabe et al., 2010). This alteration in the S1P concentration in the tissue may 
activate S1PR3 signaling on pericytes and lead to a pro-migratory phenotype and partial 
disruption of vessel integrity. However, this hypothesis needs to be proven in vivo experiments in 
S1PR3 conditional knockout mice using inflammatory or cancer models. 
In summary, this study identifies S1PR3 as novel mural cell marker and shows for the first time the 
functional role of S1PR3 in pericytes influencing the actin-myosin skeleton. Yet, the interplay of 
S1P signaling in EC and pericytes needs further investigation by the use of pericyte-specific 
deletion of S1pr3 in mice. 
 
3.3 Pericyte-specific expression of PTGER2 
Specific PTGER2 expression in human pericytes from different organs was for the first time 
discovered in this study (Figure 6). The expression of PTGER2 was exclusively observed in 
pericytes and almost absent in other mesenchymal cells in the vascular niche, analysed by a 
microarray based transcriptomic profiling and validated on RNA level (Figure 7). Only few 
publications indicate the expression of PTGER2 in mesangial cells, the specialized pericytes in the 
kidneys (Jaffer et al., 1995; Kennedy-Lydon et al., 2013). Jaffer et al. suggest an effect of PGE2 on 
mesangial migration, most probably via EP2 (PTGER2) (Jaffer et al., 1995). In contrast, PTGER2 
silenced BP did not show any difference in migration in this study (data not shown). This suggests 
an organ-specific influence of PGE2/EP2 signaling on the migration of pericytes. Interestingly, 
PTGER2 was not expressed in SMC (Figure 7). Yet, Yau et al. describe EP2 (PTGER2) expression 
(protein) and functional contribution in SMC (Yau and Zahradka, 2003). In contrast, EP2 is absent 
on SMC of the small intestine (Dey et al., 2006). Even though EP2 protein expression has been 
published (Aoki et al., 2011; Yau and Zahradka, 2003), not a single commercially available 
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antibody has been validated to specifically bind EP2. The functional role of EP2 on SMC 
proliferation is in line with the proliferation phenotype seen in pericytes (Figure 22) (Yau and 
Zahradka, 2003). However, the effects in SMC seem to be dependent on the status (quiescent or 
proliferative) of the cells (Yau and Zahradka, 2003).  
PGE2 is a factor with a short half-time and therefore typically functions in an autocrine way or on 
cells in close proximity (paracrine) (Funk, 2001). Few publications indicate that pericyte express 
PGE2 suggesting an autocrine signaling of PGE2 and EP2 on pericytes (Giurdanella et al., 2015; 
Jaffer et al., 1995). In addition, EC express PGE2 (Hsu et al., 1993; Milne et al., 2001). Their close 
anatomical relationship may suggest that EC are a source of PGE2 that can act in a paracrine 
manner on pericytes via the EP2 receptor.  
The PGE2/EP2 axis regulates angiogenesis. However, which mechanism or cells are the major 
contributor is still not fully explored. Some studies claim that EP2 expression on EC effects EC 
motility and survival (Kamiyama et al., 2006; Sakurai et al., 2011). This is contrast to this study, 
showing exclusive expression of PTGER2 in pericytes, whereas EC are devoid of PTGER2 (Figure 7). 
The majority of publications discussing EP2 and angiogenesis are in the context of tumor 
angiogenesis. It is known that the tumor microenvironment including tumor endothelial cells 
show morphological, epigenetic and gene expression changes compared to their healthy 
counterparts (Dudley, 2012). However, this study exclusively investigated the role of EP2 in the 
physiological setting. Global deletion of EP2 decreases the number of intestinal polyps in Apc∆716 
mice with reduced tumor vascular density (Seno et al., 2002; Sonoshita et al., 2001). Mostly, 
PGE2/EP2 is said to act on tumor cells resulting in release of VEGF and induction of angiogenesis 
(Eibl et al., 2003; Jain et al., 2008; Seno et al., 2002; Wang and Klein, 2007; Xiong et al., 2005). 
Albeit, these studies are all performed in global EP2 knockout mice or by using EP2 inhibitors. To 
investigate the role of different EP2 expressing cells on (tumor) angiogenesis, cell-specific EP2 
deletion needs to be performed in vivo. 
PGE2 is a main mediator in inflammation and regulates cytokine expression of immune cells  via 
EP2 (Jing et al., 2003; Johansson et al., 2013; Ricciotti and FitzGerald, 2011). Pericytes are 
described to contribute to the immunological defense of the vaculature by secreting chemokines, 
expressing adhesion molecules and attracting immune cells (Navarro et al., 2016; Pieper et al., 
2013; Stark et al., 2013). Whether PGE2/EP2 signaling in pericyte plays a role in inflammatory 
processes needs to be further elucidated. 
Overall, this study identifies PTGER2 as a specifically expressed transcript of pericytes in the 
mesenchymal niche with a contribution to pericyte function. However, further investigations 
concerning potential influence of pericyte-expressed PTGER2 on angiogenesis and inflammation 
needs to be performed in vivo. 
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3.4 Challenges of CRISPR/Cas technology   
In this study, the generation of S1pr3 floxed mice was performed using the newly emerging 
technique CRISPR/Cas. Different approaches were used to establish an efficient system to 
specifically introduce two LoxP sites into the DNA. Genome engineering refers to techniques that 
introduce targeted and permanent modifications into the genome. Until recently, gene targeting 
in mouse embryonic stem (ES) cells by plasmid-based homologous recombination was the gold 
standard for investigating gene functions and was 2007 awarded by the Nobel Prize in Physiology 
and Medicine (Capecchi, 1989). This method was a breakthrough since former techniques created 
transgenic mice based on the random incorporation of DNA via DNA injection into fertilized eggs. 
However, targeted gene editing by ES cells is impeded by several factors including low efficacy 
targeting rate, effortful screening and culturing of ES cells, chimeric mouse production and 
subsequent breeding to acquire germline transmission of the genetic modification (Capecchi, 
2001, 2005; Sato et al., 2016).  
In the past decade, genome editing using programmable sequence-specific DNA binding nucleases 
emerged. The nucleases induce DSBs and stimulate DNA repair mechanism (NHEJ and HR) by 
which the gene is disrupted or gene modifications can be introduced. These site-specific nucleases 
comprising of zink-finger nucleases (ZFNs), transcriptions activator-like effector nucleases 
(TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated 
protein-9 nuclease (CRISPR/Cas), are powerful tools to induce site-specific modifications (Gaj et 
al., 2013). CRISPR/Cas is the most recently established technique and was used in this study, since 
it demonstrates advantages in comparison to ZFNs and TALENs (Falahi et al., 2015; Jinek et al., 
2012). ZFNs exert more off-target effects (non-specific DNA modifications) and TALENs are highly 
sensitive to methylation of the targeted DNA and their design is complex and time consuming 
(Falahi et al., 2015; Valton et al., 2012). Based on publications, describing off-target effects by the 
Cas9 nuclease, the first approach was performed with the Cas9n nickase (Figure 24 and 26). The 
specificity of CRISPR/Cas is determined by the sequence of the gRNA (guide RNA). However, 
mismatches (up to 5) in the gRNA can retain the cleavage activity dependent on the mismatch 
positions in the gRNA, and result in off-target effects in the genome (Cho et al., 2014; Cong et al., 
2013; Fu et al., 2013; Hsu et al., 2013). Intriguingly, the usage of Cas9n and corresponding gRNAs 
avoids off-target mutations through the higher specificity (Cho et al., 2014; Shen et al., 2014) and 
sustains efficiency (Cho et al., 2014; Shen et al., 2014). This study shows that Cas9n was able to 
introduce two LoxP sites flanking exon 2 of S1pr3. However, the recombination efficacy strongly 
depends on the gene locus (Figure 26B and C), as published before (Miyaoka et al., 2016). An 
increase of the concentration (25 to 50 ng/µl) of the LoxP 1 constructs did not substantially 
improve the recombination efficiency of the LoxP 1 site. The low recombination efficiency of the 
LoxP 1 may explain that only few mice with both LoxP sites, but not located on the same allele, 
were generated. However, changes in the concentrations of injected CRISPR/Cas constructs (see 
Table 44) balanced the recombination efficiency of LoxP 1 and LoxP 2. In publications, the 
concentrations of injected CRISPR/Cas constructs vary from 50 ng/µl to 250 ng/µl in total (Lee and 
Lloyd, 2014; Wang et al., 2013). However, in general even the highest concentrations are 
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suggested to be low toxic when injected into the cytoplasm of the zygote (Wang et al., 2013). In 
this study, the maximal total injected concentration of 350 ng/µl into the cytoplasm of the zygote 
did not show higher toxicity but did also not result in increased efficacy (Figure 26C). 
Recombination efficiency can be improved up to 19-fold by the Ligase IV inhibitor SCR7 via 
blockage of the NHEJ pathway (Figure 27A) (Lin et al., 2016). In this study, SCR7 treatment did not 
increase recombination efficiency (Figure 27B). In the majority of publications, SCR7 was co-
injected with the CRISPR/Cas constructs into the zygotes. In this study, zygotes were incubated 
with SCR7, before and after injection. This procedure was described in the context of NHEJ 
inhibitor treatment of cells (Maruyama et al., 2015) and was well established in the transgenic 
service (DKFZ) for genome editing experiments with the Cas9 WT. Moreover, publications stating 
the increase of genome editing upon SCR7 treatment, are all performed with Cas9 WT (Chu et al., 
2015; Maruyama et al., 2015; Singh et al., 2015). This suggests that the combination of SCR7 and 
Cas9n are not as efficient as with Cas9 WT.  
Insertion of two LoxP sites flanking S1pr3 using Cas9 WT (Figure 26A) with published 
concentrations (Wang et al., 2013) revealed a high survival rate of the injected zygotes and high 
and equal efficiencies of both LoxP sites (Figure 26B). This implies that the region of the LoxP 1 
was not as accessible as the LoxP 2, since in case of Cas9n transfection the recombination of LoxP 
1 was less efficient. Here, two nucleases have to bind in close proximity and in a narrow time 
frame to induce the DSB. As discussed above, the Cas9 WT harbors the risk of off-target effects. 
To minimize this risk, designed gRNAs with the highest quality scores were chosen. The quality 
score considers target specificity and possible off-target matches, meaning the higher the quality 
score, the fewer off-target matches in the genome. Additionally, intergenic off-targets may be 
considered as acceptable, since off-targets on different chromosomes will not necessarily be co-
segregated with the floxed allele, when transgenic mice are back-crossed. However, whole 
genome sequencing will be necessary to fully exclude unspecific alterations in the genome. 
In both Cas9n approaches (Figure 26 and 27) the insertion of both LoxP sites on the same allele 
was not successful due to low efficiency of one LoxP site. In addition to the usage of Cas9 WT, a 
sequential approach (Figure 29A) was established to increase the probability of the insertion of 
both LoxP sites on one allele. This approach also prevented the origin of deletions arising from the 
simultaneous cleavage up- and downstream of exon 2. Whereas LoxP 1 was integrated with a 
similar efficiency (Figure 29B) as in the pilot experiment (Figure 28B), recombination of LoxP 2 was 
less efficient (Figure 29B). Subsequent analysis of the genome of the born mice revealed 
integration of both LoxP sites on one allele and germline transmission was confirmed in the F1 
generation (Figure 30).  
 
CRISPR/Cas is currently described to be the simplest, most precise and versatile method of 
genome editing. However, the homologous recombination of LoxP sites is highly gene locus and 
nuclease (Cas9 or Cas9n) dependent and can therefore lead to a time-consuming establishment of 
the best and efficient conditions. Yet, the sequential LoxP integration strategy turned out to be a 
suitable approach for the generation of a conditional S1pr3 knockout mouse. The availability of 
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this new mouse line will help to answer pivotal questions about the role of S1PR3 in pericyte 
biology. For instance, crossing to Ng2-Cre reporter mouse line will enable the cell-specific 
manipulation of S1pr3 in vivo. 
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4 Materials and Methods 
 
4.1  Materials 
 
4.1.1  Chemicals 
Chemicals were purchased from the following companies: 
Table 2 Chemicals 
Company 
AppliChem (www.applichem.com) 
Carl Roth (www.carl-roth.de) 
Gerbu (www.gerbu.de) 
Merck (www.merk.de) 
Roche (www.roche-applied-science.com) 
Sigma-Aldrich (www.sigmaaldrich.com) 
 
4.1.2  Vectors 
The vectors px330 and px335 were purchased from Addgene (Figure 31). The EGFP vector 
CVU55762 that was used for cloning of px335+EGFP (Figure 32) was kindly provided by Dr. Soniya 
Savant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Vectormaps of the gRNA and Cas9 WT (px330) or Cas9n (px335) expressing plasmids 
Vector maps were generated with the software Benchling (www.benchling.com).  
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4.1.3  Primers and Oligonucleotides 
All primers were purchased from MWG Biotech and Sigma Aldrich. 
 
Table 3 Cloning Primers 
Target Primer name Sequence (5'-3') 
CVU55762 Px335_EGFP_for GGGCTATTCTTTTGATTTAATGGAGTTCCGCGTTACATAA
C CVU55762 Px335_EGFP_rev ATCGGCAAAATCCCTTAGTCGCGGCCGCTTTACTT 
 
 
Table 4 Surveyor mutation assay Primers 
Target Primer name Sequence (5'-3') 
S1pr3 Intron 1 S1pr3_I1_Sur_for GCCACACTCAAAGTTCACGT 
S1pr3 Intron 1 S1pr3_I1_Sur_rev TCCCGGAGAGTGTCATTTCC 
S1pr3 Intron 2 S1pr3_I2_Sur_for TCATTTGCCAGTGTCTGCAG 
S1pr3 Intron 2 S1pr3_I2_Sur_rev CCCTCTGCCCTCTGACTTAG 
LoxP LoxP_for CTTCGTATAATGTATGCTATACGAAG 
 
 
 
 
 
Figure 33: Vector maps of the EGFP vextor CVU55762 and px335+EGFP 
Vector maps were generated with the software Benchling (www.benchling.com).  
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Table 5 Oligonucleotides used in combination with the Cas9 Nickase 
Description Oligo name Sequence (5'-3') 
gRNA 1 Intron 1 S1PR3_Intron1_Nicko_Seq1 
 
AAACGCTCCCACGTGGTGGGTGAGC 
gRNA 2 Intron 1 S1PR3_Intron1_Nicku_Seq1
S1PR3_Intron1_Nicku_Seq1 
AAACGGCACCAGGAAATACTGCGTC 
gRNA 1 Intron 2 2 o 4 AAACTCTATCACCTCTGACCTGCC 
gRNA 2 Intron 2 S1PR3_Intron2_Nicku_Seq4 AAACATTTTGCGATCTGGAGCATAC 
DNA template Intron 1 S_I1_Nickou_Seq1_HDR_for 
TACAGCTGGGAATACTGGCTTATCAGCTCCCAC 
GTGGTGGGTGAGAAGTAACGCAGTATATAACTT
CGTATAATGTATGCTATACGAAGTTATTGCCTGG
AGATTTCCAAGTGGAAGCTTGCTCGTTTCTGCTG
CAGTTACAGGATTCACAGA 
DNA template Intron 2 S_I2_Nickou_Seq4_HDR_for 
CCACCCCCAGTTCCACCTTCCCGCCGTCTATCACC
TCTGACCTGCCCAAGGCAGTCTATGATAACTTCG
TATAATGTATGCTATACGAAGTTATAAATTGGCA
TGAATCTTTTCAAGTGTTTCTGACAAGTTATCCCT
TTTCCCACCCCTGAGG 
 
Table 6 Oligoucleotides used in combination with the Cas9 WT 
Description Oligo name Sequence (5'-3') 
gRNA Intron 1 S1PR3_Intron1_Nicko_Seq1 
 
AAACGCTCCCACGTGGTGGGTGAGC 
gRNA Intron 2 S1PR3_Intron2_Nicku_Seq4 AAACATTTTGCGATCTGGAGCATAC 
DNA template Intron 1 S_I1_Nickou_Seq3_HDR_for 
CCCTCACTTTTCCTCATCCTGAGAAAAATCTGATT
CCCTCTACAGCTGGGAATACTGGCTTACATAACT
TCGTATAATGTATGCTATACGAAGTTATGGTGA
GAAGTAACGCAGTATTTCCTGGTGCCTGGAGAT
TTCCAAGTGGAAGCTTGCTCGTTTC 
DNA template Intron 2 S_I2_Nickou_Seq4_HDR_for 
CCACCCCCAGTTCCACCTTCCCGCCGTCTATCACC
TCTGACCTGCCCAAGGCAGTCTATGATAACTTCG
TATAATGTATGCTATACGAAGTTATAAATTGGCA
TGAATCTTTTCAAGTGTTTCTGACAAGTTATCCCT
TTTCCCACCCCTGAGG 
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Table 7 In vitro transcription Primers 
Target Primer name Sequence (5'-3') 
gRNA 1 Intron 1 (Nickase) S1_T7_gRNA_for TTAATACGACTCACTATAGGCTCACCCACCACGTGGGA 
gRNA 2 Intron 1 (Nickase) S2_T7_gRNA_for TTAATACGACTCACTATAGGACGCAGTATTTCCTGGTGCC 
gRNA 1 Intron 2 (Nickase) S11_T7_gRNA_for TTAATACGACTCACTATAGGCAGGTCAGAGGTGATAGA 
gRNA 2 Intron 2 (Nickase) S12_T7_gRNA_for 
TTAATACGACTCACTATAGGTATGCTCCAGATCG 
CAAAATC 
gRNA Intron 1 (Cas9 WT) S1_T7_gRNA_for TTAATACGACTCACTATAGGCTCACCCACCACGTGGGA 
gRNA Intron 2 (Cas9 WT) S12_T7_gRNA_for 
TTAATACGACTCACTATAGGTATGCTCCAGATCG 
CAAAATC 
each gRNA uni_T7_gRNA_rev AAAAGCACCGACTCGGTGCC 
Cas9 WT/ Cas9n Cas9_T7_for TAATACGACTCACTATAGGGAGAATGTACCCATACGATG
TTCCAGATTAC 
Cas9 WT/ Cas9n Cas9_rev TCAGCGAGCTCTAGGAATTCTTAGCT 
  
 
Table 8 Genotyping Primers 
Genotype Primer name Sequence (5'-3') 
S1pr3
fl/fl
 
S1pr3
fl/fl
 Intron 1 for  TCCCTCACTTTTCCTCATCCTG 
S1pr3
fl/fl
 Intron 2 for  CGACAGATGTTATAACTTGTAGTG 
S1pr3
fl/fl
 Intron 1 rev GAAACCTCAGAGTGCGAATCTG 
S1pr3
fl/fl
 Intron 2 rev TCTTCTGTTTTTCCCTCAGGGG 
 
 
Table 9 Sequencing Primers 
Target Primer name Sequence (5'-3') 
LoxP 1 S1pr3
fl/fl
 Intron 1 for TCCCTCACTTTTCCTCATCCTG 
LoxP 2 S1pr3
fl/fl
 Intron 2 for CGACAGATGTTATAACTTGTAGTG 
px335_1  SeqPx335_rev CGCTAAAAACGGACTAGCCTT 
px335_2 SeqPx335U6prom_for GGACTATCATATGCTTACCGTAAC 
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4.1.4  TaqMan assays 
All TaqMan assays were purchased from Applied Biosystems. 
Table 10 TaqMan assays 
4.1.5  Restriction enzymes 
All FastDigest Restriction Enzymes were purchased from Thermo Fisher Scientific.  
Table 11 Restriction enzymes 
Enzyme Ordering number 
AgeI (BshTI) FD1464 
BbsI (BpiI) FD1014 
NcoI FD0573 
PsiI (AanI) FD2064 
 
4.1.6  siRNA 
All Silencer® Select siRNAs were purchased from Life technologies.  
Table 12 siRNA 
siRNA ID 
siControl 4390847 
siS1pr3_1 s4454 
siS1pr3_2 s4455 
siPtger2_1 s11448 
siPtger2_2 s11450 
 
Mouse probes Ordering number Human probes Ordering number 
Mm Cd31 Mm01242584_m1 Hs ASNS Hs04186194_m1 
Mm Cdh5 Mm03053719_s1 Hs B2M Hs00984230_m1 
Mm Desmin Mm00802455_m1 Hs GSN Hs00609272_m1 
Mm Hprt Mm00446968_m1 Hs HPRT Hs02800695_m1 
Mm Ng2 Mm00507257_m1 Hs KIFAP3 Hs00183973_m1 
Mm Pdgfra Mm00440701_m1 Hs MPRIP Hs00819388_m1 
Mm Pdgfrb Mm00435546_m1 Hs MYH10 Hs00992055_m1 
Mm Ptger2 Mm00436051_m1 Hs PTGER2 Hs04183523_m1 
Mm S1pr3 Mm02620181_s1 Hs S1PR1 Hs01922614_s1 
Mm Vegfr2 Mm01222421_m1 Hs S1PR3 Hs00245464_s1 
  Hs SDC1 Hs00896423_m1 
  Hs SMAD7 Hs00998193_m1 
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4.1.7  CRISPR/Cas and PCR/RT-qPCR reagents, nucleotides and buffers 
Table 13 CRISPR/Cas, PCR and RT-qPCR reagents, nucleotides and buffers 
Reagent Company 
10 x Coral Load PCR buffer Qiagen 
Ampicillin Sigma-Aldrich 
Cas9 mRNA Tebu-bio 
Cas9 Nickase mRNA Tebu-bio 
Direct PCR Lysis Reagent PeqLab 
DNase/RNase free H2O Gibco 
dNTP mix (10mM each) Fermentas 
Ethidium bromide Roth 
O'Generuler 100bp Plus DNA ladder Thermo Scientific 
RedTaq® ReadyMix PCR Reaction Mix Sigmal-Aldrich 
TaqMan® Fast Advanced PCR Master Mix Applied Biosystems 
TOP10F competent cells Invitrogen 
 
4.1.8  Cells 
Table 14 Human cells 
Cells Description Company Medium Company 
Adi Adipocytes PromoCell 
Adipocyte 
medium 
PromoCell 
BP Brain vascular pericytes ScienceCell 
Pericyte 
medium+suppl 
Sciencell 
Fib 1 Fibroblasts Provitro 
DMEM/10%FCS 
P/S 
Gibco 
Fib 2 Fibroblasts PromoCell 
DMEM/10%FCS 
P/S  
Gibco 
HaoSMC Human aortic smooth muscle cells PromoCell 
DMEM/5%FCS 
P/S 
Gibco 
HBMEC 
Human brain microvascular endothelial 
cells 
Neuromics 
ECGM MV2/ 
+suppl 
PromoCell 
HDBEC Human dermal blood endothelial cells PromoCell 
ECGM MV/ 
+suppl 
PromoCell 
HSAVEC Human saphenous vein endothelial cells Promocell 
ECGM MV/ 
10%FCS+suppl 
PromoCell 
HUAEC Human umbilical aortic endothelial cells PromoCell 
ECGM MV/ 
10%FCS+suppl 
PromoCell 
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Table 14 Human cells – continued 
Cells Description Company Medium Company 
HUVEC 
Mixed primary isolated EC of several 
isolations from the human umbilical 
chord 
PromoCell Endopan 
PAN-
Biotech 
LP Lung pericytes 
Kindly provided 
by Bruno Peault 
Pericyte 
medium+suppl 
ScienCell 
MP Muscle pericytes 
Kindly provided 
by Bruno Peault 
Pericyte 
medium+suppl 
ScienCell 
MSC 1 
Mesenchymal stem cells  
(with collagen cell carrier) 
Bioengineering 
McCoys 5A 
Medium+suppl 
Gibco 
MSC 2 
Mesenchymal stem cells 
(without collagen cell carrier) 
Bioengineering 
McCoys 5A 
Medium+suppl 
Gibco 
PancP Pancreas pericytes 
Kindly provided 
by Bruno Peault 
Pericyte 
medium+suppl 
ScienCell 
PlaP Placenta pericytes PromoCell 
Pericyte 
medium+suppl 
ScienCell 
 
 Table 15: Mouse cells 
Cells Description Company Medium Company 
NIH3T3 Mouse embryo fibroblast cell line 
Kindly provided 
by Dr. Courtney 
König 
DMEM+Glutamax
10%FCS 
P/S 
Gibco 
 
4.1.9 Growth factors, proteins and enzymes 
Table 16 Growth factors, proteins and enzymes 
Growth factor Company 
Collagenase IV Sigma Aldrich 
DNase I Roche 
FastAP Thermosensitive Alkaline Phosphatase Thermo Fisher Scientific 
Proteinase K Gerbu 
Q5® High-Fidelity DNA Polymerase New England Biolabs 
RNase free DNAse Qiagen 
S1P Sigma-Aldrich 
S1PR3 Inhibitor TY52156 Tocris 
SCR7 Xcessbio Biosciences Inc 
T4 Ligase New England Biolabs 
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4.1.10 Cell culture reagents 
Table 17 Cell culture reagents 
Reagent Company 
Accutase PAA 
Collagen I Isolated from rat tails 
Dimethylsulfoxide (DMSO) AppliChem 
Dulbecco´s modified eagle medium (DMEM) Gibco 
Dulbecco´s phosphate buffered saline (PBS) PAA 
Endopan 3 + FCS + supplements PAN-Biotech 
Fatty acid free BSA Sigma-Aldrich 
Fetal Calf Serum (FCS, heat inactivated) PAA 
Gelatine Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Lipofectamine 2000 Thermo Fisher Scientific 
Lipofectamine 3000 Thermo Fisher Scientific 
Oligofectamine Reagent Life Technologies 
Opti-MEM I (1x) + GlutaMAX-I Gibco 
Penicillin/Strepomycin (100x 10
4
U/10mg/ml) PAA 
Pertussis toxin List Biological Laboratories 
PKH 26 Red Fluorescent Linker Kit Sigma-Aldrich 
Trypan blue Gibo 
Trypsin-EDTA solution (10x) PAA 
 
4.1.11  Western blot reagents 
Table 18 Western Blot reagents 
Reagent Company 
Bovine Serum Albumine (BSA) PAA laboratories 
Nitrocellulose membrane 
 
GE Healthcare 
 Orthovanadate Sigma-Aldrich 
PageRuler
TM
 Prestained Protein Ladder 
 
Thermo Scientific 
 Pierce ECL Western blotting substrate 
 
Thermo Scientific 
 Immobilon-P PVDF membrane Millipore 
ReBlot Plus Strong Solution Merck 
Rotiphorese Gel 30 Carl-Roth 
Super RX X-ray films 
 
 
 
Fuji 
 SuperSignal™ West Dura Extended Duration Substrate Thermo Fisher Scientific 
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4.1.12  Antibodies 
Table 19 Primary antibodies 
 
Table 20 Secondary antibodies 
Reactivity Species Dilution Conjugate Company Ordering number 
mouse IgG rabbit 1:10000 HRP DAKO P0260 
rabbit IgG goat 1:5000 HRP DAKO P0448 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antigen Reactivity Species Dilution Conjugate Company 
Ordering 
number 
Actin human rabbit 1:5000 - Santa Cruz Sc-1616_r 
CD31 human mouse 1:200 Apc-Cy7 BD Bioscience 563653 
CD31 mouse rat 1:200 Pe-Cy7 BD Pharmingen 561410 
CD45 mouse rat 1:400 FITC BD Pharmingen 553080  
ERK1/2 human rabbit 1:1000 - Santa Cruz Sc-94 
LYVE1 mouse rat 1:250 FITC eBioscience 53-0443 
PDPN mouse hamster 1:100 AF488 eBioscience       53-5381 
pERK1/2 human mouse 1:1000 - Cell Signaling 9106 S 
S1PR1 human rabbit 1:1000 - Santa Cruz Sc-25489 
TER119 mouse rat 1:200 FITC BD Pharmingen 561032 
tubulin human mouse 1:1000 - Sigma-Aldrich T8203 
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4.1.13  Kits 
Table 21 Kits 
Agilent RNA 6000 Nano Kit Agilent technologies 
Arcturus PicoPure RNA Isolation Kit Life Technologies 
DNeasy Blood & Tissue Kit Qiagen 
GenElute Mammalian Total RNA Purification Kit Sigma-Aldrich 
Gibson® Assembly Cloning Kit New England Biolabs 
MEGAclear Kit Life Technologies 
MEGAshortscript T7 Kit Life Technologies 
mMESSAGE mMACHINE T7 ULTRA Kit Life Technologies 
NucleoBond-Xtra Maxi Kit Macherey-Nagel 
PCR qiaquick purification kit Qiagen 
Pierce Bicinchoninic acid (BCA) Protein Assay Kit Thermo Scientific 
PureLink
TM
 Quick Plasmid Miniprep Kit Invitrogen 
Qiaquick gel extraction kit Qiagen 
Quantitect Reverse Transcription Kit for cDNA Synthesis Qiagen 
QuantiTect Whole Transcriptome Kit Qiagen 
Reagent Company 
Surveyor mutation assay Transgenomic 
 
4.1.14 Staining reagents  
Table 22 Staining reagents 
Reagent Company 
Annexin V eBioscience 
Annexin V Binding buffer eBioscience 
Fluorescent mounting medium DAKO 
FxCycle Invitrogen 
Hanks buffer 20mM Hepes Biomol 
Hoechst Dye 33258, 1mg/ml Sigma-Aldrich 
Phalloidin AF488 Invitrogen 
Pluronic® F-127 Biomol 
Rhod4 Biomol 
Roti-Histofix 4% (pH 7) Carl Roth 
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4.1.15  Consumables 
Table 23 Consumables 
Consumable Company 
384 well plates Roche 
Boyden chambers 8.0 µm Corning 
Cannula (18G, 19G, 27G) BD 
Cell culture dishes (6cm,10cm) TPP 
Cell scraper Corning 
Cell strainer BD Falcon 
Cover slips 12mm VWR 
Cryotubes Carl-Roth 
FACS tubes BD Falcon 
Filter containing pipette  tips Biozym 
Ibidi µ-slide Ibidi 
Microscope cover glasses VWR international 
Microscope glass slides Menzel-Gläser 
E-Plate 16 (Proliferation xCELLigence) Omni Life Science 
Cim Plate (Migration xCELLigence) Omni Life Science 
Mini PP tubes Greiner 
Pipette tips  Nerbe 
Reaction tubes (0.5ml, 1.5ml, 2ml) Eppendorf 
Reaction tubes (15ml, 50 ml) Greiner 
Sealing foil Applied Biosystems 
Sterile pipette Corning 
Syringes Dispomed 
Tissue culture 6 well/24 well plates  Greiner 
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4.1.16 Equipment 
Table 24 Equipment 
Equipment Company 
Agarose gel documentation system Peqlab 
Agilent 2001 Bioanalyzer Agilent technologies 
Amersham Imager 600 GE Healthcare 
Aria FACS Sorter BD 
Bacterial incubator Heraeus 
Bacterial incubator/shaker Edmund Bühler GmbH 
BioRad gel casting system BioRad 
BioRad gel running system BioRad 
BioRad Western Blotting equipment BioRad 
Canto II BD 
Cell culture hood Thermo Fisher Scientific 
 Cell culture incubator Thermo Fisher Scientific  
 Cell Observer Zeiss 
Cell^R microscope Olympus 
Centrifuge Beckman Coulter 
Classic E.O.S film developer 
 
Agfa 
Countess automated cell counter 
 
Invitrogen 
Developing cassette Western Blot Amersham Bioscience 
Freezing box Thermo Fisher Scientific 
 Heating block Eppendorf 
Holomonitor microscope Phiab 
iMark
TM
 Microplate Reader BioRad 
 Light cycler 480 Roche 
 Multistep pipette Eppendorf 
Nanophotometer® N60 INTAS 
Pipettes ErgoOne 
Power supply BioRad 
QIAxcel Advanced System Qiagen 
StepOnePlus Real-Time PCR System Thermo Fisher Scientific 
Table centrifuge (5417R) Eppendorf 
Thermocycler Applied Biosystems 
Tubes and adapters for flow incubation Carl Roth 
UV transluminator Intas 
Vortex Neolab 
Water bath 
 
Julabo 
xCELLigence ACEA Biosciences 
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4.1.17 Softwares 
Table 25 Softwares 
Software Company 
Chromas Lite http://chromas-lite.software.informer.com/2.1/ 
CRISPRdesign http://crispr.mit.edu/ 
FACSDiva
TM
 BD 
Fiji ImageJ 
FlowJo Miltenyi Biotec 
Genepattern http://software.broadinstitute.org/cancer/software/genepattern/ 
Graph Pad Prism Graph Pad 
Holostudio Software Phiab 
ImageQuant TL GE Healthcare 
Light Cycler 480 software Roche 
Molecular Signature Database http://software.broadinstitute.org/gsea/index.jsp 
 
 
4.1.18  Solutions and buffers 
Solutions and buffers were prepared as follows: 
Table 26 Solutions and buffers 
Buffer Composition 
5x Protein sample buffer  
250 mM   
10%  
0.5%  
50%   
                  
Tris-HCl (pH 6.8) 
SDS 
Bromophenol blue solution 
Glycerol 
add 10% β-mercaptoethanol prior to use 
Blotting buffer (1x) 
192mM 
25mM 
 
Glycine 
Trizma Base 
 
LB Agar 
12.0 g
5.0 g 
5.0 g 
1.0 g 
 
Tryptone 
Yeast extract 
NaCl 
Glucose 
Add 1l H2O 
LB medium 
12.0 g 
5.0 g 
5.0 g 
1.0 g 
12 g/l  
 
 
Tryptone 
Yeast extract 
NaCl 
Glucose 
Agar 
Add 1l H2O 
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Table 26 Solutions and buffers – continued 
Buffer Composition 
Morulae lysis buffer 
18.75 µl 
333 µl 
300 µl 
300 µl 
13.5 µl 
18 µl 
2017 µl 
125µg/ml Proteinase K  
100mM Tris-HCL (ph8.3) 
100mM KCl 
0.02% gelatin 
0.45% Tween 20 
60µg/ml yeast tRNA 
H2O 
Phosphate buffered saline (PBS) 
1.34M 
27mM 
200mM 
4.7mM 
 
NaCl 
KCl 
Na2HPO4 
KH2HPO4 
adjust pH 7.4 
RIPA lysis buffer 
 
 
 
 
50mM 
150mM 
1mM  
1%    
0.25%     
2mM      
1x                               
Tris-HCl pH 7.5 
NaCl 
EDTA 
NP-40 
Na-deoxycholate 
Na-orthovanadate 
Protease inhibitor Mix G 
Running buffer (1x) 
192mM 
25mM 
0.1% 
 
Glycine 
Trizma Base 
SDS 
 
Separating gel (15%) (1Gel) 
2.3ml 
2.5ml 
100µl 
5ml 
100µl 
4µl 
H2O 
1.5M Tris-HCl pH 8.8 
10% SDS 
30% Acrylamide 
APS 
TEMED 
Stacking gel (5%) 
2.7ml 
0.5ml 
40µl 
0.67ml 
40µl 
4µl 
H2O 
1M Tris-HCl pH 6.8 
10%SDS 
30% Acrylamide 
APS 
TEMED 
Tris-Borate-EDTA buffer (TBE) 
89 mM 
89mM 
1mM 
ris-HCL pH 7.5 
NaCl 
Tween-20 
Tris-Buffered Saline Tween-20 (TBST) 
 
10mM 
100mM 
0.1% 
Tris/HCl, pH 7.5 
NaCl 
Tween-20 
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4.2  Methods 
 
4.2.1 Cell culture methods 
 
4.2.1.1 Cell maintenance  
All cell types used in the present study were maintained at 37°C under sterile conditions, high 
humidity and 5 % CO2 and were cultured in media as indicated (Table 14 and 15). Cells were 
checked for mycoplasma contamination on a regular basis.  All primary cells were used between 
passage one and six and discarded afterwards. When cells reached 80-90% confluency, they were 
passaged and diluted 1:3 (HUVEC, HUAEC, HSAVEC, HBMEC, HDBEC, SMC, Adi), 1:5 (BP, MP, LP, 
PancP, PlaP, Fib, MSC) or 1:10 (NIH3T3). The medium was discarded and cells were washed with 
PBS. All cells were detached by accutase incubation at 37°C for 2 min, diluted in culture medium 
and centrifuged for 5 min at 200 g. The supernatant was discarded, the pellet was resuspended in 
culture medium and the desired cell dilutions were prepared. For HUVEC, cell plates were pre-
incubated on 0.2 % gelatine at 37 °C for 30 min.  
 
4.2.1.2 Cryopreservation and thawing of cells 
Cryocultures were prepared for long-term storage of cells. For this purpose, cells were 
resuspended in cell-type specific media with 10 % DMSO and additional 10% of FCS than normal 
culture media. The cell suspension (1 ml) was transferred to a cryotube and the tubes were slowly 
frozen to -80 °C in an isopropanol containing freezing box overnight and were then transferred 
into liquid nitrogen for long-term storage. For thawing of cells, the cryotube was warmed at 37 °C 
for 2 min and the cells were resuspended in 10 ml pre-warmed culture medium and centrifuged 
for 3 min at 200 g. The supernatant was discarded and the pellet was resuspended in 10 ml 
culture medium and seeded into a 10cm cell culture dish. 
 
4.2.1.3 Seeding of cells 
For seeding specific number of cells for experiments, cells were detached as described in 4.2.1.1. 
Cells were counted by mixing 10 µl of cell suspension with 10 µl of trypan blue in an automated 
cell counting mashine according to manufacturer´s manual. Cell solutions with corresponding cell 
numbers were prepared and seeded accordingly in cell culture dishes or multiwall plates. 
 
4.2.1.4 Transfection of pericytes with siRNA 
Depending on the experiment, specific numbers of pericytes were seeded in different cell culture 
plates. Table 27 shows an overview of cell numbers and corresponding volumes of reagents 
needed for transfection. Briefly, cells were transfected 24 h after seeding with two independent 
silencer select S1PR3/PTGER2 siRNAs or control siRNA using oligofectamine transfection reagent. 
siRNA (20 µM) and Opti-MEM(1x)+GlutaMAX-I (solution A)  were mixed with equal amounts of 
oligofectamine and 100 µl Opti-MEM(1×)+GlutaMAX-I (solution B). Solution A and B were 
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incubated separately for 10 min at RT and then combined and incubated for another 30 min at RT. 
Pericytes were twice washed with Opti-MEM(1x)+GlutaMAX-I. The transfection mix was carefully 
dropped on the cells, covered with defined volume of media (see Table 27). After 4 hours of 
incubation, the medium was exchanged to pericyte medium (PM) with 2% FCS/ growth factors 
and penicillin/streptomycin. All assays were performed 48-72 hours post-transfection. 
 
Table 27 Cell densities and siRNA transfection volumes 
Cell densities and siRNA transfection volumes 
Plate Cell number siRNA Oligofectamine Opti-MEM Plate 
µ-slide 10 000 1 µl 0.5 µl 10 µl 80 µl 
24-well 18 000 2 µl 1 µl 20 µl 160 µl 
6-well 80 000 10 µl 5 µl 100 µl 800 µl 
6 cm 250 000 25 µl 12.5 µl 250 µl 2 ml 
10 cm 500 000 50 µl 25 µl 500 µl 4 ml 
 
4.2.1.5 PKH labelling of pericytes and co-culture of HUVEC and BP 
48 hours before co-culturing, pericytes were transfected with siRNA as described in 4.2.1.4. 
HUVEC were seeded one day before co-culturing to form a monolayer (1.1x106 HUVEC in 10 cm 
dish; 180 000 HUVEC in 6 well). Transfected pericytes (48 post transfection) were detached as 
described in 4.2.1.1. The cell pellet was resuspended in Diluent C and centrifuged at 300 g for 5 
min at room temperature. Cells were stained in PKH red/Diluent C solution (1:250) in the dark at 
room temperature for 10 min. The staining was stopped by adding 1 ml of FCS. 5 ml of Endopan 
containing 3% FCS and supplements was added and centrifuged at 200 g for 5 min. The cell pellet 
was resuspended in 1 ml of Endopan medium and cells were counted as described in 4.2.1.3. 
Stained pericytes were seeded in a 1:2 ratio on the HUVEC monolayer in Endopan full medium.   
 
4.2.1.6 Phalloidin staining of pericytes  
Coverslips were coated with 0.2 % gelatine for 30 min at 37 °C. Pericytes were seeded at a density 
of 18 000 cells per 24 well and were transfected with siRNA (4.2.1.4). 48 hours after transfection, 
cells were washed once with PBS and fixed in 4 % PFA/H2O for 10 min at RT. After three washing 
steps (3x5 min) with TBST for permeabilization, cells were incubated with directly labelled 
phalloidin (Phalloidin-FITC) and Hoechst for 1 h at RT. The antibody solution was aspirated and 
cells were washed three times with TBST. Lastly, coverslips were mounted with Fluoromount G. 
Images were acquired using Zeiss Cell Observer. Analysis was performed using Fiji/ImageJ 
software. Phalloidin-positive area was normalized to the amount of Hoechst stained nuclei. 
 
 
 
Material and Methods 
 
83 
 
4.2.2 Cellular assays 
4.2.2.1 PTX, TY52156 treatment of BP 
For treating BP with pertussis toxin (PTX) or S1PR3 inhibitor TY52156, pericytes were seeded in 6 
wells (100 000 pericytes) or 6 cm dishes (400 000 cells). Pericytes were treated with 1 µM 
inhibitor (dissolved in 100 % ethanol) or 200 ng of PTX (dissolved in PBS) with corresponding 
controls (100 % ethanol or PBS) for 4 hours in PM containing 0.5 % FCS without growth factors. 
Subsequently, cells were stimulated with S1P and harvested for further analysis.  
 
4.2.2.2 S1P stimulation of BP 
BP were transfected with siRNA (4.2.1.4) or treated with PTX or TY52156 (4.2.2.1) as described 
above. 48 hours after transfection or 4 hours after treatment, cells were starved in 0.5 % FCS in 
PM without growth factors for 2 hours. S1P powder was reconstituted in methanol (0.5 mg/ml) 
and aliquoted in 20 µl. The methanol was evaporated with nitrogen gas and the resulting S1P 
films were frozen at -20 °C. To prepare a working solution (200 µM) S1P films were dissolved in 
130 µl of 0.4 % BSA (fatty acid free) in PBS and incubated at 37 °C for 15 min. For stimulation, the 
S1P stock was diluted in 0.1 % BSA (fatty acid free) in PM without FCS and supplements to a final 
concentration of 1 µM. Starvation medium was discarded and the S1P containing medium was 
added for 1, 5 or 10 min before cells were harvested with a cell scraper in 1 ml PBS on ice. For the 
0 min stimulation control cells were directly scraped.   
 
4.2.2.3 Transmigration assay 
BP were transfected with siRNA targeting S1PR3 and non-targeting siRNA as control (as described 
in 4.2.1.4).  
Transmigration assay with xCELLigence system: 40 000 pericytes in PM containing 0.5 % FCS and 
no growth factors were seeded into the upper inserts containing electrodes in migration plates. 
PM containing 2 % FCS and growth factors was added in the lower chamber to create a gradient 
for the cells to migrate (72 hours). Cell migration was monitored with the xCELLigence system 
detecting changes in impedance every 30 min. Each condition (2 different targeting siRNAs, 1x 
siControl) was performed in triplicates.  
Transmigration assay with Boyden chambers: 60 000 HUVEC were seeded in the 24 wells in 
Endopan containing 0.5 % FCS and no growth factors and were cultured overnight. On the next 
day, 70 000 pericytes in Endopan containing 0.5 % FCS and no growth factors were seeded onto 
the upper well of the 8.0 µm pore transwells and let adhere for 2 hours. Boyden chambers with 
seeded pericytes were positioned on top of the HUVEC monolayer with the conditioned media to 
create a gradient for the pericytes to migrate. After 6 hours, transmigration was stopped by 
fixation of the cells with histofix (4 % PFA). Transwells were washed three times with PBS and 
incubated with DAPI (in PBS, 1:2 000 for 30 min RT) to stain the cell nuclei. Transwells were 
washed three times with PBS and cells on the upper side of the filters were removed with a cotton 
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swab. Images were taken on the fluorescent microscope Olympus IX 71 and transmigrated cells 
(DAPI positive) were counted using Fiji/ImageJ software. 
 
4.2.2.4 Calcium release assay 
BP were seeded in 24 wells (18 000) and were transfected with siRNA or siControl as described 
above. For S1PR3 blockage with the inhibitor TY52156, equal numbers of cells (as transfected 
cells) were seeded in triplicates, but were left untreated during transfection procedure. Cells were 
treated as described in 4.2.2.1. All conditions were washed twice with Hanks buffer before adding 
500 µl staining solution (0.02 % pluronic acid and 0.05% Rhod4 in Hanks buffer). The Inhibitor 
TY52156 and the corresponding control (100 % ethanol) were added in corresponding wells. Cells 
were incubated for 30 min at 37 °C and 5 % CO2, following 30 min at room temperature in the 
dark. The calcium release was measured for 180 seconds by live-cell imaging using Olympus Cell^R 
microscope (20x). Pictures were taken every second. Cells were stimulated after 10 sec with 1 µM 
S1P. The increase in fluorescent intensities upon calcium release was quantified using Fiji/ImageJ 
software.    
 
4.2.2.5 Holomonitor live cell imaging 
The Holomonitor M4 is a microscope that allows non-invasive and label-free real-time imaging to 
monitor cell parameters such as cell area, volume, migration and cell count. Holographic images, 
resulting of phase-shift measurements, are taken in the incubator while imaging the cells (Alm et 
al., 2013). 
Ibidi 8-well µ-slides were used for imaging. siRNA transfected pericytes (10 000, see Table 27) 
were seeded in 0.2% gelatine coated wells. 24 hours after transfection, live-cell imaging was 
started for 60 hours. Pictures were taken every 5 min. Analysis was performed using HoloStudio 
software. 
 
4.2.2.6 Co-culture FACS 
Transfected BP and HUVEC were co-cultured in 10 cm dishes as described in 4.2.1.5. After 24 
hours of co-culture, cells were detached and incubated with an antibody against CD31 (APC-Cy7 
labeled) for 30 min on ice. Cells were gated and sorted for two single positive populations: CD31-
positive (EC) or PKH-positive (pericytes) cells. Double positive cells were excluded. Directly after 
the sort, cells were pelleted and lysed in RNA extraction buffer and frozen at -80°C. 
 
4.2.2.7 Cell proliferation assay 
Real-time and dynamic monitoring of cell proliferation was performed using xCELLigence system. 
4000 pericytes in pericyte medium containing 2 % FCS and no growth factors were seeded into 
the inserts containing electrodes in proliferation plates. Cell proliferation was monitored with the 
xCELLigence system detecting changes in impedance every 30 min. Each condition (2 different 
targeting siRNAs, 1x siControl) was performed in triplicates.  
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4.2.2.8 Annexin V apoptosis assay 
Annexin V apoptosis assay was performed to investigate the effect of S1PR3 knockdown in 
pericytes cultured with HUVEC. Annexin V binds to phosphatidylserine, which is flipped to the cell 
surface upon cell apoptosis. S1PR3 silenced pericytes were co-cultured with HUVEC in 6 wells as 
described above (4.2.1.5). After 24 hours of co-culturing, cell culture supernatant and PBS wash 
were collected to also include dead cells. Cells were detached and washed once in binding buffer. 
Subsequently, cells were stained with Annexin V-FITC (1:20 in binding buffer) for 15 min at room 
temperature. Additionally, cells were stained with FxCycle violet (1:1 000) for 30 min on ice to 
allow the discrimination of early, late apoptotic or necrotic cells. To distinguish endothelial cells 
from PKH-positive pericytes, cells were stained with CD31-APC-Cy7 (1:200). Single stained controls 
and an unstained control were used for compensation. Cells were gated in PKH-positive 
(pericytes) or APC-Cy7-positive (EC) populations. Each population was gated for Annexin V-
positive, FxCycle-positive and Annexin-V/FxCycle-double-positive cells. Quantification of the 
analysis was performed using FlowJo software. 
 
4.2.2.9 Adhesion assay 
BP were transfected with siRNA targeting S1PR3 and siControl in 6 wells as described in 4.2.1.4. 
One day after transfection, HUVEC (36 000) were seeded in 0.2 % gelatine coated 24 wells and 
were cultured overnight. The next day, transfected pericytes were detached and stained with PKH 
(see 4.2.1.5). BP (18 000) were seeded on top of the monolayer in Endopan containing 3 % FCS 
and supplements and allowed to adhere for 15 or 30 min. Non-adherent cells were carefully 
removed by washing. Attached cells were fixed with Histofix (4 % PFA) and imaged using the 
fluorescent microscope Olympus IX 71. Attached cells (PKH-positive) were counted using 
Fiji/ImageJ software. Each condition was performed in triplicates. 
 
4.2.3 Biochemical methods 
4.2.3.1 Protein isolation and concentration determination for immunoblotting 
For protein extraction from stimulated pericytes, cells were washed once with ice-cold PBS and 
scraped in 1 ml PBS. After centrifugation, the pellet was dissolved in RIPA lysis buffer (6 well: 100 
µl, 10cm dish: 300 µl). Whole cell lysates were centrifuged for 10 min at full speed at 4°C and 
supernatants were separated from the cell debris. Protein concentration was measured using 
Pierce BCA Assay according to manufacturer´s instructions. Defined protein concentrations of the 
samples were generated by diluting them in RIPA buffer. Samples were boiled in 5x protein 
sample buffer at 95 °C for 5 min and used directly for immunoblotting or were stored at -20 °C. 
 
4.2.3.2 SDS-Polyacrylamide gel electrophoresis (PAGE) and Western blot 
Proteins were separated according to their molecular weight by 10% (ERK1/2) or 12% (MLC, RhoA) 
SDS-PAGE with the BioRad gel casting and running system in 1x running buffer. Gel 
electrophoresis was started at 80 V to allow the proteins to enter the gel. After 30 min the voltage 
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was increased to 120 V for 1 h. 7 µl of PageRulerTM Prestained Protein ladder was used to 
determine the size of the proteins. After electrophoresis, proteins were blotted on a nitrocellulose 
membrane (ERK1/2) or on a PVDF-membrane (MLC) at 0.4 A for 70 min in 1x blotting buffer. The 
PVDF membrane was equilibrated for 20 sec in 100 % methanol and afterwards in 1x blotting 
buffer.  
Unspecific binding of antibodies to the membrane was prevented by subsequent blocking with 
3 % BSA/TBST for 1h at RT. For immunodetection of the desired proteins, primary antibodies (see 
Table 19) were diluted in 3 % BSA/TBST and incubated overnight at 4 °C. Three times washing with 
TBST removed unbound and unspecific bound antibody. Afterwards, the membrane was 
incubated with the corresponding horse-radish-peroxidase (HRP)-coupled secondary antibodies 
diluted in TBST (see Table 20) for 1h at RT. After three washing steps with TBST membranes were 
developed using Pierce ECL Western Blotting Substrate or SuperSignal™ West Dura Extended 
Duration Substrate according to manufacturer´s instructions. The membranes were exposed to 
Super RX X-ray films (2 sec to 30 min) and developed in the Classic E.O.S. film developer or using 
Amersham Imager 600. Signal intensities were either set in relation to a housekeeping gene (α-
tubulin) or corresponding non-phosphorylated proteins served as control for their phosphor-
protein signal.  
 
4.2.4 Molecular biological methods 
4.2.4.1  RNA isolation 
RNA of FACS-sorted mouse pericytes was isolated with the Arcturus PicoPure RNA Isolation Kit. 
Cells were centrifuged at 500 g and 4°C for 5 min and the pellet was resuspended in 50 µl Arcturus 
PicoPure extraction buffer. RNA was isolated according to manufacturer´s instructions. RNA was 
eluted in 11 µl RNase free H2O and RNA concentrations were measured using NanoPhotometer® 
N60. RNA of cell culture cells was isolated using GenElute Mammalian Total RNA Purification Kit 
according to the manufacturer´s instructions. Cells were lysed with 100-300 µl lysis buffer and 
RNA was eluted in 30 µl RNase free H2O and stored at -80°C. 
 
4.2.4.2 Reverse transcription of RNA  
Reverse transcription was performed using the QuantiTect Reverse Transcription Kit according to 
the manufacturer's instructions. Briefly, 1 µg RNA was combined with 2 µl 7xDNA Wipeout buffer 
and the total volume was adjusted to 14 µl with RNase-free H2O. Genomic DNA digestion was 
performed for 2 min at 42°C. Afterwards, 1 µl reverse transcriptase, 4 µl 5xRT-buffer and 1 µl RT-
Primer mix were added. Reverse transcription was accomplished at 42°C for 30 min and then 
stopped by 3 min incubation at 95°C. The cDNA was diluted 1:20 in H2O for qPCR. cDNA was 
stored at -20°C. 
RNA of FACS-sorted mouse cells was transcribed with QuantiTect Whole Transcriptome Kit 
according to manufacturer´s instructions.cDNA was diluted 1:100 and stored at -20°C. 
 
Material and Methods 
 
87 
 
4.2.4.3 Real time (RT) - qPCR 
Relative gene expression was determined by RT-qPCR of synthesized cDNA. TaqMan-based RT-
qPCR was used to detect differences of mRNA transcription levels. The Taqman mono-color 
hydrolysis probe method is based on using fluorescently labeled oligonucleotide probes that bind 
the gene of interest flanked by the forward and reverse primer. Taqman probes are labeled with a 
fluorophore (FAM) at the 5' end and a quencher at the 3' end that blocks fluorescence emission. 
The exonuclease activity of the Taq-polymerase allows the cleavage of the Taqman probe during 
amplification. Thereby, FAM fluorescence is detectable that is proportional to the amount of the 
amplified product. Reactions were performed in 96 or 384 well plates. One reaction contained the 
following components:     
  
Table 28 TaqMan RT-qPCR reaction mix 
 
 
 
 
 
 
 
 
Each reaction was performed in triplicates. Lightcycler®480 System (348 well plate) or StepOnePus 
Real-Time PCR System (96 well plate) was used for RT-qPCR with the following protocol:  
 
 
Table 29 TaqMan RT-qPCR program 
TaqMan RT-qPCR program 
Step Temperature [°C] Time [sec] 
Pre-denaturation 95 30 
Denaturation 95 2 
Amplification 60 20 
 
 
 
 
 
 
 
 
TaqMan RT-qPCR reaction mix 
  1x 
cDNA 3 µL 
Taqman Fast Advanced Master Mix 5 µl 
TaqMan gene expression assay 0.5 µl 
ddH2O 1.5 µL 
45x 
Material and Methods 
88 
 
RT-qPCR data analysis was performed according to the ΔΔCT method (Livak and Schmittgen, 2001). 
Briefly, CT values of the genes of interest were normalized to the respective CT values of the 
indicated housekeeping genes for each sample (∆CT). Afterwards, normalized CT values of the 
samples of interest were compared to normalized CT values of control samples (∆∆CT). Respective 
fold changes (FC) were calculated from the ∆∆CT values.  
 
∆CT = CTgene of interest - CThousekeeping gene 
 
∆∆CT = ∆CTsample of interest - ∆CTcontrol sample 
 
fold change = 2-∆∆CT 
 
In case of data sets without internal control, relative expression was calculated by 2-∆CT. 
 
4.2.4.4 Microarray  
For gene expression analysis, microarrays were performed by the DKFZ Genomics and Proteomics 
core facility (Heidelberg). Briefly, RNA was isolated with the GenElute Mammalian Total RNA 
Purification Kit and RNA quantity and quality were checked using the Agilent RNA 6000 Pico Kit on 
an Agilent 2001 Bioanalyzer. Only RNA samples with a RIN value of > 6.0 were eligible for 
microarray analysis. RNA was reverse transcribed into cDNA. cDNA was hybridized on a HumanHT-
12 Expression BeadChip Array (Ilumina) according to manufacturer´s protocol.  
Cell and RNA preparation of the expression analysis of different primary human pericytes 
compared to other mesenchymal cells was performed by Dr. Zulfiyya Hasanov. For this microarray 
analysis, only significantly differentially expressed (p ≤ 0.05) with mean intensities >400 in 
pericytes and <400 in the other mesenchymal cells were considered.  
For the microarray analysis of co-cultured pericytes, expression levels measured in the S1PR3/ 
PTGER2 silenced cells were normalized to the non-silencing controls. Only genes with a 
significantly differential expression (p ≤ 0.05) and a log2FC of 0.4/-0.4 compared to control were 
considered for Molecular Signature Database analysis (Hallmark and Reactome gene sets). 
 
4.2.5 Mouse lung pericyte isolation by FACS 
For isolation of lung mouse pericytes, the tissue was digested by collagenase IV and pericytes 
were purified by FACS. Mice (8-12 weeks) were sacrificed and lungs of adult mice were surgically 
removed and cut into small pieces. Subsequently, lungs were digested with DMEM containing 1 
mM CaCl2, 80 U/ml collagenase IV and 0.2 % DNaseI at 37 °C for 30 min and additionally 15 min. 
Digested organs were passed through 18G and 19G cannula syringes to achieve single-cell 
suspensions. Afterwards, digestion was stopped with FCS and the single-cell suspension was 
passed through a 100 µm cell strainer.  To identify lymphatic, blood and alveolar epithelial cells, 
cells were stained for PDPN, LYVE1, CD45 and TER119 (antibodies listed in Table 19) and CD31 
(Table 19) for 30 min at 4 °C in PBS /5 % FCS. Dead cells were excluded by FxCycle staining 
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(1:1000) that was added shortly before FACS. Unstained and single stained control cells were used 
for compensation. Mural cell enriched cells (FxCycle−CD45−TER119−LYVE1−PDPN−CD31− cells) and 
EC (FxCycle−CD45−TER119−LYVE1−PDPN−CD31+ cells) were sorted with a BD Biosciences FACS Aria 
Cell Sorter. Cells were centrifuged (300 g, 5 min), 50 µl RNA lysis buffer (of the picopure RNA 
isolation kit) was added and cells were immediately frozen at -80°C. In total, 5 mouse lungs were 
pooled for one FACS sample. 
 
4.2.6 CRISPR/Cas establishment 
4.2.6.1 gRNA and template design 
gRNAs for the double Nickase and the WT Cas9 approach were designed by using the online tool 
CRISPRdesign (http://crispr.mit.edu/). Pairs of gRNAs (Table 5, 6) were chosen with the highest 
quality score. The quality score considers target specificity and possible off-target matches. The 
gRNAs were designed with overhang sequences 5´- CTTC- 3´ (sense) and 3´- CAAA- 5´ (antisense 
oligo) which are complementary to overhangs generated by BbsI digestion. The oligos were 
ordered as high purity salt-free purified single-stranded oligos from eurofins. 
For the DNA template design (Table 5, 6), the 34 bp LoxP sequence (ATAACTTCGTATAATGTATGC-
TATACGAAGTTAT) was flanked by 50-80 bp long homology arms of the gene region of interest. To 
avoid degradation of the template by Cas9, intact PAM sequences (5´ -NGG- 3´) within the DNA 
template were converted by inserting silent mutations. The DNA template was ordered as high-
performance liquid chromatography (HPLC) purified single-stranded DNA (ssDNA) from Sigma-
Aldrich. 
  
4.2.6.2 Cloning of CRISPR/Cas plasmids 
 
Amplification and purification of plasmids 
For recovering the bicistronic expression vector px335 (double nickase and gRNA), bacteria of the 
glycerol stock were streaked on agar plates containing the appropriate antibiotic (ampicillin) and 
were incubated at 37°C for 12-16 hours. For the amplification of single clones, 5 ml of LB medium 
(Mini) containing ampicillin were inoculated with single colonies and incubated at 37°C on a 
shaker (300 rpm) for 12-16 hours. Plasmid DNA purification was performed using PureLinkTM 
Quick Plasmid Miniprep Kit according to manufacturer´s instructions. To confirm the validity of 
the plasmid, an enzymatic digestion with NcoI was performed, containing the following 
components: 
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Table 30 NcoI digestion mix 
 
 
 
 
 
 
 
 
 
DNA fragment sizes were checked using agarose gel electrophoresis. After confirming the 
correctness of single clones, 1 ml of the Mini-prep was transferred into a bigger volume of 300 ml 
of LB medium and was incubated at 37°C and 300 rpm for 12-16 h. The bacterial cells were 
harvested by centrifugation at 4500-6000 g for 30 min at 4°C. Plasmid purification was performed 
using NucleoBond-Xtra Maxi kit according to manufacturer´s guidelines. DNA was eluted in 400 µl 
water and measured using NanoPhotometer® N60. Glycerol stock of the vectors was prepared by 
suspending bacterial cells of 1 ml of the Mini in 1 ml of 20% glycerol. Gylcerol stock was stored at  
-80 °C. 
 
Cloning of EGFP in px330 and px335 
From the plasmid CVU55762, the EGFP coding sequence and the corresponding CMV promotor 
were amplified using flanking primers with an overhang complementary to the insertion region of 
the px335 plasmid (Table 3). For the amplification, a high fidelity proofreading polymerase (Q5® 
High-Fidelity DNA Polymerase) was used with following reaction mix and PCR protocol:    
   
Table 31 EGFP amplification PCR mix  
 
 
 
 
 
 
 
 
 
 
 
NcoI digestion mix 
 1x 
DNA (400 ng) X µL 
NcoI FastDigest 1 µL 
10 x FastDigest Buffer 1 µL 
ddH2O X µL 
total 20 µL 
EGFP amplification PCR mix 
  1x 
px335_EGFP_for (Primer for) 1.25 µL 
px335_EGFP_rev (Primer rev) 1.25 µl 
dNTPs (10mM) 0.5 µl 
5 x Reaction Buffer 5 µL 
5x Q5 High GC Enhancer 5 µl 
Q5 Polymerase 0.25 µl 
DNA (100 ng) X µl 
ddH2O X µl 
total 25 µl 
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Table 32 EGFP PCR program 
 
 
 
 
 
 
 
 
 
 
PCR product was purified by using the PCR Qiaquick purification kit according to manufacturer´s 
instructions. The PCR product was eluted in 30 µl H2O. The plasmid px335 was digested with the 
restriction enzyme PsiI (Table 33). The reaction was stopped at 65°C for 15 min. The digested DNA 
was loaded on an agarose gel and bands were excised and purified using the Qiaquick gel 
extraction kit according to manufacturer´s instructions. 
 
Table 33 PsiI digestion mix 
 
 
 
 
 
 
 
 
The Gibson Assembly® Cloning Kit from New England BioLabs was used to assemble the EGFP 
fragment and the plasmid px335. The Gibson Assembly is based on the efficient joining of 
overlapping DNA fragments. The Assembly was performed with a molar vector : insert ratio of 1:3 
for 30 min. The assembly and the subsequent transformation of Top10F competent cells were 
performed according to manufacturer´s guidelines. The next day, single colonies were amplified 
(Mini) and a NcoI digestion was performed (see Table 30). Sequencing (see primers Table 9) 
confirmed the integration and correct orientation of EGFP.  
 
gRNA annealing and cloning in px335 vector 
The vector px335+EGFP was digested and dephosphorylated with BbsI and alkaline phosphatase 
for 30 min at 37°C (see Table 34) before ligating the respective gRNA into the vector. The digested 
vector was purified by gel electrophoresis using Qiaquick gel extraction kit according to 
manufacturer´s instructions. Before ligation, single-stranded gRNAs were phosphorylated and 
EGFP PCR program 
Step Temperature [°C] Time 
1 98 30 sec 
2 98 10 sec 
3 61 30 sec 
4 72 2 min 
5 72 10 min 
6 4 forever 
PsiI digestion mix 
 1x 
DNA (4000 ng) X µL 
PsiI FastDigest 4 µL 
10 x FastDigest Buffer 4 µL 
ddH2O X µL 
total 20 µL 
25 x 
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annealed (see Table 35, 36).  Ligation of the annealed gRNAs and the digested px335+EGFP was 
performed with a molar vector to insert ratio of 1:3 for 2 h at RT (see Table 37). Transformation of 
Top10F competent cells was performed according to manufacturer´s instructions. 
 
Table 34 BbsI digestion mix Table 35 Annealing program 
 
 
 
 
 
 
 
 
   
 
Table 36 Annealing of gRNAs Table 37 Ligation reaction mix 
 
 
 
 
 
 
 
 
The integration was confirmed by BbsI/AgeI digestion. In case of correct ligation of the gRNA into 
px335+EGFP, the BbsI enzyme is not able to bind and cut, whereas AgeI can digest the plasmid 
(plasmid fragment sizes: 5646 bp and 4145 bp). In case of incorrect integration of the gRNA, BbsI 
and AgeI are able to digest the plasmid (plasmid fragment sizes: 5646, 3151 and 972 bp). Plasmid 
fragment sizes were analysed by agarose gel electrophoresis. Additionally, plasmids were 
sequenced to validate gRNA integration (see primers Table 9). Confirmed plasmids were amplified 
(see 4.2.6.2). 
 
 
 
 
 
 
Annealing program 
Step Temperature [°C] Time 
1 37 30 min 
2 95 to 25 
5 min and then 
ramp down 
5°C/min 
BbsI digestion mix 
 1x 
DNA (1000 ng) X µL 
BbsI FastDigest 1 µL 
10 x FastDigest Buffer 2 µL 
Fast Alkaline Phosphatase 1 µl 
ddH2O X µL 
total 20 µL 
Annealing of gRNAs 
 1x 
gRNA for (100 µM) 1 µL 
gRNA rev (100 µM) 4 µL 
10 x T4 Ligation Buffer 1 µL 
ddH2O 6.5 µl 
T4 PNK 0.5 µl 
total 10 µL 
Ligation reaction mix 
 1x 
Digested px335+EGFP (50 ng) X µL 
Phosphorylated and annealed 
oligo  X µL 
10 x T4 Ligation Buffer 2 µL 
T4 Ligase 1 µl 
ddH2O X µL 
total 20 µL 
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4.2.6.3 In vitro verification of CRISPR/Cas-dependent genome modifications  
 
Transfection of NIH3T3 
Transfection of NIH3T3 cells with px335+EGFP containing the respective gRNA was performed 
using Lipofectamine 2000 reagent according to manufacturer´s guidelines. Briefly, 100.000 
NIH3T3 cells were seeded in 24 wells. The day after, cells were transfected with 500 ng DNA (250 
ng per gRNA) with the lowest concentration of Lipofectamine (2 µl) indicated in the manual. After 
48 hours, genomic DNA was isolated using the DNeasy Blood & Tissue Kit according to 
manufacturer´s guidelines.  
For transfection of NIH3T3 cells with the gRNA and the nuclease-containing plasmids and the DNA 
template, the reagent Lipofectamine 3 000 was used according to manufacturer´s instructions. 
Cells were seeded in 12 well plates and were transfected with 1 000 ng of DNA (330 ng per gRNA 
and 330 ng template) and 1.5 µl Lipofectamine 3 000. After 48 hours, genomic DNA was isolated 
using the DNeasy Blood & Tissue Kit according to manufacturer´s guidelines.  
 
Surveyor mutation assay 
The analysis of Cas9-induced repaired DSB and subsequent mismatches in the DNA was analysed 
using the Surveyor Mutation Detection Kit from Transgenic. This kit is based on the ability of an 
endonuclease only cleaving DNA at sites of mismatches resulting in distinct restriction fragments, 
which can be detected by agarose gel electrophoresis.  
The DNA region of the expected mismatches was amplified by primers resulting in a PCR product 
of about 1000 bp with the high fidelity proofreading polymerase Q5® to prevent DNA synthesis 
errors (see Table 38, 39). The PCR product was purified using PCR Qiaquick purification kit 
according to manufacturer´s instructions. The digestion of the PCR products with the surveyor 
nuclease and the analysis with agarose gel electrophoresis was performed according to the 
manufacturer´s guidelines.  
 
Table 38 Surveyor PCR program 
 
 
 
 
 
 
 
 
 
Surveyor PCR program 
Step Temperature [°C] Time 
1 98 30 sec 
2 98 10 sec 
3 58 30 sec 
4 72 1 min 
5 72 2 min 
6 4 forever 
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Table 39 Surveyor PCR mix 
 
 
 
 
 
 
 
 
 
PCR analysis for LoxP integration 
LoxP integration into the genome of transfected NIH3T3 cells with CRISPR/Cas plasmids and DNA 
template was confirmed by PCR analysis (see Table 40, 41). A primer binding directly to the LoxP 
site was used. In case of LoxP integration, a PCR product (PCR product size: LoxP 1 and 2 500 bp) 
could be detected with agarose gel electrophoresis.  
 
 
Table 40 LoxP PCR mix Table 41 LoxP PCR program 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surveyor PCR mix 
  1x 
Primer for 10 µM (see Table 4) 2.5 µL 
Primer rev 10 µM (see Table 4) 2.5 µl 
dNTPs (10mM) 1 µl 
5 x Reaction Buffer 10 µL 
5x Q5 High GC Enhancer 10 µl 
Q5 Polymerase 0.5 µl 
DNA (100 ng) X µl 
ddH2O X µl 
total 50 µl 
LoxP PCR mix 
  1x 
LoxP_for 10 µM 1 µL 
Primer rev 10 µM (see Table 7) 1 µl 
dNTPs (10 mM) 0.5 µl 
5 x Reaction Buffer 5 µL 
5x Q5 High GC Enhancer 5 µl 
Q5 Polymerase 0.25 µl 
DNA (100 ng) X µl 
ddH2O X µl 
total 25 µl 
LoxP PCR program 
Step Temperature [°C] Time 
1 98 30 sec 
2 98 10 sec 
3 58 30 sec 
4 72 1 min 
5 72 2 min 
6 4 forever 
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4.2.6.4 In vitro transcription and quality control for in vivo application of 
CRISPR/Cas 
 
In vitro transcription 
For transcription of Cas9n mRNA and gRNA from the plasmids, the T7 promoter was added to 
Cas9n coding region by PCR amplification (see Table 42, 43). T7-Cas9n product was gel purified 
using Qiaquick gel extraction kit and served as template for in vitro transcription (IVT) using 
mMESSAGE mMACHINE T7 ULTRA Kit (Life Technologies) according to manufacturer´s 
instructions. T7 promoter was added to gRNA by PCR amplifications using primer listed in Table 7. 
The T7-gRNA PCR product was gel purified by Qiaquick gel extraction kit. 350 ng of the PCR 
product were used as template for in vitro transcription (IVT) using MEGAshortscript T7 kit (Life 
Technologies) according to manufacturer´s instructions. Both, Cas9n mRNA and gRNA were 
purified by MEGAclear kit (Life Technologies) and eluted in RNase-free water according to 
manufacturer´s guidelines. 
For the double nickase/SCR7 experiment as well as for the following Cas9 WT experiments, 
commercially available Cas9n and Cas9 WT mRNA were used for the injection. 
 
Table 42 IVT PCR Mix Table 43 IVT PCR program 
 
 
 
 
 
 
 
 
 
 
 
 
Bioanalyzer  
For the analysis of quality and quantity of gRNA and Cas9n mRNA, the Agilent RNA 6000 Nano Kit 
was used on an Agilent 2001 Bioanalyzer according to manufacturer´s guidelines. Samples were 
immediately frozen at -80°C. In case of the necessity to thaw already used transcribed mRNA 
samples, Bioanalyzer analysis was repeated before injecting in vivo.  
 
 
 
IVT PCR mix 
  1x 
Primer for 10µM (see Table 7) 2 µL 
Primer rev 10 µM (see Table 7) 2 µl 
dNTPs (10 mM) 2 µl 
5 x Reaction Buffer 20 µL 
5x Q5 High GC Enhancer 20 µl 
Q5 Polymerase 1 µl 
DNA (2 ng) X µl 
ddH2O X µl 
Total 100 µl 
IVT PCR program 
Step Temperature [°C] Time 
1 98 30 sec 
2 98 10 sec 
3 58 1 min 
4 72 1 min 
5 72 2 min 
6 4 forever 
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4.2.6.5 One-cell embryo injection 
All in vivo experiments in the context of the CRISPR/Cas establishment were performed by Frank 
van der Hoeven and Ullrich Kloz (Transgenic Service, DKFZ). All animal experiments were approved 
by the local regulatory committee (Bezirksregierung Karlsruhe, Germany; permit: G-154-14). 
Briefly, C57BL/6N female mice (5-8 weeks old) were super ovulated and mated overnight with 
C57BL/6N male mice (older than 7 weeks). On the next day, zygotes were harvested from the 
ampullae of super ovulated females. The gRNAs, Cas9n or Cas9 mRNA and the DNA templates 
were injected into the cytoplasm of zygotes.  
For the pilot experiment, injected zygotes were incubated in 5.5 % CO2 at 37 °C for 2-3 days until 
they developed to morulae. For experiments, in which the 2-cell stage embryos should be 
transferred into the uterus of pseudo-pregnant mice, injected zygotes were cultured for 24 hours 
before oviduct transfer in mouse embryo culture medium KSOM. In the case of SCR7 treatment, 
zygotes were incubated for 1 h with 50 µM SCR7 before injection. Injected zygotes were 
incubated further 24 hours with 50 µM SCR7 previous to embryo transfer.  
Used concentrations of Cas9n/Cas9 WT, each gRNA and each DNA template is listed as follows: 
 
Table 44 Nucleotide concentrations for zygote injections 
 
 
4.2.6.6 Genotyping/ Sequencing PCR 
Genotyping of morulae was performed by PCR of genomic DNA. Morulea were lysed in 10 µl 
morulea lysis buffer for 10 min at 56°C and afterwards 10 min at 95°C. 2 µl of supernatant were 
directly used for the genotyping PCR (see Table 8). 2 µl of this PCR product were used for 
subsequent PCR2. Morula lysate was stored at -20°C for later re-genotyping.   
Genotyping of mice was performed by PCR of genomic DNA extracted from mouse tails. Tails were 
lysed in 100 µl DirectPCR Lysis Reagent with 10 µg proteinase K at 55 °C and 300 rpm overnight. 
The next day, proteinase K activity was stopped by incubating the tail lysate for 15 min at 95°C. 
The lysate was centrifuged at full speed for 5 min and 2 µl supernatant was directly used for the 
genotyping PCR. Lysates were stored at -20°C for later re-genotyping.   
The genotyping/sequencing PCRs for the different alleles were performed using RedTaqMix and 
primers as depicted in Table 8 and 45. S1pr3fl/fl genotyping generates a wild-type and a mutant 
Concentrations for zygote injections 
experiment Cas9n/Cas9 WT (ng/µl) gRNA (ng/µl) DNA template (ng/µl) 
Pilot test ´Cas9n´ 100 25 50 
Experiment ´Cas9n´ 100 50 75 
Experiment ´SCR7´ 80 
LoxP 1: 80 
LoxP 2: 15 
LoxP 1: 90 
LoxP 2: 80 
Pilot test ´Cas9 WT´ 100 75 75 
Experiment ´Cas9 WT sequential´ 100 75 75 
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band of 185 bp/219 bp (LoxP 1) and 186bp/220 (LoxP 2), respectively. The PCR was performed 
with an Applied Biosystems thermocycler according to the PCR programs shown in Table 46. The 
PCR reactions were analysed by 2% agarose gel electrophoresis or with QIAxcel Advanced system 
according to manufacturer´s instructions. 
 
Table 45 S1pr3fl/fl genotyping PCR mix Table 46 S1pr3fl/fl genotyping PCR program 
S1pr3
fl/fl
 genotyping PCR mix 
 1x 
dd H2O 9.5 µL 
RedTaq Mix 12.5 µL 
Primer S1pr3
fl/fl
 for (10µM) 1 µL 
Primer S1pr3
fl/fl
 rev (10µM) 1 µL 
DNA 2 µL 
 
 
4.2.6.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments obtained in the genotyping PCR 
reaction. Agarose was dissolved in 1x TBE buffer to generate 2% [w/v] agarose gels. 5 µl ethidium 
bromide was added to 100 ml gel. The entire PCR mix of the genotyping reaction and 7 µl of the 
O’Generuler 100 bp Plus DNA ladder were loaded onto the gel. Electrophoresis was performed at 
140 V for 45 min. Bands were detected with a UV transluminator and band size was determined 
relative to the DNA ladder. 
 
4.2.6.8 DNA extraction from agarose gels 
For sequencing PCR amplicons, DNA bands of desired size were cut out of the agarose gel. DNA 
extraction was performed with the QIAquick Gel Extracton Kit according to the manufacturer´s 
guidelines.   
 
4.2.6.9 Sequencing 
The sequencing of plasmids or genomic DNA was performed by GATC Biotech. Purified genomic or 
plasmid DNA was diluted to an end concentration of 10-20 ng/µl. Primers (see Table 9) were used 
at a concentration of 10 pmol/µl.  
 
 
 
 
 
 
 
S1pr3
fl/fl
 genotyping PCR program 
Step Temperature [°C] Time 
1 94 3 min 
2 94 1 min 
3 62 2 min 
4 72 1 min 
5 72 10 min 
6 4 forever 
35x 
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4.2.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism Software. Unless otherwise stated, data 
are expressed as mean±s.d. Statistical significance was determined by ANOVA followed by 
Dunnett´s Multiple Comparison Test. A p-value of less than 0.05 was considered statistically 
significant and marked by asterisks (*P<0.05, **P<0.01, ***P<0.001). n represents the number of 
independent mice or in vitro treated cell culture samples analysed per group. 
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Abbreviations 
  
A Ampere 
Abcc9 ATP-binding cassette, subfamily C (CFTR/MRP) 
Acta2 Smooth muscle actin gene 
ACTA2 Alpha actin 2  
Adi Adipocytes 
AF Alexa Fluor 
Angpt1 Angiopoietin 1 
Anpep Amino peptidase N 
APS Ammonium persulfate 
ASNS Asparagine synthetase 
B2M Β2- Microglobulin 
BBB Blood brain barrier 
BCA Bicinchoninic acid  
BCL2L1 B-cell lymphoma 2 like protein 1 
bFGF basic FGF  
BM Basement membrane 
bp Base pair  
BP Brain pericytes 
BSA Bovine serum albumin 
c Concentration; Centi 
Ca2+ Calcium 
Cas CRISPR-associated 
Cas9n Nickase 
CASP3 Caspase 3 
CCDC34 Coiled-coil domain containing 34 
CD Cluster of differentiation 
CDH5 Cadherin 5 
cDNA Complementary DNA 
Cer Ceramide 
CNS Central nervous system 
CO2 Carbon dioxide 
Col7A1 Collagen type 7 alpha 1 chain 
COX cyclooxygenase 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CT Threshold cycle 
Cu Copper 
DAPI 4´, 6-diamidino-2-phenylindole 
DLK1 delta-like 1 homolog 
DMEM Dulbecco’s modiﬁed Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP Deoxynucleoside triphosphate 
DP Prostaglandin D2 receptor 
DPH3 Diphthamide biosynthesis 3 
ds Double stranded 
DSB Double-strand break 
EC Endothelial cells 
ECL enhanced chemiluminescence 
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ECM Extracellular matrix 
EDG Endothelial differentiation gene 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced green fluorescent protein 
ELOF1 Elongation factor 1 homolog 
EndMT Endothelial mesenchymal transition 
EP2 Prostaglandin E2 receptor 
ER Endoplasmatic reticulum  
ERK Extracellular signal-regulated kinase 
ETOH ethanol 
FACS Fluorescence activated cell sorting 
FAK Focal adhesion kinase 
FC Fold change 
FCS Fetal calf serum 
FDR False discovery rate 
Fib Fibroblasts 
FITC Fluorescein isothiocyanate 
For Forward 
FP Prostaglandin F receptor 
FSC Forward scatter 
GSL Glycosphingolipid 
GSN Gelsolin 
GTP Guanosine-triphosphate 
h hours 
H2O Water 
HBMEC Human brain microvascular endothelial cells 
HCl Hydrochloric acid 
HDBEC Human dermal blood endothelial cells 
HPRT Hypoxanthin-guanin-phosphoribosyltransferase 
HR Homologous recombination 
HRP Horseradish peroxidase 
Hs Human 
HSAVEC Human saphenous vein endothelial cells 
HSC Hepatic stellate cells 
HSPG Heparan sulfate proteoglycans 
HUAEC Human umbilical artery endothelial cells 
HUVEC Human umbilical vein endothelial cells 
Ifitm1 Interferon induced transmembrane protein 1 
IGFR2 Insulin-like growth factor receptor 2 
Indels Insertions and deletions 
IP Prostacyclin receptor 
Kcnj8 potassium inwardly rectifying channel, subfamily J 
kD Kilo Dalton  
KDR Kinase insert domain receptor 
LoxP Locus of crossover in P1 
LP Lung pericytes 
LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 
MAPK Mitogen-activated protein kinase 
Min Minutes 
MMP Metalloproteases 
MP Muscle pericytes 
MPRIP Myosin phosphatase Rho interacting protein 
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mRNA Messenger ribonucleic acid 
MRPL55 Mitochondrial ribosomal protein L5  
Ms Mouse 
MSC Mesenchymal stem cells 
MSigDB Moleculare Signature Database 
MTORC1 Mammalian target of rapamycin complex 1 
MYH10 Myosin heavy chain 10 
NG2 Neural/glial antigen 
NHEJ Non-homologous end joining 
NRP Neuropilin 
NSAID Nonsteroidal anti-inflammatory drug 
O2 oxygen 
Opti-MEM Optimized Minimal Essential Medium 
p pico 
PAM Protospacer adjacent motif 
PancP Pancreas pericytes 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
Pdgfb Platelet-derived growth factor beta 
PDGFRα Platelet derived growth factor receptor α 
PDGFRβ Platelet-derived growth factor receptor β  
PDPN Podoplanin 
PECAM1 Platelet endothelial cell adhesion molecule 1  
PFA Paraformaldehyde 
PGD2 Prostaglandin D2 
PGDS Prostaglandin D synthase 
PGE2 Prostaglandin E2 
PGES Prostaglandin E synthase 
PGF2α Prostaglandin F2α 
PGFS Prostaglandin F synthase 
PGG2 Prostaglandin G2 
PGH2 Prostaglandin H2 
PGI2 Prostaglandin I2/Prostacyclin 
PGIS Prostaglandin I synthase 
PGT Prostaglandin transporter 
pH power of hydrogen 
PI3K Phosphoinositide-3-kinase 
PIGF Placental growth factor 
PLA2 Phospholipase A2 
PlaP Placenta pericytes 
PLCy Phospholipase C 
PPAR Peroxisome proliferator-activated receptor 
PTGER1-4 Prostaglandin E Receptor 1-4 
PTX Pertussis toxin 
Rev Reverse 
RGS5 Regulator of G-protein signaling 5  
RNA Ribonucleic acid 
RNase Ribonuclease 
RT Room temperature 
RTCA Real time cell analyzer 
RT-qPCR Real time-quantitative polymerase chain reaction 
S100A4 S100 calcium-binding protein A4 
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S1P Sphingosine-1-phosphate  
S1PR1-5 Sphingosine-1-phosphate receptor 1-5 
SDC1 Syndecan 1 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sec Seconds 
SGPP Sphingosine-1-phosphate phosphatases 
siRNA Small interfering RNA 
SM Sphingomyelin 
SMA Smooth muscle actin  
SMAD7 Mothers Against Decapentaplegic Homolog 7 
SMC Smooth muscle cells 
SPHK Sphingosine kinase 
SPNS Sphingosine-1-phosphate transporter 
SSC Side scatter 
Taq Thermus aquaticus 
Tek TEK tyrosine kinase, endothelial 
TGFβ Transforming growth factor β 
Tie Tyrosine kinase with immunoglobulin-like and EGF-like domains  
Tm Melting temperature 
TP Thromboxane receptor 
TSC1 Tuberous sclerosis protein 1 
TXA2 Thromboxane A2 
TxAS Thromboxane synthase 
U Unit 
UV Ultra violet 
V Volt 
v/v Volume/volume (volume concentration) 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
Vtn Vitronectin 
WB Western Blot 
Zic1 Zink finger protein 201 
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